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ABSTRACT
The checkpoint kinase (chk) 1 is an essential component of the DNA damage checkpoint 
acting as the effector of the DNA damage to block the cell cycle at the G2-M transition. 
The studies reported here were aimed at elucidating the molecular mechanisms 
regulating the G2 checkpoint after DNA damage and at investigating Chkl as a 
potential therapeutic target for new cancer treatments. The promoter region o f the 
human Chkl gene was at first isolated and characterized. It was possible to show a p53 
dependent downregulation of the Chkl gene. The transcriptional factor E2F1 was also 
found to have a role in modulating Chkl promoter activity. To further understand the 
interplay between p53 and Chkl in the G2 checkpoint, the cellular response to 
anticancer treatments in isogenic cellular systems differing in the expression of Chkl 
and p53 was studied. The expression of Chkl was downregulated by siRNA, in the 
HCT-116 colon carcinoma cell line and in its isogenic systems lacking either p53 or p21. 
The inhibition of Chkl in p21 -/- and p53-/- cell lines caused a greater abrogation of the 
G2 block and a greater sensitization to anticancer treatments than in the parental cells 
with an intact G1 checkpoint. Tetracycline-inducible expressing Chkl siRNA clones 
have been obtained in HCT-116 wt and p53 deficient cells and have been transplanted in 
nude mice. Experiments are undergoing to verify the downregulation o f Chkl upon 
addition of tetracycline in mice drinking water. The last part of my thesis focused on the 
investigation of the physiological role of Chkl in cancer somatic cell lines. The 
understanding of this aspect appears particularly important as Chkl has been proposed 
to be a potential drug target for anticancer therapy. The effects of the lack of Chkl by 
siRNA transfection were studied in different human somatic cell lines. The
1
downregulation of Chkl by siRNA in the HCT-116 isogenic cellular systems did not 
alter cell growth or compromise survival of these cells independently from the status of 
p53 and p21. On the other hand, in different cell lines, like U20S and HeLa, an effect in 
cell growth, and in the cell phenotype was observed. These data suggest that the lack of 
Chkl may have different consequences depending on the intrinsic genetic background of 
the cell line studied.
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CHAPTER 1 
INTRODUCTION
1.1 CELL CYCLE REGULATION, CHECKPOINTS AND CANCER
The cell cycle is a succession of very well organized molecular events that give the 
ability to the cell to produce the exact itself s copy. The DNA replication and the 
segregation of replicated chromosomes are the main events of the cell cycle. The DNA 
replication occurs during the so called S phase (synthetic phase) which is preceded by 
the DNA synthesis preparatory phase (Gapl or G1 phase), whereas the nuclear division 
occurs in mitosis (M phase) and is preceded by the mitotic preparatory phase (gap 2 or 
G2 phase). The Gl, S and G2 phases represent the interphase o f a proliferating cell and 
constitute the time lapse between two consecutive mitoses. The differentiated cells that 
do not proliferate enter in the so called GO phase which is a steady state phase or resting 
phase (Nurse, 1994; Nurse, 1994; O'Connell and Nurse, 1994; Vermeulen et al., 2003). 
The progression of a cell through the cell cycle is strictly regulated by key regulatory 
proteins called CDK (cyclin dependent kinase) which avoid the initiation of a cell cycle 
phase before the completion of the preceding one (figure 1.1-1.2) (Sherr and Weber, 
2000; Vermeulen et al., 2003). The cdks are a family of serine/threonine protein kinases 
that are activated at specific points of the cell cycle consisting of a catalytic subunit with 
a low intrinsic enzymatic activity and of a fundamental positive regulatory subunit 
called cyclin (Morgan, 1995; Lees, 1995; Arellano and Moreno, 1997; Pavletich, 1999). 
Cyclin protein levels rise and fall during the cell cycle, activating the corresponding cdk, 
whereas the cdk protein levels are kept constant throughout the cell cycle. Once the 
complex cdk-cyclin is formed, it gets activated by the protein CAK (cdk activating 
protein) which phosphorylates the complex ensuring the subsequent phosphorylation of 
target gene products required for the progression of the cell through the cell cycle
4
Cdkl-cyclinB
Cdk4/6-cyclinD
Cdkl-cyclinA
Cdk2-cyclinE
Cdk2-cyclinA
Figure 1.1 Cell cycle phases and main cell cycle regulators
A cell cycle scheme with the main cyclins and CDK regulators proteins is represented.
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(Morgan, 1995; Pines, 1995a). When quiescent cells are stimulated by mitogen 
signals, CDK4 and CDK6 are activated by association with D type cyclins. These 
above cited cdk-cyclin complexes are important for the progression through the G1 
phase and the restriction point preparing the cell to the replicative phase by 
phosphorylating the oncosuppressor protein pRb which causes the activation o f the 
E2F family transcription factors. The activation of CDK4 and CDK6 is followed by 
the subsequent activation of CDK2 by cyclin E and cyclin A, which in turn initiates 
DNA replication. As the DNA replication process finishes, the Cdkl/cyclin B 
complex is activated leading to mitosis (Sherr, 2000; Vermeulen et al., 2003). The 
activation status of the cdk-cyclin complexes is also monitored by negative 
regulation of the ATP binding site by phosphorylation in specific residues and 
subsequent reactivation by specific phosphatases which dephosphorylate the same 
residues. Inhibitory proteins also contribute to negatively regulate the cdks by 
forming either binary complexes with cdks or ternary complexes with cyclin cdk dimers 
(figure 1.2). Three distinct families of these so called cyclin dependent kinase inhibitors 
(CKI) can be distinguished (Sherr and Roberts, 1999). The first one is called INK family 
and is composed by four members: pl5, pl6, pl8 and pl9. They mainly regulate the Gl- 
S transition of the cell cycle targeting to CDK4 and CDK6 by binding the cdk subunit 
and causing a conformational change of the kinases which become inactive precluding 
the cyclin binding (Russo et al., 1998). The second family of inhibitors is the Cip/Kip 
family and consists of three members: p21clpl, p27kipl and p57 kip2. The components of 
this group negatively regulate the cdk2/cyclinA and cdk2/cyclinE complexes whereas 
they positively regulate the cdk4/6 cyclinD complexes by facilitating and stabilizing
6
the association o f cyclin and CDKs (Cheng et al., 1999). The final class of inhibitors 
is the pRb protein family which consists o f two members: p i07 and p i30. These 
proteins, better known as transcriptional inhibitors, act as potent cyclin E/A-cdk2 
inhibitors by binding both to cyclin and to cdk sites (Cobrinik, 2005).
An additional level of cdk regulation is the control of nuclear import/export which can 
be easily exemplified by the cyclinBl-Cdkl complex that is kept out of the nucleus 
through an active nuclear export until late G2, when the nuclear exporting signals are 
inactivated by phosphorylation ensuring nuclear accumulation. The regulation of the 
Cdkl-cyclinBl complex via cytoplasmic sequestration together with the negative 
regulatory phosphorylation of Cdkl prevents premature phosphorylation of mitotic 
targets and the entry in mitosis (Yang et al., 1998). Other examples are the CDK 
inactivating kinases Weel and Mytl located respectively in the nucleus and Golgi 
complex protecting the cells from premature mitosis and the 14-3-3 group o f proteins 
that regulate the intracellular trafficking of different proteins such as the phosphatase 
Cdc25C (Liu et al., 1997; Peng et al., 1997). The above mentioned events are very well 
monitored by signaling pathways called checkpoints which constantly make sure that 
upstream events are successfully completed before the initiation of the next phase. It’s in 
fact important that alterations in duplication of the DNA during S phase do not occur, to 
avoid the segregation of aberrant genetic material to the daughter cells hence ensuring 
accurate genetic information’s transmission throughout cellular generations. Lack of 
fidelity in cell reproduction processes creates a situation of genetic instability which 
contributes to the development of cancer desease. In cancer, the genetic control o f cell 
division is altered resulting in a massive cell proliferation. Mutations mainly occur in
7
CKI
Cdk
cyclin
Synthesis
Cyelin/cdk
CAK
mOA
Active Cyclin/cdk
CKI
Cell cycle transition
Figure 1.2 Schematic recapitulaton of the levels of regulation of the cyclin 
dependent kinases (Cdk)
1 and 2 . Synthesis and degradation of cyclins at specific stages of the cell cycle. 3. 
Association of cdks to cyclins in order to be active. 4. Activation o f the cdk/cyclin 
complexes by CAK. 5. Inactivation of cdk/cyclin complexes by phosphorylation at thr 14 
and tyr 15 (5a) and reactivation by phosphatases acting on these sites (5b). 6. Cdk 
inhibitor proteins (CKI) preventing either the assembly of cdk/cyclin complexes (6a) or 
the activation of the cdk in the complex (6b). The activated cdk/cyclin complexes can 
phosphorylate substrates necessary for transition to the next cell cycle phase.
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two classes of genes: proto-oncogenes and tumor suppressor genes. In normal cells the 
proto oncogenes products act at different levels in pathways that stimulate proper cell 
proliferation while the mutated proto-oncogenes or oncogenes can promote tumor 
growth due to uncontrolled cell proliferation. Tumor-suppressor genes normally keep 
cell numbers down, either by halting the cell cycle and thereby preventing cellular 
division or by promoting programmed cell death. When these genes are rendered non­
functional through mutation, the cell becomes malignant. Defective proto-oncogenes and 
tumor-suppressor genes act similarly at a physiologic level: they promote the inception 
of cancer by increasing tumor cell number through the stimulation of cell division or the 
inhibition of cell death or cell cycle arrest. Uncontrolled cell proliferation which evolves 
in cancer can occur through mutation of proteins important at different levels of the cell 
cycle such as CDK, cyclins, CKI and CDK substrates. Defects in cell cycle checkpoints 
can also result in gene mutations, chromosome damages and aneuploidy all o f which can 
contribute to tumorigenesis (Sherr, 1996; McDonald, III and El Deiry, 2000). 
Understanding the molecular mechanisms regulating the cell cycle progression and how 
these processes are altered in malignant cells may be crucial to better define the events 
behind such a complex and devastating desease like cancer.
1.2 DNA DAMAGE CHECKPOINT
A faithful transmission of genetic informations from one cell to its daughters requires 
the ability of a cell to survive to spontaneous and induced DNA damage to minimize the 
number of heritable mutations. To achieve this fidelity, cells have evolved surveillance 
mechanisms composed by an intricate network of checkpoint proteins that tells the cell
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to stop or delay the cell cycle progression providing enough time for DNA repair. When 
the damage can not be repaired cells undergo apoptosis.
Many different lesions can occur in the cells which are coupled to different repair 
mechanisms. First, normal metabolic processes or exposure to external ionizing 
radiations generate free oxygen radicals and can break the phospho diester bonds in the 
backbone of the DNA helix (single strand break). When two of these breaks are close to 
each other but on opposite DNA strands, a double strand break (DSB) is present. 
Second, alkylating agents can modify purine bases and can cause intra strand or inter 
strand crosslinks. Inhibitors o f DNA topoisomerase can cause DNA lesions leading to 
enhanced single or double strand break depending on which topisomerase is inhibited 
and on the phase of the cell cycle. Different mechanisms are required to repair the 
damage to the DNA backbone or to the DNA bases and the repairing mechanisms may 
also vary depending on the different phases of the cell cycle (Kastan and Bartek, 2004; 
Froelich-Ammon and Osheroff, 1995). Briefly, the signal transduction pathway 
activated after DNA damage consists of many different components departing from 
sensor proteins that recognize the damage on the DNA and trasmit the signals that are 
amplified and propagated by adaptors/mediators to the downstream effectors that 
connect the checkpoint with the cell cycle machinery (figure 1.3).
This molecular cascade is very well conserved form yeast to humans and nowadays the 
proteins involved in this pathway have been identified (Kastan and Bartek, 2004; Zhou 
and Elledge, 2000; Lukas et al., 2004b).
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1.2.1 GENERAL ORGANIZATION OF CHECKPOINTS COMPONENTS
After DNA damage exposure an arrest of the cell cycle progression should take place 
rapidly. This is ensured by the PI(3)K (phosphatidyl-inositol-3-OH kinase) - like kinase 
(PIKKs), ATM (ataxia telangiectasia mutated) and ATR (ATM-and Rad3 related), that 
are almost instantly activated following stress exposure and recognize the damage, 
initiating the DNA damage response (Durocher and Jackson, 2001; Lavin, 1999). They 
are both able to be quickly recruited to sites of DNA damaged where they form 
complexes with other proteins such as the replication factor RFC and PCNA (Shiloh, 
2001; Balajee and Geard, 2001; Unsal-Kacmaz et al., 2002).
While the ATM kinase is activated following DNA damage, the ATR kinase is critical 
for cellular response to the arrest of the DNA replication forks. They are both large 
protein kinases that phosphorylate many substrates to achieve their physiological 
functions.
ATM is autophosphorylated in ser 1,981 after DNA DSB (double strand breaks) leading 
to a conformational change, causing the dissociation of a homodimer to monomer which 
can subsequently phosphorylate, at the nucleoplasmic level, its substrates like p53, 
NBS1 (Nijmegen breakage syndrome 1), BRCA1 (breast cancer 1) and SMC 1 
(structural maintenance of chromosomes 1) at the sites of DNA breaks. The 
heterodimeric ATM does not need to bind to the DNA break to cause its 
autophosphorylation as it has been shown to sense changes in chromatin structure at 
some distance away from the site of the DNA break (Bakkenist and Kastan, 2003). It has 
been recently observed that the multiprotein complex MRE11 (meiotic recombination 
ll)/rad50/NBSl (MRN) contributes to the actvation of ATM after DSB (Uziel et al.,
12
2003; Horejsi et al., 2004). Patients, mice and cells lacking ATM are viable, suggesting 
that the ATM kinase is not essential for critical cellular functions such as normal cycle 
progression or cellular differentiation (Shiloh and Kastan, 2001).
ATR together with ATM is the most well characterized damage “sensor” (Abraham, 
2001). It exists in a complex with the ATR interacting protein (ATRIP), both before and 
after exposure of stresses such as ultraviolet radiation. It has been observed that the in 
vitro binding of ATRIP to single stranded DNA is ensured by the replication protein A 
(RPA), a single stranded DNA binding protein involved in DNA replication. The 
binding of the ATRIP to RPA is determinant for ATR to localize to sites o f replication 
fork arrest as the accumulation of RPA on ssDNA (single strand DNA) leads to the 
recruitment of the ATRIP protein and its heterodimeric partner ATR, which once 
localizes to the ssDNA regions can phosphorylate its substrates such as rad 17 and Chkl 
(Cortez et al., 2001; Zou and Elledge, 2003). In order for ATR to carry out its cellular 
functions, several other proteins and complexes have to be recruited to the ssDNA site, 
such as the clamp loading, Rad 17-containing complex, which is necessary for the 
loading of the RAD9-RAD1-Husl (9-1-1) sliding clamp into the chromatin and the 
claspin protein, which is independently recruited to chromatin as well (Osborn et al., 
2002; Lin et al., 2004). Cells and animals lacking ATR are not viable thus suggesting 
that this protein has a critical role in the normal cell cycle progression independently on 
the presence of cellular stress. Recent evidences attributed to ATR a crucial role in the 
normal progression of the DNA replication forks and consequently in all cellular 
responses that share inhibition of replication fork progression as in the presence of DNA 
damage, whereas ATM seems to be activated just following DSB (Brown and
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Baltimore, 2003; Shechter et al., 2004). The activity of ATM and ATR is modulated by 
the checkpoint mediators. They act facilitating the interactions between ATM/ATR and 
their substrates, helping to provide signal transduction specificity and mediating the 
spatio temporal assembly of multiproteins complexes in the chromatin regions 
surrounding the DNA damage sites. As they are recruited to the sites of DNA damage 
independently of ATM and ATR, they could have the ability to sense the DNA lesions 
as well (Goldberg et al., 2003). The ATM related mediators include MDC1, 53BP1 and 
BRCA1. These are large multi domain proteins containing 2 tandem BRCT (BRCA-1 
carboxy terminal) domains at their C terminus working promoting protein- 
phosphoprotein binding modules to facilitate eventually the transient multiple 
interactions of checkpoints and repair proteins near the DNA damage sites (Stewart et 
al., 2003; Manke et al., 2003; Wang et al., 2002). Their accumulation to sites of DNA 
damage depends on ATM mediated phosphorylation of histone H2AX. MDC1 
represents one of the earliest proteins to localize at DNA DSB and it works like a 
molecular bridge between the yH2AX and the NBS1 component of the MRN complex 
helping to facilitate interactions for these and other checkpoints and the repair proteins 
(including the activated ATM) in the proximity of the DNA damaged sites (Celeste et 
al., 2003; Lukas et al., 2004a; DAmours and Jackson, 2002).
On the other hand, the ATR controlled checkpoint signaling, through Chkl activation, 
relies on a different mediator called claspin which is structurally unrelated to the 
mediators involved in DSB. It interacts with chromatin structures created by active 
replication forks, ensuring ATR mediated phosphorylation events being so related to 
Chkl activation (Chini and Chen, 2004; Lee et al., 2003).
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In general the multiprotein interactions mediated by these mediators contribute to ensure 
a prompt checkpoint response. In fact cells lacking any of these mediators show 
enhanced sensitivity to DNA damaging agents such as IR (ionizing radiation) and 
impaired intra S-phase and G2/M cell cycle checkpoints.
As I already mentioned, the ATR and ATM mediated phosphorylations trigger 
respectively and preferentially the activation of the so called checkpoint downstream 
kinases Chkl and Chk2. The ATM-Chk2 and ATR-Chkl cascades modules share many 
substrates among the checkpoint effector proteins which are for example the three 
human phosphotyrosin phosphatases, Cdc25A, B and C that dephosphorylate the cyclin 
dependent kinases that act on proteins directly involved in cell cycle transitions (Zhou 
and Elledge, 2000; Bartek and Lukas, 2003).
1.3 G1 CHECKPOINT
To prevent the entry in S phase in the presence of DNA damage, the G1 checkpoint is 
activated in the cells thus inhibiting the initiation of DNA replication. Under normal 
conditions cells gain the ability to enter the S phase at a stage called restriction point 
which in mammalian cells precedes the DNA synthesis by about two hours, but when 
DNA damage is introduced, the DNA synthesis is prevented even if the cells have 
reached the restriction point. In the G1 checkpoint response, two distinct effectors, the 
Cdc25A phosphatase and the p53 transcription factor are phosphorylated and activated 
by the transducing kinases ATM/ATR and Chkl/Chk2 and more specifically depending 
on the kind of damage either by the ATM/Chk2 or by the ATR/Chkl pathway. The 
phosphorylation of these two effectors occurs rapidly and simultaneously although the
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impact of these events on cell cycle machinery is faster in case of the Cdc25A cascade 
not requiring transcription and accumulation of new synthesized proteins like in the p53 
pathway (Bartek and Lukas, 2001). The phosphorylation of Cdc25A on serine residues 
by Chkl and Chk2 kinases results in its inactivation by nuclear exclusion and ubiquitin- 
mediated proteolytic degradation (Sorensen et al., 2003; Zhao et al., 2002). Once 
inactivated, the Cdc25A can not anymore induce the activatory dephosphorylation of the 
catalytic subunit of cyclinE/Cdk2 and cyclinA/cdk2, thus preventing the initiation of the 
DNA synthesis by inhibiting the loading onto chromatin of Cdc45, a protein required for 
recruitment of DNA polymerase a into the assembled pre-replication complexes 
(Mailand et al., 2000; Falck et al., 2001). The checkpoint pathway that targets Cdc25A is 
implemented rapidly, independently on a transcriptional event and it delays the Gl-S 
transition only for few hours (Molinari et al., 2000). On the other hand the activation of 
the p53 dependent mechanism ensures the maintenance of the G1 arrest in response to 
DNA damage (Figure 1.4) (Bartek and Lukas, 2001). This protein is present at low 
levels in unstressed conditions but after damage a very rapid accumulation in the nucleus 
can be observed because of the detachment of its binding protein mdm2 as a 
consequence of translational modifications, especially N terminal phosphorylations in 
the region which binds mdm2. In addition mdm2 is also targeted after DNA damage by 
ATM/ATR (Khosravi et al., 1999; Maya et al., 2001). The p53 stabilization and 
activation mediates the maintenance of the Gl/S checkpoint arrest, which becomes fully 
operational several hours after the detection of DNA damage (Bartek and Lukas, 2001). 
After DNA damage p53 gets phosphorylated by the protein kinases Chkl and Chk2 and 
also directly by the upstream checkpoint kinases ATM and ATR particularly on serl5
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Schematic representation of the main molecular mechanisms involved in the activation 
of the G1 checkpoint after DNA damage. (Modified by Sancar A. et al. 2004).
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(Shiloh, 2003; Kastan and Lim, 2000). Once activated, p53 transcriptionally 
transactivates its target genes, including p21WAF'1/Clpl which binds to and inhibits the S- 
phase promoting Cdk2-CyclinE complex, thus maintaining the Gl/S arrest. p2lWAF'1/Cipl 
also binds to the Cdk-CyclinD complex and prevents it from phosphorylating Rb, which 
once phosphorylated releases the E2F transcription factor required for the transcription 
of S-phase genes in order for S phase to proceed (Bartek and Lukas, 2001; Harper et al., 
1993; Lin etal., 2001).
Althoguh there is an evidence that p21 transcription can be induced following DNA 
damage even in the absence of p53 (Vikhanskaya et al., 1995), its transcription is mostly 
controlled by p53, and cells lacking the DNA binding domain of p53 or presenting 
mutations in this domain, fail to activate p21 and have a strongly reduced ability to 
induce G1 arrest (Fan et al., 1995; Wahl et al., 1996). The importance of p21 in 
mediating p5 3-induced G1 arrest has been further demonstrated by the generation of 
somatic p21 -/- cells which lack the ability to induce G1 arrest following damage 
induction, even in the presence of a functional p53 (Waldman et al., 1997).
1.3.1 THE ONCOSUPPRESSOR p53
A high percentage of human cancers present mutations in the p53 tumor suppressor 
protein as a result either of missense point mutations in the p53 gene or functional 
inactivation of the p53 protein by rapid degradation or by viral oncoproteins. In normal 
conditions p53 is present as a latent transcription factor with a short half life. DNA 
damage or oncogenic activation leads to the translational modification and stabilization 
of the p53 protein.
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1.3.1.1 P53 GENE AND PROTEIN AND ITS REGULATION
The p53 gene, mapping on chromosome 17, codes for a protein of 393 aminoacids with 
an apparent molecular weight of 53 KDa. The cDNA coding for p53 is highly conserved 
among different species and it consists of different domains each characterized by a 
specific function (figure 1.5)(Haffner and Oren, 1995).
The central DNA binding domain confers to p53 the ability to act as a transcription 
factor and is particularly conserved through the evolution. The specific DNA sequence 
targeted by p53 is 5’PuPuPuCT/AT/AGPyPyPy3’(Levine, 1997). The N-terminus 
region constitutes a transcriptional activation domain which is able to interact with 
the basal transcription machinery and positively regulates gene expression. It is also 
the region recognized by the negative regulator of p53, mdm2 (Bottger et al., 1997). 
The crucial amino acids responsible for the binding o f p53 to mdm2 have been identified 
thanks to the availability of the crystal structure of the N-terminal region of mdm2 with 
a p53-derived peptide containing amino acids 13-29 (Kussie et al., 1996). Interestingly 
this region of the protein contains different phosphorylatable aminoacidic residues 
that ensure the detachment of p53 itself from mdm2. It has been shown that the 
residues in p53 protein important for the interaction with mdm2 are mostly serl5 and 
ser20 which upon damage can be phosphorylated in vitro by different kinases, 
including ATM,ATR, DNA-PK, Chkl and Chk2, depending on the kind o f damage 
the cell has received (Meek, 1998; Kapoor and Lozano, 1998; Banin et al., 1998; 
Chehab et al., 2000; Shieh et al., 2000). Seri5 o f p53 for example is clearly 
phosphorylated by ATM following IR and by ATR following UV (Meek, 1998; 
Kapoor and Lozano, 1998; Lane, 1998).
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Figure 1.5 Structure and domains of the p53 protein
The amino terminal part comprises the acidic tansactivation domain and the mdm2 
protein binding site, following a series o f conserved repeated proline residues. The 
central region contains the DNA binding domain which is the target o f  90% of p53 
mutations found in human cancers. The carboxy terminus o f p53 contains the 
oligomerization domain necessary for p53 dimerization and the nuclear localization 
signals.
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The C-terminal region contains the residues important for oligomerization, as the 
native p53 protein is present as a tetramer (Haffner and Oren, 1995; Oren, 1985). 
This region contains another DNA binding domain that recognizes the DNA in a 
structure specific manner rather than in a sequence specific way (Ahn and Prives, 
2001). The p53 molecule is present in two conformationally distinct forms, one latent 
and the other active in sequence specific binding to DNA. One of the functions of the C- 
terminus of p53 is thought to be the ability to drive the molecule toward these two forms 
(Ahn and Prives, 2001; Hupp and Lane, 1994).
In normal, unstressed conditions, levels of p53 are very low. Immediately after a 
stress, p53 is induced by rising its levels rapidly and it accumulates in the nucleus 
(Vogelstein and Kinzler, 1992; Ko and Prives, 1996; Oren and Prives, 1996). This 
mechanism is mainly post-translational, and one of the crucial steps is mediated by 
the interaction of p53 with its regulator mdm2. In normal conditions, p53 is bound by 
mdm2, and this binding is a signal leading to ubiquitination and nuclear export 
(Michael and Oren, 2002; Haupt et al., 1997). Once ubiquitinated, p53 is degraded 
through the proteasome. Mdm2 exerts an E3 ubiquitin ligase activity towards p53 
(Honda et al., 1997). The role o f mdm2, however, is not only that of simply adding 
ubiquitin molecules to p53, but recent evidence indicates that there are consecutive 
regulated steps that occur before degradation o f p53 takes place. In fact p53 
ubiquitination occurs mainly in the nucleus, and p53, thus modified, is then exported 
through an active mechanism controlled by mdm2 into the cytoplasm, where it is 
degraded by cytoplasmic proteasome (Geyer et al., 2000; Boyd et al., 2000). To 
support this mechanism, mdm2 contains in its structure nuclear localization and
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export signals which are necessary for its shuttling between nucleus and cytoplasm 
(Roth et al., 1998). The importance of mdm2 in the homeostasis of p53 has become 
clear when attempts to generate knock out mice for mdm2 failed due to embryo 
lethality. This lethality was shown to be avoided by preparing mdm2 knock out mice 
in a p53 null background (Montes de Oca et al., 1995). The reason why mdm2 mice 
did not proceed to birth is probably because levels of p53 are constantly high, 
lacking its main negative regulator, thus inducing growth arrest and/or apoptosis in 
all cells in the absence of stress induction (de Rozieres et al., 2000).
The activation of p53 following damage needs the detachment of p53 itself from 
mdm2. Two distinct mechanisms have been described. The first one is, as I just 
mentioned, related to the ability of p53 to undergo phosphoryation at the N-terminus 
following stress induction. Another mechanism which mediates the detachment of 
p53 from mdm2 has been reported in cells activated by oncogenic transformation. In 
this case the mechanism leading to dissociation o f mdm2 from p53 involves the 
p l4arf protein (Eischen et al., 1999). p l4 arf is able to bind mdm2 at residues different 
from those necessary for the interaction with p53. Once bound by p l4 arf, mdm2 is 
localized to nucleolar structures and sequestered (Pomerantz et al., 1998; Weber et 
al., 1999), thus resulting in a release o f p53 and a rise in its levels.
Besides the region important for binding to mdm2, p53 is phosphorylated at other bl­
and C-terminal sites (Siliciano et al., 1997; Giaccia and Kastan, 1998; Meek, 1998). 
Different kinases responsible for these post-translational modifications have been 
identified, including Casein Kinase II (CKII), protein kinase C, CDKs (Giaccia and 
Kastan, 1998; Meek, 1998). These modifications are thought to be important for the
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stabilization of sequence specific for DNA binding and possibly for determining the 
substrate specifcity in transcriptional activation of downstream genes (Oren and 
Prives, 1996). For example phosphorylation at ser46 has been shown to be essential 
for the activation of apoptosis related genes (Oda et al., 2000b).
The acetylation is another post-translational modification o f p53. It has been shown 
in fact that p53 is a substrate of HAT, being efficiently acetylated at the C terminus 
(Gu and Roeder, 1997). These acetylations, occurring at lysine 320, 372, 373, 382 
and 381, mediated by the HATs P300 and pCAF were found in cells in response to 
various stimuli (Prives and Manley, 2001; Liu et al., 1999). The acetylation o f p53 
does not seem to stimulate the sequence specific binding, but could be important for 
the recruitment of transcriptional co-activators or for p53 localization (Prives and 
Manley, 2001), although this issue is yet to be defined.
1.3.1.2 P53 FUNCTION
P53 exerts its activity mainly as a transcription factor. Following activation, it activates 
the transcription of distinct classes of genes. Two important classes of genes are 
activated by p53: those involved in cell cycle arrest and in apoptosis (Waldman et al., 
1997; Ko and Prives, 1996; Bates and Vousden, 1996; Vogelstein et al., 2000) 
depending on the kind and extent of damage. Two genes, p21 and bax, are among the 
most studied p53 downstream genes responsible for p53 induction of cell cycle arrest 
and apoptosis, respectively (El Deiry et al., 1993; Miyashita et al., 1994). Many other 
genes, however have been implicated in p53-mediated cell cycle arrest or apoptosis, 
including the 14-3-3 sigma protein, GADD45, FAS, Noxa, PUMA, the family o f PIGs,
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AIP (Vogelstein et al., 2000; Kastan et al., 1992; Hermeking et al., 1997; Muller et al., 
1998; Oda et al., 2000a; Oda et al., 2000b; Yu et al., 2001; Nakano and Vousden, 2001). 
It has been shown that the critical decision between activating either apoptotic or growth 
arrest inducing genes is mediated both by the sequence of the DNA element and by the 
different post translational modifications of p53. The first evidence is dictated by the 
difference of the p53 responsive elements present in the DNA regulatory sequences of 
p21 and bax genes. The element present in the bax promoter, in particular, is less 
efficiently bound by p53 and, in transcription experiments using heterologous reporter 
genes, it has a weaker transcriptional response compared to the analoguos element in 
p21 (De Feudis et al., 2000).
As already outlined the p53 post translational modifications are important as 
demonstrated by the observation that one of the p53 responsive genes involved in 
apoptosis, the AIP gene, is not efficiently transcribed, if p53 is not phosphorylated at 
residue serine 46, which probably induces a conformational change in p53 allowing 
efficient binding and transactivation ability for this specific gene (Oda et al., 2000b; 
Hofmann et al., 2002).
p53 can also exert its activity via trasncriptional repression (Vogelstein et al., 2000; 
Vogelstein and Kinzler, 1992). This process is another relevant mechanism responsible 
for its activity. The molecular mechanisms responsible for transcriptional repression 
have been less well elucidated. The ability of p53 to interfere with transcription factor 
Spl activity and binding to DNA has been discussed (Bargonetti and Manfredi, 2002).
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1,3.2 THE p53 HOMOLOG p73
p53 was thought for a long time to be the only member of the p53 protein family. 
Recently, the identification of two p53-related proteins, termed p73 and p63 revealed 
that p53 belongs to a small family of sequence specific nuclear transcription factors 
(Kaghad et al., 1997).
p53 family members share the three major functional domains: the N-terminal 
transactivation domain, the central core sequence specific DNA binding domain 
highly conserved across the family, and the C-terminal oligomerization domain. The 
genomic organization of p73 is quite similar to that of p53. The p53 gene is 20 kb in 
length and contains 11 exons whereas the p73 gene is larger than 60 kb in length and 
contains 14 exons (Irwin and Kaelin, 2001). Unlike p53, though, p73 is expressed as 
at least 6 variants (p73 a,p,y,5,s,Q with different C-terminal ends, arising from 
alternative splicing (Kaghad et al., 1997; Ueda et al., 1999). Among them p73a is the 
longest form containing a sterile a motif domain (SAM domain) and an extreme C- 
terminal region while the p73p lacks most of these two regions. Each o f these 
splicing variants contains an intact N-terminal transactivation domain and exerts its 
transcriptional activity to various degrees, and the C-terminal differences among the 
variants attribute different transcriptional and biological properties. The C-terminal 
region of p73 might indeed possess a regulatory role which modulates its 
transactivation and pro-apoptotic activity (Ueda et al., 1999; Ozaki et al., 1999; Lee 
and La Thangue, 1999). These splicing variants are differentially expressed among 
normal tissues and cell lines, suggesting that they might have distinct physiological 
functions (Ueda et al., 1999). In addition to the differential splicing variants, p73
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contains a second transcriptional starting site within intron 3, giving rise to the N- 
terminal truncated forms of p73 (ANp73a and ANp73p) with little transcriptional 
activity (figure 1.6) (Yang et al., 2000).
ANp73 displays a dominant negative behaviour toward p73 as well as wild type p53 
and has oncogenic potential (Pozniak et al., 2000; Stiewe et al., 2002b). This 
inhibition occurs at the oligomerization level or by the competition for the binding to 
the same p53/p73 responsive elements as ANp73 would displace Tap73 and p53 from 
the DNA binding site (Stiewe et al., 2002a; Melino et al., 2002). A harmonic balance 
between the intracellular expression levels of pro-apoptotic Tap73 or p53 and anti 
apoptotic ANp73 might contribute to regulate cell fate determination.
It has been recently shown the existence of a functional p53/p73 responsive element 
within the ANp73 promoter region. The expression of ANp73, in fact, is directly 
transactivated by Tap73 and/or wt p53, creating a dominant negative feedback loop 
which regulates the activities of both Tap73 and wt p53 (Grob et al., 2001; Zaika et 
al., 2002). Recent finding attributed to ANp73 p but not to ANp73a a weak but 
distinct transactivation activity, inducing cell cycle arrest and/or apoptosis (Liu et al., 
2004). The expression levels of endogenous p73 are kept low under physiological 
conditions and, similar to p53, p73 is stabilized by post translational modifications at 
the protein levels in response to many DNA damaging agents resulting in either Gl/S  
cell cycle arrest or cell death through apoptosis (Irwin et al., 2003). p73 stability is 
directly linked with its activity. Chemical modifications o f p73 such as 
phosphorylation or acetylation would prolong its half life with enhancement o f its
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Figure 1.6 Structure of TA p73 and of AN p73
Schematic representation of the structure o f TA and o f AN isoforms o f p73.
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both transcriptional and pro- apoptotic activity. Experimental evidences suggest that 
p73 turnover is regulated through ubiquitination dependent and ubiquitination 
independent degradation pathway (Ozaki and Nakagawara, 2005). It has been shown 
that mdm2 interacts directly with the N-terminal transactivation domain o f p73 
promoting the p73 mediated transactivation activity and apoptosis without provoking 
the ubiquitination of p73 (Zeng et al., 1999). Thus, p73 stability seems to be 
regulated through a pathway distinct from that of p53, as also the evidence that the 
additional newly identified p53 induced E3 ubiquitin protein ligase pirh2 had a 
negligible effect on p73 (Leng et al., 2003; Wu et al., 2004). It has been recently 
shown that the HECT-type E3 ubiquitin protein ligase Itch, interacts with p73 
through the WW protein-protein interaction domain of Itch and the p73 region with 
the PY motif and has the ability to ubiquitinate and degrade p73. The levels of this 
protein strongly decrease after DNA damage induced by different chemotherapic 
agents thereby increasing the stability and activity of p73. The same type of 
interaction was seen between p73 and a novel E3 ubiquitin protein ligase NEDL2. 
The NEDL2 mediated ubiquitination of p73 increased the stability o f p73 and 
enhanced the p73 dependent transcriptional activity, thus indicating that a non 
proteolytic regulatory role of ubiquitination may exist (Rossi et al., 2005; Miyazaki 
et al., 2003).
Some studies demonstrated that the N-terminal truncated form of p73 (ANp73) is 
much more stable than Tap73, suggesting that p73 mediated transcriptional 
activation is required for the rapid turnover of p73 and that, like p53, one or more 
transcriptional targets of p73 might promote its proteolytic degradation (Wu et al.,
28
2004). Alternatively it was also reported that p73 may be degraded by ubiquitin 
independent manner through the binding to cyclin G, one of the direct transcriptional 
targets of p53 and p73, although the mechanism is yet to be defined (Ohtsuka et al.,
2003).
1.3.2.1 P73 FUNCTION
As p73 has a p53 like property and is mapped in a chromosome region frequently 
lost or mutated in a wide variety of human tumors, it was thought that p73 could act 
as a tumor suppressor gene. Unlike p53 which is mutated in a high percentage of 
tumors, it was however found that p73 is infrequently mutated (p73 mutations 
detected in fewer than 0.5% of human cancers) (Kaghad et al., 1997; Ikawa et al., 
1999). p73 deficient mice exhibit severe developmental defects but they do not 
develop spontaneous tumors, suggesting that p73 does not link directly to tumor 
suppression but may participate to the regulation o f normal development in vivo, 
especially neural development and apoptosis (Yang et al., 2000). Some data support 
the evidence that in some way, p73 has an ability to enhance the activity of wild type 
p53. It has been shown recently that p53 dependent apoptosis requires the 
contribution of another p53 family member. P73 would cooperate with p53 to 
promote apoptotic cell death further emphasizing the functional importance of p73 in 
the regulation of the DNA damage induced apoptotic response. Some evidences 
strongly suggest that the pro-apoptotic activity of p73 would also be regulated 
through a pathway distinct from that one used for p53. This is further confirmed by
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the evidence that p73 has the ability to promote apoptotic cell death in p53 deficient 
cells (Flores et al., 2002).
1.4 S-PHASE CHECKPOINT
DNA damage registered during S phase can interfere with the functioning DNA 
replication and may lead to genomic instability. For this reason cells developed the 
ability to detect the damage during S phase causing transient reversible inhibition of 
firing replicons that have not yet been replicated (Larner et al., 1997). Unlike the G1 
or the G2-M checkpoint the S phase response to DNA damage is short and lacks the 
sustained maintenance phase o f the cell cycle arrest; in fact cells that experience 
genotoxic stress during DNA replication only delay their progression through S 
phase in a transient manner and if damage is not repaired during this delay, once 
exiting S phase they arrest later during the G2 (Abraham, 2001; Bartek and Lukas, 
2001; Shiloh, 2003). The main function of the S phase checkpoint is to maintain fork 
integrity, thus cell viability results as an indirect effect o f prevention o f DNA 
replication fork catastrophe (Tercero et al., 2003). Many different proteins 
participate to the S phase checkpoint activation. First o f all it is possible to 
distinguish among replication independent and replication dependent S phase 
checkpoint (figure 1.7). The replication dependent intra S phase checkpoint, also 
commonly called replication checkpoint, is initiated when the progression o f  
replication forks becomes stalled in response to stresses such as depletion o f dNTP 
pools, chemical inhibition o f DNA polymerases or as a consequence of collision of 
replication forks with damaged DNA or aberrant DNA structures. The key
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components o f this checkpoint include RPA, the ATR-ATRJP complex, the mediator 
claspin, Rad 17 and the 9-1-1 complex. This checkpoint acts to inhibit the initiation 
of DNA replication from unfired origins by targeting the cyclin-CDK and Cdc7- 
DBF4 kinases that regulate the assembly and firing of replication origins, and protect 
the integrity of the replication forks allowing the recovery o f cell cycle progression 
after DNA repair or restoration of the dNTP pool (Nyberg et al., 2002; Lopes et al., 
2001). Compounds such as hydroxyurea (HU) and aphidicolin (APH) trigger the 
replication checkpoint. HU is a ribonucleotide reductase inhibitor that leads to 
depletion of the small pool o f cellular deoxyribonucleotide triphosphates while APH 
directly inhibits the activity o f polymerase a. Treatment with these inhibitors leads to 
the accumulation of stalled replication forks and the activated S checkpoint acts to 
protect the replication fork from collapsing while DNA synthesis is stalled (Lopes et 
al., 2001). The replication independent intra S phase checkpoint does not require 
active replication forks for its initiation being activated by genotoxic agents such as 
IR or radiomimetic drugs that can cause DSB in the genome. Defects in the intra S 
phase checkpoint response to IR result in the incapability o f cells to reduce the rate 
of DNA replication when irradiated, phenomenon known as radioresistant DNA 
synthesis (RDS) (Painter and Young, 1980; Merrick et al., 2004). Both ATM and 
ATR are required to prevent RDS thus activating the intra S phase checkpoint. ATM 
has a major role to sense DSB, as I already mentioned, (Shiloh, 2001) and a complex 
o f three proteins, M rell, Rad50 and Nbsl termed the MRN complex, contributes to 
the recruitment of active ATM to sites o f DSBs (van den et al., 2003; Lisby et al.,
2004).
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Figure 1.7 Activation of the S-phase checkpoint
Schematic representation of the distinct S phase checkpoint possibly activated by 
replicative stress (a), defects during DNA replication (b) and genotoxic agents (c). 
(Modifed by Bartek J. et al., 2004)
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M rell presents an exonuclease activity while Rad50 and Nbsl stimulate M rell 
enzymatic activity. Nbsl also has a BRCA-1 C terminal domain (BRCT) responsible 
for protein-protein interaction. Once ATM is actively present on the DSB sites, Chk2 
gets activated diffusing rapidly throughout the nucleus (Lukas et al., 2003). 
Downregulation of both the ATM target effector kinase Chk2 and MRN are 
necessary for a complete recovery of radioresistant DNA synthesis thus suggesting 
that two parallel pathways (ATM-Chk2 and ATM-MRN) cooperate during the intra S 
phase checkpoint (Falck et al., 2002). Although the initial response to DSB is strictly 
ATM dependent, the ssDNA resulting from the processing o f DSB promotes a slower 
activation of ATR which cooperates with ATM in the maintenance o f the intra S 
checkpoint and in the inhibition of late origin firing (Shechter et al., 2004; Merrick et 
al., 2004). The ssDNA gets coated with replication protein A (RPA) which works as 
a template for the specific recruitment of the ATR interacting protein ATRIP-ATR 
heterodimer (Zou and Elledge, 2003).
As I previously mentioned both ATM and ATR exert their function through the 
cooperation and interaction o f a class of checkpoint regulators called mediators. The 
proper timing and velocity o f ATM controlled response, relies on the functional 
interplay of at least three mediators: MDC1, 53BP1 and BRCA1. It has been shown 
that BRCA1 can be phosphorylated by ATM or ATR. Furthermore ATR not only 
phosphorylates but also colocalizes with BRCA1 in nuclear foci during stalled 
replication (Gatei et al., 2000; Tibbetts et al., 2000). Nonethless BRCA1 facilitates 
the ability o f ATM or ATR to phosphorylate some downstream targets such as Chk2, 
p53 and Nbsl and is also required for the activation o f the effector kinase Chkl
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(Foray et al., 2003; Yarden et al., 2002). Mediator of DNA damage checkpoint 
(MDC1) is another BRCT containing protein with a central role in the S phase 
checkpoint. It binds to pH2AX and is required for the recruitment o f Nbsl to broken 
DNA (D’Amours and Jackson, 2002; Lukas et al., 2004a; Petrini and Stracker, 2003). 
MDC1 also promotes the assembly of 53BP1 and BRCA1 into foci and facilitates the 
phosphorylation of SMC1 by ATR (Stewart et al., 2003; Yazdi et al., 2002). SMC1 is 
a component o f the cohesion complex that is required for sister chromatid cohesion 
during S phase. It is predominantly phosphorylated by ATM in an Nbsl and BRCA1 
dependent manner (Yazdi et al., 2002; Kim et al., 2002). The 53BP1 (p53 binding 
protein 1) is important for the intra S phase checkpoint as it regulates the 
phosphorylation of Chk2, BRCA1 and SMC1 following IR (Wang et al., 2002; 
DiTullio, Jr. et al., 2002). In addition to these three proteins, signaling through the 
ATR controlled checkpoint involves claspin, another checkpoint mediator that 
specifically interacts with DNA structures generated by active replication forks (Lee 
et al., 2003; Kumagai and Dunphy, 2000). In mammals Claspin phosphorylation in 
response to DNA damage and replication stress results in recruitment and 
phosphorylation of BRCA1 and subsequent activation of Chkl (Lin et al., 2004).
The ATM/ATR downstream target kinases Chkl and Chk2 once activated lead to the 
Cdc25A degradation resulting in the inhibition of the cyclinA/E-Cdk2 activity thus 
provoking the block of the loading o f Cdc45 onto the chromatin and preventing 
subsequently the initiation of new origin firing (Bartek and Lukas, 2003; Bartek et 
al., 2004). To understand the regulation o f the turnover of the Cdc25A into the intra 
S phase checkpoint it is necessary to underline that even during unperturbed S phase
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Cdc25A is a relatively unstable protein with a half life o f 20-30 minutes (Sorensen et 
al., 2003; Mailand et al., 2000; Falck et al., 2001; Molinari et al., 2000; Mailand et 
al., 2002). The basal turnover o f Cdc25A requires ATR, claspin and especially Chkl 
which through the phosphorylation of several serine residues in the regulatory 
domain o f Cdc25A regulates the physiological levels of Cdc25A in unperturbed S 
phase preventing the accumulation of this powerful replication promoting activity 
(Sorensen et al., 2003; Zhao et al., 2002; Sorensen et al., 2004). After DNA damage, 
the proteolysis is accelerated by the additional phosphorylation o f serl23 o f Cdc25A 
by Chk2 which would amplify the physiological Chkl dependent mechanisms 
(Bartek and Lukas, 2003; Sorensen et al., 2003).
The S-M checkpoint represents another additional type of S phase checkpoint. It 
ensures that cells do not try to divide before the completion of a faithful DNA 
duplication; its failure results in catastrophic mitosis of cells that have incompletely 
replicated their DNA. This checkpoint depends on defects occurring during DNA 
replication and the cyclinBl-Cdkl complex is the key target of this mechanism 
(figure 1.7) (Bartek et al., 2004; Brown, 2003).
1.5 G2 CHECKPOINT
To ensure accurate segregation of chromosomes cells must prevent entry into mitosis 
in the presence of DNA damage. In fact, attempts to segregate either broken or 
unrepaired chromosomes, would lead to cell death or to a level o f genomic instability 
with subsequent cell death or tumorigenesis. Cells have therefore evolved a G2 DNA 
damage checkpoint control that prevents cells from initiating mitosis when they
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experience DNA damage during G2 or when they progress into G2 with some 
unrepaired damage inflicted during previous S or G2 phases (Nyberg et al., 2002; Xu 
et al., 2002). In normal conditions, the mitosis, the most spectacular phase o f the cell 
cycle, is controlled by the cyclin Bl-Cdkl kinase activity (Nurse, 1990). Cdkl 
activity, necessary to the G2-M transition, depends on the dephosphorylation of 
Thrl4 and Tyrl5 through the activity of the dual specificity phosphatase Cdc25C 
which neutralizes the effects o f the opposite kinases Weel and Mytl that keep Cdkl 
in a phosphorylated form during interphase (Nigg, 2001). Cdc25C is normally 
localized in the cytoplasm and translocates to the nucleus just before mitosis (Russell, 
1998; Raleigh and O'Connell, 2000). The mechanism responsible for translocation of 
Cdc25C between cytoplasm and nucleus implicates the association with 14-3-3 proteins 
(not the sigma isoform) (Dalai et al., 1999; Lopez-Girona et al., 1999). When the 
phosphatase is bound to 14-3-3 proteins, it remains cytoplasmic and the dissociation is 
necessary for nuclear import. The region of Cdc25C interacting with 14-3-3 proteins 
contains a phosphorylation site, serine 216, which has been shown to be indeed 
phosphorylated throughout interphase but not during mitosis (Ogg et al., 1994). The 
phosphorylation of serine 216 of Cdc25 is necessary for the association of this 
phosphatase with the 14-3-3 protein. The kinase responsible for the phosphorylation of 
Cdc25C on serine 216 during interphase has been cloned and named C-TAK1 (for Cdc 
Twentyfive C Associated protein Kinase) (Peng et al., 1998). C-TAK1 is ubiquitously 
expressed in the cytoplasm of human cells, where it would facilitate the phosphorylation 
of Cdc25C while it is being synthesised in the cytoplasm. Following stress induction, 
increased phosphorylation of Cdc25C is observed, which prevents activation of
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Cdkl/cyclin B complex and arrests cells in G2 (Dalai et al., 1999; Smits and Medema, 
2001). Depending on the kind o f damage inflicted to the cell, Cdc25C gets 
phosphorylated on ser216 either by the nuclear checkpoint kinase Chkl or Chk2 both 
previously phosphoryated and then activated by the upstream kinases ATM and 
ATR. This phosphorylation creates a binding site for 14-3-3 proteins (as I mentioned 
already) the association of which inhibits Cdc25C by causing its sequestration in the 
cytoplasm and/or masking some residues required for the interaction with cyclinBl- 
Cdkl leading to the G2 block (Nyberg et al., 2002; Dalai et al., 1999; Kumagai and 
Dunphy, 1999; Morris et al., 2000). At first Cdc25C was thought to play the main 
role in regulating the G2-M checkpoint then subsequently it was found that Cdc25 -/- 
mice have a normal G2-M checkpoint (Peng et al., 1997; Chen et al., 2001). Recently 
it has been shown that the 2 other Cdc25 family members, Cdc25A and B are both 
implicated in the G2 DNA damage pathways in unperturbed cell cycle 
progression(Mailand et al., 2002; Donzelli and Draetta, 2003). Cdc25A gets 
stabilized in mitosis through phosphorylations on serl7 and serll5  by CyclinBl- 
Cdkl, thus uncoupling it from its ubiquitin proteasome mediated turnover (Mailand 
et al., 2002). Following DNA damage, Cdc25A gets degraded through a ubiquitin 
proteasome depedent pathway and its phosphorylation on residue of Thr507 by 
Chkl provokes its cytoplasmic exclusion via 14-3-3 binding that in turn prevents its 
association with Cdkl (Chen et al., 2003). This is basically what occurs also in the 
G1 and intra S phase checkpoint, making the Cdc25A pathway the most conserved 
mechanism shared by the three major checkpoints operating at Gl-S, S, and G2-M 
(Bartek and Lukas, 2003; Donzelli and Draetta, 2003; Mailand et al., 2002; Xiao et
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al., 2003). Experimental data evidenced that after UV, the mitogen activated kinase 
p38 gets activated and contributes to the initiation of the G2 checkpoint by 
phosphorylating Cdc25B at ser309 and 361, thus inducing the binding o f the 14-3-3 
protein which prevents the access of substrates to Cdc25B (Bulavin et al., 2001; 
Forrest and Gabrielli, 2001). Studies with specific inhibitors of p38 showed a decrease 
in initiation of G2/M checkpoint following UV radiation (Bulavin et al., 2001). This 
mechanism has been clearly observed following UV radiation, but not with other types 
of damage suggesting that it could represent an example o f “damage specific” 
checkpoint activation. It has been shown that the protein kinase Weel also undergoes 
Chkl dependent phosphorylation on residue ser549. This phosphorylation promotes 
the binding of the 14-3-3 protein that enhances the inhibitory activity o f the kinase 
towards Cdkl consolidating the G2 arrest upon damage (Lee et al., 2001; Rothblum- 
Oviatt et al., 2001).
The regulation of the cyclin B1 localization could also contribute to the G2-M 
checkpoint control. Cyclin B 1 is initially localized in the cytoplasm during S and G2 
phases and traslocates to the nucleus at the beginning o f mitosis (Pines and Hunter, 
1991). The nuclear exclusion during S and G2 is due to the cytoplasmic retention 
signal at the N terminal part o f the protein containing a hydrophobic nuclear export 
signal that binds the nuclear export factor CRM1 (Pines and Hunter, 1994; Li et al., 
1995; Hagting et al., 1998). DNA damage leads to the retention o f cyclin B1 in the 
cytoplasm and distruction o f its nuclear exporting signal would compromise the 
DNA damage induced G2 arrest (Jin et al., 1998). Some studies suggest an additional 
regulation of the G2 block by the two members o f the polo like kinases family
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(PLK), Plkl and Plk3 that play a role in several mitotic events like initiation and exit 
from mitosis and centrosomes function as well (Glover et al., 1998; Nigg, 1998). 
Interestingly the polo like kinase 1 seems to phosphorylate in serl47 cyclinBl thus 
ensuring its nuclear translocation (Jackman et al., 2003; Toyoshima-Morimoto et al., 
2001). Recent experimental evidences attribute to BRCA1 a role in the G2 
checkpoint either through ATM/ATR or directly by activating Chkl. The relevance 
of this protein in this checkpoint is still under further investigation and clarifications 
(Tibbetts et al., 2000; Yarden et al., 2002; Larson et al., 1997; Somasundaram et al., 
1997).
1.5.1 ROLE OFP53 IN  THE G2 CHECKPOINT
Although p53 has been mainly involved in regulating the G1 checkpoint, it has also an 
important role in controlling the G2/M transition (Taylor and Stark, 2001). p53 is able to 
activate the transcription of three distinct genes interfering with the activity o f Cdkl. It 
strongly activates the cdk inhibitor p21 which inhibits the Cdkl kinase activity, although 
p21, as already discussed much less inhibit Cdkl activity compared to other cdks (El 
Deiry et al., 1993). It has been described that p21 interacts with PCNA-Cdkl-cyclinBl, 
thus excluding Cdc25C from interacting with Cdkl to dephosphorylate it for mitotic 
progression (Ando et al., 2001). p21 may also act by blocking CAK which activates 
Cdkl through phosphorylation on thrl61 (Pines, 1995b; Smits et al., 2000). p53 
transcriptionally activates the GADD45a gene (growth arrest and DNA damage 
inducible 45 alpha), which is able to dissociate the complex between Cdkl and cyclin B 
(Wang et al., 1999; Zhan et al., 1999). GADD45, which has specific activity against the
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Cdkl/cyclin B complex, does not efficiently inhibit the activity o f the CDK2/cyclin E 
complex. This fact is likely to be the reason why its role in G1 arrest is negligible (Zhan 
et al., 1999). Immunoprecipitation studies showed that GADD45 associates with Cdkl 
and not with cyclin B, again indicating that it inhibits Cdkl activity by preventing its 
binding to cyclin B (Zhan et al., 1999).
The third p53 downstream gene inhibiting Cdkl activity is 14-3-3 sigma. This gene is 
particularly responsive to p53 in vitro (Hermeking et al., 1997). Its product, the protein 
14-3-3 sigma, inhibits Cdkl activity with a mechanism distinct from those activated by 
p21 or GADD45. The Cdkl/cyclin B complex needs to be present in the nucleus to exert 
its activity and to activate mitosis, through a mechanism involving the binding of 
importin alpha and beta. The 14-3-3a protein is able to bind Cdkl and to anchor the 
complex Cdkl/cyclin B in the cytoplasm (Taylor and Stark, 2001; Chan et al., 1999). 
Prevention of nuclear translocation of Cdkl/cyclin B is sufficient to halt the cells in G2. 
An additional p53 dependent mechanism of G2 arrest is the direct repression of cyclin B 
and Cdkl gene transcription. As already discussed (see chapter 1.3.1.2) not only p53 
activates the transcription of different genes through direct binding to a recognition 
DNA sequence, but it can also repress the transcription of different genes through 
several distinct mechanisms, including squelching of transcription factors, binding to 
proteins, such as the histone acetyl transferase p300 necessary for transcriptional 
activation of certain genes interfering with sequence specific transcription factors 
(Levine, 1997). Among the genes repressed by p53 is cyclin B1 (Innocente et al., 1999; 
Krause et al., 2000). The cyclin B1 promoter region responsible for these effects of p53 
has been mapped. Even for Cdkl there are data suggesting a direct transcriptional
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Figure 1.8 G/M DNA damage checkpoint: molecular players
Schematic representation of the principal molecular mechanisms involved in the 
regulation of the G2-M transition following DNA damage.
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repression by p53, and a promoter region of the Cdkl gene has been mapped and shown 
to be susceptible to p53 (Yun et al., 1999; Taylor et al., 2001).
It has been observed that many cell types that lack p53 still have the ability to 
accumulate in G2 after DNA damage thus indicating that redundant p53 independent 
mechanisms such as the BRCA1 dependent expressiom of p21 and GADD 45 may 
cooperate with the p53 pathway to sustain the G2 arrest (Zhan, 2005). This 
phenomenon has indeed inspired efforts to interfere with the G2 checkpoint as a 
potential strategy to sensitize cancer cells deficient in their G l-S checkpoints 
pathways to radiation or drug induced DNA damage, as I will further discuss in the 
chapter 1.9.
In figure 1.8 the principal components involved in the G2 checkpoint activation and 
just described are summarized.
1.6 MITOTIC SPINDLE CHECKPOINT
During mitosis, the two daughter cells have to receive just one copy o f each 
chromosome. In this phase microtubules organize into a bipolar spindle which 
segregates the duplicated chromosomes (Meier and Ahmed, 2001). A specialized DNA- 
protein complex, known as the kinethochore, allows the attachment of sister chromatids 
to microtubules emanating from opposite poles of the mitotic spindle. When all 
kinetochores have bound microtubules, the mitotic spindle can proceed to pull the sister 
chromatids apart. This process must be tightly controlled because mis-segregation of 
chromatids will lead to aneuploidy (Jallepalli and Lengauer, 2001).
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A surveillance mechanism known as spindle checkpoint is essential to ensure fidelity on 
chromosome transmission. This checkpoint monitors the correct attachment of 
kinethocores to microtubules and inhibits sister chromatids separation, thus onset of 
anaphase, when a defect is detected (Straight, 1997; Allshire, 1997).
The crucial steps in the progression through mitosis are controlled by the disruption of 
the mitotic inhibitory proteins, a phenomenon occuring when these proteins are 
ubiquitinated by APC/C (anaphase promoting complex/cyclosome) and targeted to the 
proteosome for degradation (Morgan, 1999; Harper et al., 2002). Basically, just before 
the end of mitosis the APC ubiquitin ligase coupled to the Cdc20 adaptor protein, 
becomes phosphorylated and thereby activated, by cyclin CDK enzymes. Together with 
ubiquitin carrier proteins (Ubc) the activated APC transfer Ub to several substrates 
including cyclinA and B whose destruction is necessary to complete DNA segregation. 
The two cyclins thus trigger to a chain of events that lead to their own destruction which 
is necessary to initiate the new cell cycle. At the beginning of the following G1 phase, 
the APC swaps its substrate binding adaptor from Cdc20 to Cdhl maintaining APC 
activated to allow complete destruction of mitotic regulators of the previous cycle and 
avoiding their premature accumulation. Before S phase begins, Cdhl is phosphorylated 
and dissociates from APC which gets inactivated re allowing accumulation o f APC 
substrates required for DNA synthesis and next mitotic entry thus closing the cycle 
(Lukas and Bartek, 2004). The mitotic checkpoint directly inhibits the APC/C function 
(Wassmann and Benezra, 2001). Genes able to signal and activate this checkpoint have 
been discovered and include the Mad and Bub genes which have been well characterized 
in Saccharomyces. cerevisiae.
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Mammalian homologs have been recently discovered and also found to play a similar 
role in the mitotic checkpoint (Li and Benezra, 1996; Taylor et al., 1998).
1.7 CHK1 AND CHK2: TWO KEY CHECKPOINT REGULATORS
The mammalian kinases Chkl and Chk2 are two critical messenger o f the genome 
integrity checkpoints well conserved throughout the eukaryotic evolution. They are 
structurally unrelated serine/threonine kinases activated in response to diverse 
genotoxic insults, playing some redundant role by sharing a wide spectra o f known 
substrates involved in the activation of the DNA damage checkpoint response 
(Bartek and Lukas, 2003).
1.7.1 CHK1
The human checkpoint kinase 1 (Chkl) gene was identified in 1997 by Sanchez et al. by 
a degenerated PCR strategy, basing on the already identified gene encoding Chkl in 
Saccharomyces pombe, finding out a very high similarity of this checkpoint gene among 
the eukaryotic kingdom (Sanchez et al., 1997). The function of Chkl has been studied 
both in S. pombe and mammalian cells and found to be similar. In S. pombe, Chkl is 
essential for cell cycle arrest following DNA damage (Lindsay et al., 1998) by activating 
an analogous checkpoint pathway involving the homologs of the mammalian 
ATM/ATR, and Cdc25C as I will describe in the next paragraph.
The chromosomal location of Chkl was mapped to 11 q24 by fluorescence in situ 
hybridization. That is a region adjacent to the one containing the gene encoding
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ATM at llq23 presenting frequent deletions and LOH (loss o f heterozygosity) in a 
numbers o f cancers including breast, ovary and lung. The human protein encoded by a 
cDNA of 1,891 bp, is a nuclear protein of 476 amino acids with a molecular size of 54 
KDa. The predicted human Chkl protein is 29% identical and 44% similar to S. pombe 
Chkl, 40% identical and 56% similar to Caenorhabditis elegans Chkl, and 44% 
identical and 56% similar to Drosophila Chkl (Sanchez et al., 1997). Northern blot 
analysis revealed ubiquitous expression of human Chkl, with large amounts in human 
thymus, testis, small intestine and colon (Sanchez et al., 1997). Chkl protein is 
expressed specifically at the S to M phase of the cell cycle (Kaneko et al., 1999) and is 
absent or expressed at very low levels in quiescent and differentiated cells (Kaneko et 
al., 1999; Lukas et al., 2001). It is activated even in unperturbed cell cycles although it is 
further activated after DNA damage or stalled replication (Sorensen et al., 2004; Zhao et 
al., 2002; Kaneko et al., 1999) and its activation does not require Chkl dimerization and 
autophosphorylation.
Mutations in the Chkl gene are rare in human tumors (than those found with respect to 
other checkpoint genes such as Chk2). The presence of a nucleotide stretch o f nine 
consecutive adenines in the coding region of Chkl led to the hypothesis that tumors with 
defects in mismatch repair and hence with microsatellite instability could accumulate 
mutations around this region. This hypothesis was indeed found to be correct. In tumors 
of the colon and endometrium, in which microsatellite instability occurs frequently, 
insertion/deletion of one nucleotide in the coding region of Chkl could be found 
(Bertoni et al., 1999; Vassileva et al., 2002; Furlan et al., 2002). The insertion/deletion 
of one nucleotide leads to a frameshift mutation that in the case of CHK1 results in a
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protein inactivated and truncated of 243 aa (polyAlO) or 238 aa (polyA8) in comparison 
with the normal length of 476 aa (Bertoni et al., 1999). Those truncated forms are 
predicted to be defective due to the lack o f the C-terminal end o f the catalytic domain 
and the complete loss of the SQ-rich regulatory domain. The mutations 
found were always heterozygous and one wt allele was always present. A shorter 
isoform of Chkl mRNA, predicted to encode a protein which lacks a conserved 
subdomain in the catalytic domain of Chkl which is involved in substrate specificity, 
has been also detected in a subset of small cell lung carcinomas (Haruki et al., 2000). 
Sequence analysis revealed a highly conserved N-terminal kinase domain (residues 1- 
265), a flexible linker region and a less conserved C-terminal region with undefined 
function (figure 1.9).
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Figure 1.9 Structure of human Chkl gene
The kinase domain and the serine/glutamine domains are indicated. N and C indicate the 
amino and carboxy terminal respectively.
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The crystal structure of the human Chkl kinase domain (residues 1-289) revealed 
structural features important for kinase activity and substrate selectivity, suggesting that 
Chkl becomes fully active upon substrate binding, and that its activity is not regulated 
by phosphorylation within the kinase domain (Chen et al., 2000). The crystal analysis 
also suggested a potential regulatory role o f the less conserved C terminal region of 
Chkl which could control the access o f substrates to the Chkl kinase domain by 
interacting with the substrate binding site at the front o f the kinase domain (Chen et 
al., 2000). An oriented peptide library approach could be utilized to define the 
consensus substrate motifs for Chkl kinase protein, as well as for Chk2, as they 
share several substrates (O'Neill et al., 2002). Several independent peptide libraries 
each containing over 108 potential substrates targets were analyzed and gave the 
following consensus sequence motif preference: ®-X-p-X-X-(S/T)-®. ® in position - 
5 and +1 has to be a hydrophobic residue playing an important anchoring function to 
the kinases catalytic pocket according to the crystal Chkl structure (Chen et al., 
2000; O'Neill et al., 2002); X can be any aa residue and p at position -3 would be 
better be a basic aa especially either R or K (O'Neill et al., 2002; Hutchins et al.,
2000). In terms of relative preference for Chkl and Chk2 substrates, positions -3>- 
5 » + l .
1.7.h i  CHK1 FUNCTION
Chkl was originally identified in fission yeast (S. pombe) by genetic studies as a 
protein kinase required to delay entry of cells in mitosis after DNA damage 
(Walworth et al., 1993; al Khodairy et al., 1994; Walworth and Bernards, 1996).
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DNA damage-induced mitotic delay was ascribed in fission yeast primarily by a 
inhibitory Tyrl5 P of Cdkl (O'Connell et al., 2000). In response to DNA damage 
Chkl is activated in a Rad3-dependent manner (yeast homolog of mammalian ATM 
and ATR) (Lopez-Girona et al., 2001), preventing the activation of Cdkl by 
inhibiting Cdc25 phosphatase, a Cdkl activator (Rhind et al., 1997; Furnari et al., 
1999), and stimulating the activity o f the Mik tyrosine kinase, a Cdkl inhibitor 
(Baber-Fumari et al., 2000; Christensen et al., 2000).
In mammalian cells, several experimental data have provided biochemical evidence 
that as in fission yeast Chkl participates in the G2/M DNA damage checkpoint by 
phosphorylating and modulating the activity of the Cdkl regulators Cdc25C 
phosphatase and Weel kinase, relatives of S pombe Cdc25 and Mikl respectively 
(Rhind and Russell, 2000). Additional evidences for an in vivo role for Chkl in the 
mammalian G2/M DNA damage checkpoint come from the observation that Chkl 
deficient embryonic cells (ES) die o f p53-independent apoptosis showing a defective 
G2/M checkpoint (Liu et al., 2000; Takai et al., 2000). Furthermore, analysis of 
Chkl deficient mouse blastocysts revealed that Chkl is indispensable in mammals 
for proper embryogenesis. Chkl null mice, in fact, exhibit embryonic lethality (E6.5) 
due to a preimplantation defect, and this lethality was not rescued in a p53 null 
background (Liu et al., 2000; Takai et al., 2000).
In general, introducing Chkl in the DNA damage transducing signal cascade, as I 
just described, it has to be underlined that it is phosphorylated on ser317 and ser345 
by ATR after UV and replicative stress and these phosphorylaton events are required 
to amplify the signal to downstream targets (Sorensen et al., 2003; Zhao et al., 2002).
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ATR mediated phosphorylation of Chkl requires the DNA binding protein claspin, 
which may be responsible of the recruitment of Chkl to the DNA lesions where ATR 
resides (Kumagai and Dunphy, 2000). The main Chkl target proteins are the Cdc25 
phosphatases which regulate the cell cycle progression by activating the cyclin 
dependent kinases (CDKs) (Sanchez et al., 1997; Furnari et al., 1997). Chkl 
mediated phosphorylation and inhibition o f Cdc25 phosphatases (thereby cdks) has 
been implicated in cell cycle checkpoint control of G1/S-S-G2/M phases as I 
mentioned in the previous sections (Sorensen et al., 2003; Zhao et al., 2002; Mailand 
et al., 2000; Mailand et al., 2002; Sanchez et al., 1997; Furnari et al., 1997). Recently 
it has been shown that the standard parallel subdivision of Chkl activation by ATR 
after UV and replicative stress and by ATM after IR exposure is not valid anymore. 
In fact, in a recent paper (Jazayeri et al., 2006) it was shown that in response to IR, 
ATM and ATR function in the same pathway leading to Chkl phosphorylation. ATM 
and its regulatory partner Nbsl would promote DSB induced ATR dependent Chkl 
phosphorylation by regulating the formation of RPA coated ssDNA that is required 
for ATR recruitment to sites o f DNA damage. These events also require M rell 
nuclease activity implying another link between ATM and ATR and new important 
implications of the understanding o f how checkpoint activation is coordinated with 
DSB repair. It is to mention that data also attested a connection between Chkl and 
the homologuos recombination repair protein rad51 (Sorensen et al., 2005).
Recent data showed that after Chkl activation by agents that induce replicative 
stress, such as CPT, a time dependent down regulation o f the activated protein 
subsequently occurred in both normal and transformed cell lines. Basically the ATM
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dependent phosphorylation in ser345 would serve also as a target for subsequent 
Chkl polyubiquitination and proteasomal degradation thus limiting the duration of 
Chkl signaling during low intensity replication stress and preventing the active 
protein kinase from accumulating to levels that would be deleterious to normal S 
phase progression. The targeted destruction of activated Chkl may have the meaning 
to limit the duration of ATR dependent S phase checkpoint during the normal cell 
cycle. The temporal delay between Chkl activation and the onset o f Chkl 
ubiquitination is due to the time required for the mobilization of activated Chkl from 
chromatin to the soluble nuclear compartment where Chkl meets the Cull/cul4a 
complex containing E3 ligases. The delayed degradation of Chkl presumably allows 
sufficient time for the activated protein kinase to exert its protective effect at stalled 
forks prior to its modification by the E3 ligases (Zhang et al., 2005).
1.7.1.2 ROLE OF CHK1 IN  CHECKPOINTS ACTIVATION AND CELL PHYSIOLOGY: NEW  
EXPERIMENTAL SYSTEMS LACKING CHK1 
In these past few years a lot of research has been focused on the attempt to create 
experimental systems lacking the Chkl function in order to better understand its role 
in the cell physiological context to provide a clearer insight in its involvment in the 
DNA damage checkpoints. RNAi mediated knockdown of Chkl in human cells 
confirmed its requirement in the G2-M checkpoint in response to IR and some other 
DNA damaging agents (Gatei et al., 2003; Xiao et al., 2003) and revealed an 
essential role o f this kinase in the control o f Cdc25A protein turnover in both normal 
S phase and the intra S phase DNA damage checkpoint (Sorensen et al., 2003; Zhao
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et al., 2002). A nice contribution to the understanding o f the role of Chkl in somatic 
vertebrate cells was supported by Zachos et al. with the construction by gene 
targeting o f the avian B-lymphoma DT40 cell line Chkl -/- (Zachos et al., 2003). 
Chkl is not essential for the viability of vertebrate somatic cells under normal 
culture conditions, similarly to what it was observed in yeast, although they grow 
slowly probably because of an increase incidence of apoptotic cell death (p53 
independent as these cells do not have p53). This is in contrast to what have been 
observed in early development in both mouse and Drosophila, suggesting additional 
specific functions for Chkl during embryonic development no longer required in 
somatic cells. The avian Chkl-/- cell line fails to arrest in G2 after exposure to IR, 
supporting the previous observations just described and confirming a crucial role for 
Chkl in activating the G2/M checkpoint after DNA damage. These Chkl deficient 
cells were more sensitive to DNA damage agents and DNA synthesis inhibition, 
showing that some Chkl dependent processes promote cell survival after DNA 
structure or metabolism perturbations. In order to elucidate the role of Chkl in the S- 
M checkpoint control in vertebrate cells, the effect o f DNA synthesis inhibition on 
mitotic entry was investigated in the Chkl-/- DT40 cell line. It was observed that 
cells deficient in Chkl enter mitosis with incompletely replicated DNA, when DNA 
synthesis is inhibited, but only after an initial delay. This mitotic entry is associated 
with an induction of Cdkl catalytic activity which occurs in the absence o f any loss 
of Cdkl tyrl5 phosphorylation. Mitotic entry from S phase would be due to the loss 
of the capacity to synthesize DNA even though DNA replication in these cells 
remains incomplete (Zachos et al., 2005) probably because of the degeneration o f
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viable replication structures which are normally stabilized by Chkl during 
replication arrest (Zachos et al., 2003; Feijoo et al., 2001). Chkl would so maintain 
the S-M checkpoint indirectly by stabilizing viable replication structures whose 
presence contributes to delay mitosis in vertebrate cells until DNA replication is 
complete.
Additional observations were conducted on DT40 Chkl -/- after the release from a 
shorter replication arrest, consisting o f 8h exposure with aphidicolin instead o f 12h. 
At first it was observed that the shorter replication block did not inhibit the S-M 
checkpoint in Chkl-/- cells that delay the mitosis as well as wt cells. Moreover after 
aphidicolin release the majority of Chkl-/- cells fails to enter mitosis, being unable 
to recover from replication arrest, which had caused DNA damage. It was also shown 
that after release, the replication forks which were active prior to aphidicolin 
treatment in Chk-/- cells got progressively unable to resume replication and new sites 
of replication, futile origin firing, progressively accumulated. This was not observed 
in the wt cells providing a genetic proof that Chkl is essential to maintain the 
viability o f stalled replication and suppress origin firing when DNA synthesis is 
inhibited (Zachos et al., 2003). Taken together these evidences demonstrate that 
Chkl is essential for the recovery from replication arrest and that in contrast to its 
secondary role in fission yeast (Sanchez et al., 1999), Chkl dependent replication 
checkpoint functions are important determinants of vertebrate cell survival under 
conditions o f DNA synthesis ihibition. These data further confirm observations 
regarding the putative role played by Chkl on replication checkpoint, as for example 
the observation that Xenopus Chkl is activated by replication arrest and is required
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to prevent premature mitosis in egg extracs in vitro (Kumagai et al., 1998; Michael et 
al., 2000). Chkl deficient mouse blastocysts were found to undergo premature 
mitosis when DNA synthesis was inhibited with aphidicolin suggesting a role of 
Chkl in S-M checkpoint in vivo (Takai et al., 2000). Furthermore, a selective 
inhibitor of Chkl (UCNOl) impaired the replication fork viability and disturbed the 
control o f origin firing in mammalian cells when DNA synthesis was inhibited 
(Takai et al., 2000; Feijoo et al., 2001).
To investigate the role of Chkl in adult tissue and its role in tumorigenesis, a mouse 
conditional KO for Chkl in the mammary gland was generated (Lam et al., 2004). It 
was observed that Chkl was essential for mammary epithelial cell growth; in 
addition the phenotype appeared strong also in the heterozygous background 
suggesting a possible role of Chkl (-/+) as a haploinsufficient tumor suppressor. 
Briefly in the haploinsufficient tissues it was observed an inappropriate entry into S 
phase, an accumulation of DNA damage during replication and a failure to restrain 
mitotic entry in the presence of damaged S phase. The inappropriate entry in S phase 
could be explained by a possible role played by Chkl in regulating the Gl-S  
transition through its direct control o f Cdc25A protein levels. With lower levels of  
Chkl cells could inappropriately exit G1 because o f the increase o f Cdc25A levels 
which accelerate the Gl-S transition through a premature activation of cyclin E and 
A dependent kinases. The accumulation of spontaneous DNA damage during S phase 
was underlined by the accumulation o f a high number of foci containing MDC1, 
53BP1 and pH2AX proteins in the Chkl+/- tissues. Physiological Chkl protein 
levels could play a critical role in the regulation o f DNA replication (Feijoo et al.,
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2001; Lee et al., 2003) thus haploinsufficiency for this function would lead to 
inability to properly repair replication problems resulting in the accumulation of 
damage at replication structures, further corroborating the already discussed data on 
Chkl’s critical role in DNA replicational stress (Zachos et al., 2003; Zachos et al., 
2005; Feijoo et al., 2001). The increased levels o f Cdc25A in haploinsufficient 
systems can override the restraint of mitotic entry during S phase, by activating 
Cdkl/CyclinB complexes during S phase, which causes the inhibition o f PP1 (protein 
phosphatase 1) and the accumulation of Aurora B driving cells into mitosis (Goto et 
al., 2002; Sugiyama et al., 2002). These data would suggest for Chkl a role as a 
haploinsufficient tumor suppressor and imply that inactivation o f a single Chkl allele 
in human tumors by mutation, chromosomal deletion, or epigenetic silencing may be 
a common source of genomic instability driving tumorigenesis.
To further corroborate these last observations, recently Bartek J. and his group 
showed in Chkl inactivated human cells (by siRNA or inhibitors) how Chkl plays an 
important role during normal S-phase progression by minimizing the occurrence of 
aberrant replication-associated events (Syljuasen et al., 2005). In response to Chkl 
inhibition, Cdc25A is stabilized leading to an increase of CDKs activity related to 
increased initiation o f DNA replication, measured by increased loading o f Cdc45 
protein to chromatin and an increased rate of DNA synthesis. This is accompanied by 
an increased binding of RPA to ssDNA with subsequent ATR activation and 
phosphorylation of its targets. During this process DNA is destabilized leading to 
formation o f DNA strand breaks. An alternative possibility is that in response to 
Chkl inhibition, replication forks may collapse due to a lack of Chkl mediated
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maintenance o f stalled replication forks during normal S phase progression, thus 
resulting in the formation o f ssDNA and DNA breaks and phosphorylation o f ATR 
targets (Syljuasen et al., 2005). These data would suggest that these human cellular 
models behave differently from the highly genetically unstable chicken cells used in 
Zachos’s experiments.
1.7.1,2,1 Chkl, centrosomes and mitotic entry control
It has been recently observed that the Chkl protein localized not only in the nucleus 
but also in the centrosomes of interphase cells suggesting a new Chkl involvment in 
the regulation o f mitotic entry in unperturbed cell cycle progression (Kramer et al., 
2004). According to these data, Chkl dissociates from centrosomes at the onset of 
prophase concomitant with centrosomes separation. As Chkl controls Cdkl activity 
during normal unperturbed cell cycle progression (Hu et al., 2001) and the 
disappearance of Chkl from centrosomes correlates with Cdkl activation, it is likely 
that a centrosome associated pool of Chkl works as a negative regulator of 
centrosomal Cdkl. It was previously observed that Cdkl-cyclinBl accumulates at 
the centrosomes during interphase where initial activation o f the complex occurs in 
late prophase (Bailly et al., 1989; Bailly et al., 1992; Jackman et al., 2003). Those are 
the initial activation of Cdkl by dephosphorylation of tyrl5 (De Souza et al., 2000) 
and o f Cyclin B by phosphorylation of serl26 and serl33 (Jackman et al., 2003). 
Experimental evidences attributed to Cdc25B phosphatase the role o f the initial 
activation of the mitotic complex Cdkl/CyclinBl at the centrosomes during 
unperturbed cell cycle progression. In fact this phosphatase has been reported to
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localize to the centrosomes during mitosis after being phosphorylated on ser353 by 
aurora A kinase (Dutertre et al., 2004). Basically the idea is that positive and 
negative pathways for the initiation o f mitosis are integrated at the centrosomes with 
Cdc25B-CyclinB Cdkl acting as common downstream targets and Aurora A and 
Chkl upstream positive and negative regulators respectively. During interphase 
centrosomal Chkl would keep the complex in an inactivated form by negatively 
regulating Cdc25B; at the onset of prophase, when Chkl is detached from 
centrosomes, Cdc25B is phosphorylated and activated by the centrosomal Aurora A 
thus ensuring mitosis by its recruitment in the centrosomes and subsequent activation 
of the centrosomal Cdkl-cyclinBl (Dutertre et al., 2004).
These evidences indicate that mammalian centrosomes might have an important role 
in regulating cell cycle progression from G2 phase into mitosis in addition to the 
already postulated functions in cytokinesis and Gl/S transition.
1,7,1,2.2 Biology o f  centrosomes
The centrosome is a small non membranous organelle (1-2 pm in diameter) normally 
localized at the periphery of nucleus. Its primary function is to anchor microtubules, 
in fact it is often denoted as a major microtubule organizing center (MTOC). In 
animal cells the centrosome consists of a pair of centrioles and a number o f different 
proteins surrounding the centriole pair called pericentriolar material (PCM) 
(Paintrand et al., 1992).
The centrioles differ from each other as one of those present a set o f appendages at 
the distal ends (mother centriole) while the other one does not have appendages
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(daughter centriole). The appendages appear to be essential for anchoring 
microtubules and the daughter centriole acquires them in late G2 phase o f the cell 
cycle (Bornens, 2002).
During interphase centrosomes organize the cytoplasmic microtubule network which 
is involved in vescicle transport, proper distribution o f small organelles, control of 
cellular shape and polarity.
During mitosis, centrosomes become the core structures of spindle poles and direct 
the formation of bipolar mitotic spindles which is an essential event for accurate 
chromosome segregation into daughter cells.
Since each daughter cell receives only one centrosome upon cytokinesis, the 
centrosome, like the DNA, must duplicate once prior to the next mitosis. DNA and 
centrosomes represent the only two organelles that undergo semiconservative 
duplication once every single cell cycle.
At this regard, animal cells are equipped with a mechanism that coordinates these 
two events, likely to ensure these two organelles to duplicate only once (Mazia, 
1987).
Centrosome initiates duplication by physical separaton of the paired centrioles at 
Gl/S transition.
In the proximity of each pre existing centriole a procentriole progressively elongate 
during S and G2 and two centrosomes continue to mature by recruiting PCM. By late 
G2 two mature centrosomes are generated (figure 1.10).
The initiation o f DNA and centrosomes duplication is coupled by the activation of 
CDK2/cyclinE (Lacey et al., 1999; Matsumoto et al., 1999). The presence o f more
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Figure 1.10 Centrosomes duplication
Schematic representation o f the centrosomes duplication cycle o f every single cell 
cycle. (Modified by Fukasawa, 2005)
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than two centrosomes (centrosome amplification), severely disturbs mitotic 
progression and cytokinesis via formation of more than two spindle poles, resulting 
in an increased frequency o f chromosome segregation errors (chromosome 
instability). Destabilization o f chromosomes by centrosome amplification aids 
acquisition of further malignant phenotypes, thus promoting tumor progression 
(Fukasawa, 2005).
1,7.2 CHK2
Chk2 was at first identified in 1994 in budding yeast as a kinase involved in many 
checkpoint responses and called Rad53 (Allen et al., 1994). Homologs o f Rad53 
were subsequently found in the fission yeast and in higher eukaryotes (Murakami 
and Okayama, 1995; Brown et al., 1999). The overall structure of Chk2 proteins is 
similar in all eukaryotes with a degree of homology of the protein sequence across 
species that roughly reflects the evolutionary distance among the different organisms. 
The human protein encoded by the human cDNA of 1,731 bp, is a nuclear protein o f 543 
amino acids with a molecular size of 60 KDa. The Chk2 protein consists of three distinct 
functional domains (figure 1.11 A). The N-terminal domain contains the SQ/TQ cluster 
domain (SCD, residues 19-69) with five SQ and two TQ motifs which satisfy the 
primary substrate motif for ataxia-telangiectasia mutated (ATM) kinase (Kim et al., 
1999), especially the residues 67-70 STQE containing the key phosphorylatable site 
Thr68 (O'Neill et al., 2000). The central forkhead associated domain (FHA, residues 
112-175), conserved from yeast to human, consists of 11 beta sheets forming a structural 
core and connecting loops conferring diversity in phosphopeptide recognition. It works
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in trans to modulate protein-protein interactions but also in cis to affect other functional 
domains within the protein itself (Li et al., 2000). The C-terminal Ser/Thr kinase domain 
(residues 220-486) which shares homology to other Ser/Thr or Tyr kinases, related to the 
Ca2+/ calmodulin dependent protein kinase (CaMK) family. Differently to the 
expression of Chkl restricted to S-G2-M phases, Chk2 remains stably expressed and can 
become activated upon DNA damage in all phases of the mammalian cell cycle as well 
as in non proliferating and terminally differentiated or quiescent cells. In humans Chk2 
is homogenously or heterogeneously nuclear expressed in all the tissues with the 
exception of neuronal cells with a predominant cytoplasmic localization (Lukas et al.,
2001). Accumulating experimental evidences attributed to Chk2 a role of tumor 
suppressor. The first indication of a tumor suppression function for Chk2 came from the 
finding of rare germline mutation in the Chk2 gene in families with Li Fraumeni 
syndrome (LFS), a familial cancer predisposition syndrome usually associated with 
germline p53 mutations (Evans and Lozano, 1997). This Chk2 mutation confers 
increased breast cancer risk independent of mutation in the breast cancer susceptibility 
associated loci (BRCA) (Vahteristo et al., 2002; Meijers-Heijboer et al., 2003; Meijers- 
Heijboer et al., 2002). Several other missense mutations could be found in all three 
functional domains in a variety of tumor types (Sodha et al., 2002; Schutte et al., 2003) 
with different functional impact depending on the location of the mutation.
1.7.2.1 ACTIVA TIONAND FUNCTION OF CHK2
Chk2 gets largely activated following DNA damage induced by IR and different 
DNA damaging agents. ATM is mainly involved in its activation as multiple lines o f
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evidence suggested (Matsuoka et al., 1998; Brown et al., 1999; Chaturvedi et al., 
1999). ATM directly phosphorylates Chk2 at thr68 in vitro and alanine substitution 
of this residues prevented activation o f Chk2 after IR in vivo (Ahn et al., 2000; 
Melchionna et al., 2000). Chk2 may also be activated by ATR after high levels of 
damage, UV and HU (Matsuoka et al., 2000). The inactive Chk2 exists as a monomer 
and upon DNA damage it gets phosphorylated in thr68 and undergoes dimerization 
with a region spanning phosphorylated Chk2 at thr68 in one Chk2 molecule binding 
to the FHA domain of second molecule (figure 1.1 IB) (Ahn et al., 2002; Ahn and 
Prives, 2002). Dimerization is followed by multiple intermolecular phosphorylation 
events including thr383 and thr387 within the autoinhibitory loop resulting in kinase 
activation (Lee and Chung, 2001). The phosphorylation in thr68 appears to be 
necessary for the first dimerization and activation while its maintenance is not 
required for sustained kinase activity (Ahn and Prives, 2002), although it appears to 
be important for the association of other checkpoint proteins as for example MDC1. 
As I just described for Chkl, an oriented peptide libraries analysis allowed to picking 
up the phosphorylatable consensus motif of Chk2 which is basically the same as the 
one described for Chkl. The main Chk2 substrates are the two members o f the cell 
division cycle 25 dual specificity phosphatase family, Cdc25A and Cdc25C. Cdc25A 
is destabilized by Chk2 phosphorylation at serl23 (Falck et al., 2001; Sorensen et al., 
2003) most likely by increasing susceptibility to the beta SCFtcrp complex which 
mediates Cdc25A turnover (Busino et al., 2003; Jin et al., 2003). Chk2 
phosphorylation of ser216 in Cdc25C creates a binding site for 14-3-3 proteins 
resulting in persistent cytoplasmic Cdc25C localization thus preventing the G2-M
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Figure 1.11 Structure and activation of human Chk2
Chk2 functional domains (A) and a model o f Chk2 activation following DNA 
damage (B). (Modified by Ahn J. et al. 2004)
62
transition as the Cdkl/cyclinBl can not be activated (Peng et al., 1997; Dalai et al., 
1999). Chk2 phosphorylates E2F1 at ser364 in response to DNA damaging agents 
thus regulating both E2F1 stabilization and transcriptional activity (Stevens et al., 
2003) which is strictly related to the regulation o f the apoptotic pathway after DNA 
damage. It has been shown that both BRCA1 and PML can interact with Chk2 and 
may be phosphorylated by Chk2 following DNA damage (Lee et al., 2000; Yang et 
al., 2002). In particular Chk2 interacts with both the substrates in the absence of 
DNA damage and phosphorylates them after DNA damage resulting in subsequent 
inhibition of binding with Chk2 thus ensuring the activation of other Chk2’s 
substrates. It has been shown that BRCA1 and Nbsl component o f the MRN 
complex are required for ATM dependent activation o f Chk2 after DNA damage 
(Foray et al., 2003). Many other newly discovered checkpoints mediators are 
involved in the Chk2 activation pathway such as 53BP1 and MDC1, with 
mechanisms that have still to be clearly elucidated (Fernandez-Capetillo et al., 2002; 
Stewart et al., 2003; Hirao et al., 2002).
Differently to Chkl KO mice, Chk2 deficient mice are viable, fertile and do not 
show a tumor prone phenotype except when exposed to carcinogens (Hirao et al., 
2002; Takai et al., 2002). Although there are some discrepancies in the results among 
different studies with Chk2 deficient mice and cells derived from them, the observed 
phenotype is dominated by the increased resistance of the Chk2-/- mice to IR, 
cellular defects in p53 function and in some checkpoint responses including 
apoptosis. Recently, in contrast to what was observed in cells lacking Chkl, it was 
shown that cells lacking Chk2 did not enter mitosis prematurely with incompletely
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replicated DNA when DNA synthesis is blocked (Zachos et al., 2005). This is also in 
contrast to what was observed in budding and fission yeast, where Rad53 and cdsl 
(Chk2 homologs) are activated when DNA synthesis is inhibited and are considered 
to be the primary effectors of mitotic delay when replication is blocked (Santocanale 
and Diffley, 1998; Kim and Huberman, 2001).
It was recently shown that Chk2 can interact with the Polo Like Kinase 1 (PLK1), a 
centrosome associated kinase implicated in mitotic progression colocalizing with this 
protein in the centrosomes. Interestingly PLK1 can phosphorylate residues in the N- 
terminus of Chk2 including Thr68 (Tsvetkov et al., 2003). The related kinase PLK3 
also interacts with Chk2 and phosphorylation of Chk2 and PLK3 by one another has 
been reported (Xie et al., 2002; Bahassi et al., 2002).
1.7.3 CHK1 AND CHK2 INTER-RELATIONSHIP WITHp53 AN Dp73
The cell cycle checkpoint kinases Chkl and Chk2 have been shown to phosphorylate 
multiple sites in the N terminal domain of p53 leading to p53 stabilization and 
activation (Shieh et al., 2000; Chehab et al., 2000; Meek, 1998). Recently, additional 
Chkl and Chk2 phosphorylatable sites have been identified in the C-terminal domain 
of p53, upon DNA damage (Hirao et al., 2000). These C terminal phosporylations 
would differentially regulate C terminal p53 acetylations thus having a role in the 
differential p53 downstream target genes. Although it is probable that Chkl and 
Chk2 are involved in the N terminal phosphorylations in vivo, gene KO or ablation 
by siRNA in certain cancer cell lines questioned this possibility (Ahn et al., 2003; 
Jallepalli et al., 2003). For example it was shown that the elimination of Chk2 by
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gene KO or its downregulation by siRNA resulted in only partial or no defects in the 
DNA damage induced phosphorylation and stabilization o f p53. This is also 
consistent with the Chk2-/- mice model proposed by Takai et al. where only a 30- 
50% reduction in p53 stabilization was observed and human p53 introduced in MEFs 
Chk2-/- resulted phosphorylated normally after IR, indicating that in murine tissue, 
Chk2 makes a partial contribution to p53 stabilization while other factors clearly 
contribute (Takai et al., 2002). No G2 or S phase checkpoint was observed in this 
Chk2 null mice model but they did observe a deficient Gl-S arrest consistent with 
impaired p53 signaling. Moreover the p53 derived peptide containing the Chk2 
targeted phosphorylated sites thrl 8 and ser20 is a poor substrate for Chk2 and do not 
fit with the consensus sites found in other Chk2 substrates, thus increasing the 
controversial effective role of Chk2 in phosphorylating p53 in vivo.
In fact the N-terminal activation domain o f p53 does not contain the classical 
substate motif o f Chkl and Chk2 and the physiological tetrameric form of p53 seems 
to be required for an efficient phosphorylation of thrl 8 and ser20 o f p53 by these two 
kinases (O'Neill et al., 2002; Seo et al., 2003). Furthermore it turns out that to be 
efficiently phosphorylated by Chkl and Chk2, p53 requires physical binding to 
docking sites in its central domain inducing allosteric changes in Chkl and Chk2 
(Craig et al., 2003).
A strict relationship between Chkl and p53 has been put forward by two different 
groups (Damia et al., 2001; Gottifredi et al., 2001), suggesting that upon damage 
Chkl phosphorylates and activates p53, that is then able to induce a downregulation 
of Chkl. This is likely to occur in cells with moderate damage, in which repair of the
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lesion has occurred and hence the cell cycle needs to be restarted after the transient 
block. It has been shown that the p53 dependent repression of Chkl requires the 
transactivation function of p53 and is mediated by p21 and pRB (Gottifredi et al., 2001). 
The strong p53 dependent decrease of Chkl protein levels at late time points after drug 
treatments together with a related observation that cell lines with a wt p53 express lower 
levels of Chk2 compared with mutant p53 expressing cells (Tominaga et al., 1999), can 
be considered the way the cells tend to abrogate the G2 block induced by anticancer 
treatments. This phenomenon is consistent with the observation that in cancer cells 
lacking p53 there is a more prolonged and sustained arrest in the G2 phase of the cell 
cycle than in cells expressing a functional wild-type p53 (Pollack et al., 1996; Sugiyama 
et al., 2000). This subtle inter relationship existing between p53 and Chkl suggests how 
the different molecular components participating in the cell cycle checkpoint cascade 
activated upon DNA damage can be closely linked. This is further confirmed by the 
recent data establishing an inter-relationship among Chkl, Chk2 and p53 related gene 
p73. It has been shown that Chkl and Chk2 control the induction of the p53 related 
transcription factor p73 following DNA damage, through the modulation of the 
stabilization and activation of E2F1, which is involved in the activation o f the TAp73 
promoter (Urist et al., 2004). It was previously observed indeed that the E2F1 
transcription factor can induce p73 mRNA and p73 is required for E2F1-induced 
apoptosis (Irwin et al., 2000; Lissy et al., 2000; Stiewe and Putzer, 2000). Consequently 
the ability of Chkl and Chk2 to regulate the expression of E2F1 a factor involved in the 
regulation of TAp73 transcription, is critical for induction of p73 and for their indirect 
role in apoptosis as well. Furthermore Chkl but not Chk2 was recently shown to
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phosphorylate in vitro and in vivo p73 at ser47 (Gonzalez et al., 2003), after DNA 
damage, thus possibly contributing to the p73a apoptotic response to DNA damage.
1.8 E2F FAMILY IN  CELL CYCLE REGULATION AND 
CHECKPOINTS
The E2F family is a very important group of transcription factors linked with cell 
cycle control and apoptosis. The founding member E2F1 was discovered in 1980 as a 
transcriptional activator of the adenovirus E2 promoter (Kovesdi et al., 1986), then 
the family grew through the addition of new members in mammals and the discovery 
of homologs in other eukaryotes.
1.8.1 E2F FAMILY MEMBERS ORGANIZATION AND REGULATION
The E2F family consists o f eight proteins in mammals: E2F1-6 are the older and 
better characterized members, while E2F7 and E2F8 have been only recently 
identified (de Bruin et al., 2003; Maiti et al., 2005), bearing only little homology 
with the rest of the family members. The established six components (E2F1-6) 
possess N terminal DNA binding domain and dimerization domains with the marked 
box, a conserved region involved in dimerization and DNA bending. They all have a 
C terminal transactivation domain (with the exception of E2F6) containing the 
pocket protein binding region. The E2F family is divided into three groups based on 
their different homology. E2F1-3 constitutes the activating group due to their ability 
to induce S phase entry in quiescent cells and get arrested by the pl6ink4a cdk
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inhibitor (CDKI) (Johnson et al., 1993; DeGregori et al., 1997; Lukas et al., 1996). 
On the other hand E2F4 and 5 constitute the repressor group which is important for 
cell cycle exit and terminal differentiation processes (Fajas et al., 2002). Finally 
E2F6, has a unique ability to interact with members of the mammalian polycomb 
complex (PcG) and not with the pocket proteins like the other members do (Morkel 
et al., 1997; Cartwright et al., 1998). Functional E2F depends on the formation of 
heterodimers with members of the DP family of transcription factors, which have 
significant homology with E2Fs sharing the dimerization and DNA binding domains 
(Girling et al., 1993). The cooperation between E2F and DP is suggested to optimize 
DNA binding activity in a synergistic fashion (Bandara et al., 1993; Krek et al., 
1993). The E2F cell cycle activity is mainly dependent on the phosphorylated state of 
the pocket proteins. The pocket protein family includes the retinoblastoma protein, 
pRb, which is the most prominent member, p i07 and p i30 (Classon and Harlow, 
2002; Zhu et al., 1993; Cobrinik et al., 1993). They all share the ability to regulate 
cell cycle progression and arrest cells in G1 when they are overexpressed (Qin et al.,
1992). Interestingly pRb deficient mice die in the embryogenesis while p i07 and 
p i30 deficient mice do survive thus not behaving as classical tumor suppressor. 
Generally when a pocket protein is hypophosphorylated, it can physically associate 
and inactivate E2F. The pocket protein/E2F-DP complex is guided to E2F binding 
sites in different promoters where it can recruit histone deacetylases (HDACS) and 
suppress transcription by remodeling the nucleosome (Ferreira et al., 1998; 
Magnaghi-Jaulin et al., 1998). The first and most important pocket/E2F interaction 
detected was that between pRb and E2F1 (Helin et al., 1993). E2F gets activated
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when cyclin/CDKs phosphorylates the pocket protein relieving E2F from its 
inhibitory effect, having next the ability to interact with histone acetyltransferase 
(HAT), which can act as coactivator (Brehm et al., 1998). E2F1-3 bind selectively to 
pRb, while E2F5 binds to p i30 and E2F4 interacts with all pocket proteins (Dyson, 
1998). Other than the pocket protein interaction as E2F regulation, this family 
present additionally subtle regulator aspects, such as transcriptional control, 
subcellular localization and post translational modifications. It has been shown that 
the transcription of activating E2Fs is subjected to an E2F dependent self inhibitory 
loop regulation (Araki et al., 2003; Adams et al., 2000). CyclinA/CDK2 
phosphorylates E2F1 at serine 375 and increases its binding affinity for pRb (Peeper 
et al., 1995). On the other hand phosphorylation at ser403 and thr433 within the 
activation domain by the basal TF TFHII triggers E2F degradation (Vandel and 
Kouzarides, 1999). ATM/ATR dependent phosphorylation of E2F1 induces its 
activity by inhibiting its degradation through the action of the phosphoserine protein 
14-3-3 tau (Wang et al., 2004). Additionally, E2F can be posttranslationally modified 
by acetylation with probable effect to increase their halflives and DNA binding 
activity (Marzio et al., 2000; Martinez-Balbas et al., 2000).
1.8.2 E2F FAMILY FUNCTIONS
The E2F family, especially the founding member E2F1, has to be considered as a 
central component of the cellular machinery that regulates a wide spectrum of genes 
involved in various functions. In fact a great number o f genes implicated in cell cycle 
control, DNA licensing and synthesis, mitosis DNA repair and apoptosis contains the
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E2F responsive site in their promoter ( [T/C]TT[C/G][G/C]CG[C/G]) (Slansky et al.,
1993). The most studied and best understood function o f E2F is its ability to regulate 
the Gl/S transition and S phase entry during the cell cycle. During GO and early G l, 
E2F activity is mediated by E2F4 and 5 which are bound preferentially to p i30 
exerting an inhibitory effect on the E2F responsive genes. At the same time the 
activator E2Fs are bound and inactivated by pRb. As the cells progress in late Gl 
phase, pRb and p i30 are phosphorylated at first by cyclinD/CDK and later by 
cyclinE/CDK thus releasing the activating E2Fs (Lundberg and Weinberg, 1998). It’s 
noteworthy to underline that E2F is not only a simple regulator o f the G l/S transition 
transcriptional machinery and this is evidenced by the finding that many putative 
E2F target genes have functions required for mitosis (DeGregori, 2002). These 
include genes with functions in centrosomes duplication, spindle checkpoints, 
chromosome condensation and segregation, cytokinesis and centromeric proteins. 
Mad2, a known E2F target gene involved in spindle checkpoint appears 
misexpressed in cells with deregulated E2F activity and this leads to mitotic defects 
and aneuploidy (Hernando et al., 2004). Experimental evidences attributed to E2F a 
role in the inhibition o f the anaphase promoting complex further confirming its 
crucial role in cell cycle progression (Garbe et al., 2004). Furthermore it has been 
shown that E2F3 inactivation leads to centrosomes amplification, mitotic spindle 
defects and aneuploidy suggesting that E2F3 functions to coordinate the DNA 
replication with the centrosome duplication cycle (Saavedra et al., 2003). Several 
experimental evidences suggested a functional role for E2F1 in the DNA damage 
response. E2F1 protein levels increase in cells treated with DNA damaging agents and
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this induction can be attributed to an increase stability of the protein principally due to 
its phosphorylation at ser31 by ATM and ATR and additionally to the phosphorylation 
at ser364 by Chk2 upon DNA damage (Stevens et al., 2003). Damage induced E2F1 
activity can result in p53 dependent apoptosis through both the expression of  
proapoptotic p53 cofactors and by inducing the expression of p i 4. The apoptotic activity 
of E2F1 can also occur by p53 independent mechanisms through p73, caspase ,9 and 
the pro apoptotic members of the Bcl2 family (Stiewe and Putzer, 2000; Seelan et al., 
2002; Nahle et al., 2002; Hershko and Ginsberg, 2004). Interestingly the p73 
promoter region contains at least three E2F1 binding sites and the enforced 
expression of E2F1 strongly stimulates the transcription of p73 through the direct 
binding to the E2F1 responsive elements in the p73 promoter (Irwin et al., 2000; 
Stiewe and Putzer, 2000). The E2F1 mediated regulation o f p73 results in a 
significant induction of apoptosis. E2F1 acetylation is required to induce p73 
transcriptional activation (Pediconi et al., 2003).
Several studies had also suggested a role for E2F in checkpoint control. Upon DNA 
damage and ATM phosphorylation, the transcriptional activity, the apoptotic and the 
S phase inducing activities o f E2F1 are inhibited by binding to TopBPl which 
recruits E2F1 to BRCA1 containing nuclear foci. Furthermore E2F1 has been 
implicated in the recruitment of the M rell recombination repair complex to origins 
of DNA replication, suggesting a direct role for E2F1 in DNA damage checkpoint or 
repair (Liu et al., 2003).
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1.9 DNA DAMAGE CHECKPOINT PATHWAYS AND CANCER 
THERAPY
Current approach in cancer therapy to obtain more encouraging clinical response, 
focuses on the identification o f specific molecular targets against which drugs can be 
developed. Cancer is a complex disease caused by many genetic abnormalities, so 
interfering with a single target might not be sufficient to produce a response. On the 
other hand many tumors share similar characterisitcs such as genetic instability and 
high proliferative rates which can be targeted by various DNA damaging agents. 
Anticancer agents targeting DNA are the most effective in clinical use and have 
produced significant increases in the survival of patients with cancer when used in 
combination with drugs that have different mechanisms of actions. These agents can 
be divided into four main classes: alkylating agents (such as cis-platinum), anti 
metabolites (such as 5-FU), topoisomerase inhibitors (such as etoposide) and 
radiomimetics (such as bleomyicin). Despite their effectiveness as anticancer drugs, 
these agents have some key limitations. In fact many patients with cancer either do 
not respond or develop resistance to them. These agents can also be extremely toxic 
and show only a very limited therapeutic window, also known as therapeutic index 
representing the ratio between the toxic dose and the therapeutic dose o f a drug. The 
selectivity of these treatments depends on quantitative differences in the rates of 
division between cancer and normal cells and on the presence of tumor defects in 
pathways that are related to the target o f the treatment such as particular checkpoint 
signaling pathways. A good strategy to improve the therapeutic window would be 
either to reduce the activity of the checkpoint and DNA repair in tumor cells or to
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reduce the damage induced apoptosis in normal cells (Zhou and Bartek, 2004). 
Among the genes and pathway commonly altered in human cancer, p53 represents 
the best example, being compromised in over 50% of human tumors thus 
representing the most frequently altered gene in humans. This can be due to p53 
mutations, overexpression o f its negative regulator mdm2 or inactivation by the E6 
of an oncogenic human papillomavirus (HPV) (Hollstein et al., 1991; Michael and 
Oren, 2002). p53 deficiency alters the cellular response to DNA damage leaving the 
cells with attenuated DNA damage checkpoint controls and a reduced propensity to 
undergo apoptotic cell death. Thus the DNA repair capacity of these cells is reduced 
but the survival is increased, promoting genomic instability and contributing to the 
resistance o f the p53 deficient cells to cytotoxic agents. As p53 has a crucial role in 
the Gl checkpoint, resistance of p53 deficient cancer cells to therapy is at least in 
part due to their ability to repair DNA damage during G2 phase arrest. A good 
strategy to sensitize specifically those p53 mutated cells to anticancer agents would 
be to disable the G2 checkpoint favoring the accumulation of DNA damage and the 
subsequent death of the only cancer cells while the normal cells with an intact p53 
and Gl checkpoint would not be affected by such sensitization. Recently many 
efforts have been put in studying the signal transduction pathways that mediate the 
responses to various DNA damaging agents and in particular the two G2 checkpoint 
kinases Chkl and Chk2 as possible key target molecules whose inhibition will 
ultimately lead to a new generation o f adjuvant therapeutics which could 
significantly improve the efficacy and selectivity o f DNA damaging agents in the 
clinic (Dixon and Norbury, 2002).
73
1.10 AIMS
The DNA damage response is essential to ensure cellular life and to avoid 
tumorigenesis. It occurs by rapidly transducing the damage signal to many intracellular 
systems such as the DNA repair mechanism and the cell cycle checkpoints. As outlined 
in the introduction (chapter 1.2-1.6), the cell cycle checkpoint consists of regulatory 
mechanisms that do not allow the initiation of a new cell cycle phase before the previous 
one is completed and temporarily arrest the cell cycle whenever damage is sensed to 
allow time for DNA repair or to promote apoptosis if the damage is unrepairable. The 
misfimction of these checkpoints promotes genetic instability favoring neoplastic 
transformation. In the majority of cancer cells one or more of DNA damage checkpoints 
components have lost their function. The better understanding of the role o f these 
checkpoint proteins in tumor cells may represent a starting point for the design of 
new molecules against cancer targets to be used in cancer therapy in combination 
with common anticancer agents with the aim to increase the therapeutic index.
The serine threonine kinase Chkl was chosen in this project to better define the 
molecular mechanisms regulating the G2 checkpoint induced after DNA damage. 
Indeed, recent experimental evidence attributes to this protein a fundamental role in 
activating not only the G2-M but also the S phase checkpoint following DNA 
damage. In comparison the oncosuppressor p53, which has been found mutated in a 
high percentage of human tumors, has a relevant role in the Gl checkpoint (chapter
1.3). The definition of the molecular mechanisms at the basis of the G2 checkpoint 
assumes particular importance in tumor cells, as cells almost invariably harbor 
defects in the Gl checkpoint, due to p53 mutation, but experience a persistent G2
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block after anticancer drug treatment. One might hypothesize that the abrogation of 
this residual G2 checkpoint by inhibiting specific targets renders tumor cells more 
sensitive to anticancer treatments than normal cells having an intact Gl checkpoint. 
The rationale o f the work described in this thesis is three-fold:
I. The starting point of the first part of my thesis relies on the previous observation 
of the existence o f an interplay between Chkl and p53 following DNA 
damage. Chkl can contribute to the rapid phosphorylation and activation o f p53 
soon after the DNA damage. At later time points from the introduction of the 
damage Chkl would be downregulated by p53 to try to resume the cell cycle 
once the damage has been repaired (figure 3.1). In order to further investigate the 
p53-dependent downregulation of Chkl and to understand how Chkl is 
transcriptionally regulated, the human Chkl gene promoter has been isolated and 
structurally and functionally characterized.
II. The second part of this work describes different strategies attempted to inhibit 
the Chkl function in isogenic cellular systems either with an intact Gl 
checkpoint or with Gl checkpoint defects due to p53 or p21 inactivation with the 
aim to abrogate the G2 checkpoint following different anticancer treatments and 
to evaluate the possibly increased sensitivity to such treatments. The colon 
carcinoma cell line HCT-116 wt and its isogenic systems p53-/- and p21 -/- were 
chosen. The siRNA strategy constituted the most successful technique to inhibit 
the Chkl function. It was also used to inhibit in parallel another key molecular 
player of the G2 checkpoint, the protein kinase Chk2.
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III. The third part of my thesis has the goal to further investigate and clarify the 
physiological role played by Chkl in different human somatic cell lines in the 
absence of genotoxic agents.
Taken together the studies described in my thesis have the overall aim to discover 
molecular mechanisms regulating the G2 checkpoint after DNA damage and to define 
the possible role played by the kinase protein Chkl as a potential target for anticancer 
therapy.
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CHAPTER 2
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2.1 CELL CULTURE
2.1.1 CELL CULTURE CONDITIONS
Cell culture procedures were carried out aseptically in a class II laminar flow hoods. 
Cells were maintained in a Heraeus CO2 Auto-Zero incubator at 37°C with 5% CO2 
and tested for mycoplasma contamination once a month. The human cancer cell lines 
used in my investigations were: the ovarian cancer cell lines SKOV-3 and A2780, 
the osteosarcoma cell lines SAOS-2 and U20S, the colon carcinoma cell line HCT- 
116 and the cervical cancer cell line HeLa with the specific human papillomavirus 
type 16 E6 gene integrated in the genome (coding for the E6 protein which binds to 
p53 and targets it for accelerated ubiquitin-mediated degradation). They were all 
obtained from The American Type Culture Collection (ATCC, Rockville, MD, 
USA). The two human ovarian carcinoma cell lines were maintained in RPMI-1640 
media supplemented with 10% fetal calf serum and 2 mM L-Glutamine. The 
osteosarcoma cell lines and HeLa cells were maintained in DMEM supplemented 
with 10% of FCS and 2 mM of L-Glutamine. The HCT116 human colon-carcinoma 
cell line was maintained in ISCOVE’s modified medium supplemented with 10% 
fetal calf serum and 2 mM L-Glutamine.
The SAOS-2-E2F1 clone was previously obtained in our laboratory after stable 
transfection and selection in G418 (500pg/ml) of an expression plasmid encoding for a 
wt hE2Fl, kindly provided by Dr. Helin, (European Institute of Oncology, Milan, Italy). 
Retinoblastoma (Rb) inducible H562 human small cell lung cancer cells (clone 10D5) 
were kindly provided by Dr. G.W. Kristal (Me Guire VA, Medical Center 11 IK,
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Richmond, Virginia) and were grown in RPMI 1460 supplemented with TET System 
Approved FBS (fetal bovine serum) (BD Palo Alto, US) which replaced the fetal calf 
serum. The HCT-116 tetracycline inducible clones used in my work were maintained in 
the same medium as the parental cell line, supplemented with TET System Approved 
FBS as well as the Rb inducible clone. The tetracycline inducible clones derived from 
the human carcinoma cell line HCT116 and HCT116 p53 -/-, clone Trex 8A and clone 
Trexl5A, were previously isolated in my laboratory. These clones were maintained 
under selection with blasticidine (working solution: 5j4,g/ml). The clones derived from 
the human colon-carcinoma cell line HCT-116, clone 379.2 originated by targeted 
deletion of the p53 gene (p53 -/-) and clone p21 -/- originated by targeted deletion of the 
p21 gene (p21 -/-) were kindly supplied by Dr. Vogelstein from John Hopkins 
University (Baltimora, MA, USA).
The different media were purchased from Sigma and contained the mineral and 
supplements necessary for the growth of the cells except for the serum, which was added 
when needed. Cells were passaged routinely before they reached confluence, to maintain 
a logarithmic growth. The cells were replaced with fresh liquid nitrogen stocks after 
every four-five months of culture. Procedures to detach and subculture cells were the 
same for all the cell lines used and consisted of two washes with warm sterile phosphate 
buffer saline (PBS, Sigma) and detachment with a solution of IX trypsin/EDTA 
(Sigma). The trypsin activity was stopped by adding calf serum-containing medium. 
After centrifugation at 1,200 rpm for 10 minutes, cells were resuspended in the 
appropriate medium counted by the Counter method (Coulter Counter, ZM) and seeded 
at the desired density.
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2.1.2 LONG TERM STORAGE OF CELLS
To generate and maintain batches of cells, exponentially growing cells were washed 
twice with PBS and centrifuged at 1,200 rpm for 10 minutes at room temperature. The 
cell pellet was resuspended in culture medium containing 50% of cryoprotective 
medium (Bio-Whittaker, Milan-Italy) and 20% of calf serum to a density of 5,000,000 
cells/ml. Aliquots of 1 ml were kept on ice for 30 minutes, cooled slowly for 3 h in 
liquid nitrogen vapour and then immersed in liquid nitrogen. Cells were recovered from 
the cell bank by rapid thawing to 37 °C in a water bath, centrifuged at 1,200 rpm for 10 
minutes, resuspended in the appropriate culture medium and transferred to a tissue 
culture flask. The day after, the medium was removed and new, fresh medium was 
added.
2.2 CELL GROWTH ANALYSIS
2.2.1 PREPARATION OF DRUG SOLUTIONS
Cis-dichloro-diamminoplatinum (DDP) was prepared freshly for any experiment by 
preparing a solution of 0.5 mg/ml in medium and allowing this solution to equilibrate 
with proteins present in the serum at 37°C for 30 minutes before treatments. Etoposide 
(VP-16) was prepared in DMSO as 5mM stock solution and subsequently diluted in 
fresh medium the day of treatment. The stock solution was maintained at -20  °C. 
Hydroxyurea (HU) was made freshly for each experiment by preparing a solution 500 
mM concentrated in medium with no serum. The dissolution was enhanced by vortexing
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for few seconds. IR treatments were made using the RadGil Machine (Gilardoni-Italy), 
while a UV lamp was used to UV irradiate the cells.
2.2.2 CELL GROWTH CURVE
To detect the effects on the cell growth of the small interfering RNA transfected cells (in 
HCT116 p53 +/+, p53 -/- and p21 -/- and in U20S cells), of the cells inducible 
expressing the dead kinase Chkl and of the single or double inducible expressing Chkl 
siRNA, the growth of the cells was followed by counting the cells through the Counter 
Method (Coulter Counter, ZM) each 24 hours after transfection or induction with the 
inducer doxycycline (2pg/ml) (a more stable tetracycline analogue), starting from 24 
hours and ending up to 144 hours after transfection. This investigation thus permitted the 
construction of the cell growth curve.
2.2.3 COLONY ASSAY
The effects of DDP and IR on mock or siRNAs transfected cells (HCT116 and isogenic 
cell lines), the effects of DDP and UV on the doxycycline inducible HCT-116 clone 
overexpressing the dead kinase Chkl and the effects of DDP and VP-16 on the HCT116 
cell lines induced to express the single siRNA Chkl were evaluated by a standard 
clonogenic assay. Briefly, in the first case, cells plated on 24 well plates were treated, 48 
hours after transfection with siRNAs, with different doses of DDP for two hours or 
irradiated for different time. At the end of each treatment, cells were washed in PBS, 
trypsinized and seeded at 200 cells/ml (HCT 116 and HCT 116 p53-/- cells lines) and
81
400 cells/ml (HCT 116 p21 -/- cell line) in 6 well plates. Colonies were allowed to grow 
for about 8 to 10 days. When the control cell colonies were visible under the 
microscope, the medium was aspirated and the wells washed with 1 ml of PBS. Then the 
colonies were stained with crystal violet (BDH, Milan, Italy) by adding 1 ml o f the 
commercially available solution (1% concentrated) and, after extensive washes in water, 
with the final two washes in distilled water, the plates were air dried and the number of 
stained colonies counted by the Entry level Image System (Immagini & Computer, 
Italy). A background correction was made and the smallest control colony was taken as 
the minimum for the establishment of the cut-off point. All the data are the mean + SD 
of at least three experiments, done in triplicate.
In the second and third case, cells were seeded at low density in 6 well plates and either 
induced or not with doxycycline 2pg/ml every 48 hours. At 72 hours from the first 
induction cells were treated with different doses of drugs for 2 hours. At the end of each 
treatment, cells were washed in PBS, recovered in the proper culture medium and stored 
at 37 °C in the incubator leading to the formation of the colonies. The subsequent steps 
of staining and data analysis were performed as above described.
2.3 GENOMIC DNA ANALYSIS
2.3.1 SCREENING OF GENOMIC LIBRARIES
Genomic clones containing the genomic Chkl sequences were isolated by screening a 
genomic library spotted on filters obtained through the UK Human Genome Mapping 
Project Resource Centre (UK-HGMP-RC). The human PAC library RPCI1 has been
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constructed in the vector, pCYPAC2N. The source is a normal male blood donor, and 
the insert size is about 110 kb. The library consists of approximately 120,000 clones 
which have been spotted on 22.2 x 22.2 cm Hybond N nylon membranes (Amersham). 
Each clone has been spotted twice to give 36,864 (18,432 x 2) spots on each membrane. 
Seven filters cover the whole library. The 7 filters were preybridized at 65°C in 25 ml of 
a solution containing 6x SSC, 100 pg/ml of salmon sperm, 0.5% SDS and 5x Denhardt’s 
solution (a 50x Denhart solution is prepared by dissolving 1 g of Ficoll 400, 1 g of 
polyvinylpyrrolidone and 1 g of BSA fraction V in 100 ml of water; the solution is then 
filtered and stored at -20°C) with gentle, continuos agitation. To this solution, 
radiolabeled specific Chkl cDNA probe containing a 5’ Chkl genomic region of 170 bp 
(prepared as reported next in paragraph 2.3.2.5) was added and the incubation continued 
for further 16 hours at 65°C. The filters were then washed twice at room temperature in 
2x SSC, followed by two washes of 15 min each at 65°C with 2 x SSC + 1% SDS and a 
final wash in 2x SSC without SDS for 10 minutes and exposed to autoradiographic 
films. Once developed, the films were oriented with the grid supplied with the filters and 
the positive clones identified. This procedure was facilitated by the double spotting of 
each clone.
The 2 identified positive clones, called 53pl3 and 253, were requested to the UK- 
HGMP-RC and obtained as glycerol stock. From these stocks, the PAC clones were 
isolated using the Qiagen midi preparation kit following the procedures reported in the 
instruction manual.
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2.3.2 SOUTHERN BLOT ANALYSIS
Briefly, this technique consists in transferring DNA molecules from an agarose gel onto 
a nitrocellulose membrane. Southern blotting is designed to locate a particular sequence 
of DNA within a complex mixture. In our specific investigation this approach was used 
to isolate shorter genomic fragments containing the 5’region of the Chkl gene from the 
isolated DNA of the PAC clones.
2.3.2.1 DNA RESTRICTION ENDONUCLEASE DIGESTION
Before loading onto an agarose gel, genomic DNA must be digested with one or more 
restriction endonuclease enzymes. An aliquot of the genomic DNA previously isolated 
(usually around 20pg) was digested with different restriction enzymes in their 
appropriate buffer supplied together with the enzyme, for 16 hours at 37°C. The total 
volume of the digestion is 100 pi containing 10 pi of appropriate IX dilution buffer and 
5 pi of restriction enzyme.
2.3.2.2 DNA ELECTROPHORESIS
The entire restriction reaction was loaded on 0.8% agarose gels before adding 1/6 of 
volume of loading buffer. After loading, the gel electrophoresis was performed in TAE 
buffer (IX) at a constant voltage o f 80 V, for 5-6 hours.
Agarose gel is prepared by dissolving lg  o f ULTRA pure agarose (Sigma) in 100 ml o f  
IX  TAE buffer:
TAE Buffer (5OX) final concentration
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242 g Tris base 2 M
100 ml EDTA 0.5M, pH  8 50 mM
57.1 ml glacial acetic acid 
to 1 1 with deionised water.
The solution was stored at room temperature.
The solution was heated in a microwave oven and boiled until all the agarose is 
dissolved. The solution was then cooled to approximately 50°C before pouring in a 
casting tray. At the end of the run the gel was stained in a solution of 1 jig/ml of 
ethidium bromide in TAE buffer for 30 minutes and the DNA bands visualized with a 
UV transilluminator to visualize a smear which is indicative of a good digestion and 
separation. The DNA was then denaturated into single stranded form before blotting 
onto a membrane.
2.3.23 DNA DENATURATION
The agarose gel was placed in a box containing 250 ml of denaturation solution and 
shaken gently for 45 minutes.
Denaturation solution final concentration
30 mlNaCl 5M 0.6M
20 ml NaOH 5M 0.4 M
to a final volume o f250 ml with deionised water
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After this incubation, the agarose gel was rapidly washed in deionised water and 
incubated for 45 minutes in neutralization solution.
Neutralization solution final concentration
125 ml Tris-HCl IM pH  7.5 0.5 M
75 ml NaCl 5M 1.5 M
to a final volume of250 ml with deionised water
Before to proceeding with blotting, the agarose gel was washed with deionised water.
2.3.2.4 BLOTTING PROCEDURE
A capillary blot was set up using a solution of 20X SSC as transfer buffer.
SSC Buffer (20X) final concentration
175.3 g  NaCl 3 M
88.2 g  Na citrate 0.35 M
to 1 1 with deionised water.
The pH  was adjusted to 7 with NaOH and the solution autoclaved.
The wick was made up of 2 pieces of 3MM paper with each end dipping into the transfer 
solution. The gel was placed on the wick with wells facing down, and air bubbles were 
gently removed. A nylon membrane (GeneScreen plus, NEN) of exactly the same size of 
the gel was soaked in 20X SSC for at least 10 minutes and carefully placed on top of the 
gel and gently squeezed to remove air bubbles. Three sheets o f 3MM paper where then 
added over the membrane followed by Kleenex towels. The blot system was left for lb- 
24 hours after which the membrane was removed, washed by immersion in deionised
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water, left to dry at room temperature for approximately 30 min. The blot was stored at 
4°C until ready for hybridization.
2.3.2.S PREPARATION OF PROBE FOR SOUTHERN BLOT ANALYSIS
The 5’ Chkl gene specific probe of 170 bp was the same used also for the screening of
the genomic libraries and was prepared by using the gene insert excised from the
plasmid by restriction enzyme digestion. The radioactive probe was prepared using a
Klenow fragment of polymerase I to copy the probe sequence while incorporating
radioactive nucleotides. A commercially available kit (Rediprime, Amersham) was used
for this purpose. For labelling, 50 ng of DNA as starting material were used and all the
steps described in the manual were followed using as radioactive nucleotide 32P-labeled
dCTP (Amersham, 3,000 Ci/mmole). Purification of the probe from unlabelled
nucleotide was performed using Sephadex G50 columns (Boheringher-Mannheim)
exactly following the manufacturer’s instructions. The incorporated radioactivity was
detected by Cherenkov counting and the probe was diluted to have a final concentration
of 500,000 cpm/ml of hybridization solution. Hybridization and washing conditions
were the same used for the screening of the genomic filters. The autoradiograph was
compared to the ethidium bromide picture and the bands which hybridized with the
probe identified. A second digestion was then performed on the remaining genomic
DNA maintaining exactly the same conditions previously used.
Once separated on the agarose gel, the band chosen of about 10 kb was excised and 
isolated using the QIAgel extraction kit (Qiagen) and cloned in a pBluescript plasmid 
(BSSK) following the procedure I will describe in the next paragraph.
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2.4 MOLECULAR CLONING STEPS AND GENERATION OF 
CELLULAR CLONES
2.4.1 PREPARATION OF CONSTRUCTS
During the work I’m presenting in this thesis I applied the molecular cloning strategy 
several times. To transfer the gene of interest in the genome of host cells by a specific 
vector, I used, depending on the necessity, two possible strategies: 1) excising the 
fragment from an existing construct; 2) cloning the fragment by PCR. In the first case 
the DNA was excised from the plasmid of origin by restictrion endonuclease digestion 
and subcloned in the appropriate expression vector. The expression vectors used in our 
experiments were the pCDNA vectors series produced by Invitrogen for stable or 
transient overexpression of the cDNA of interest (pcDNA3 vector represented in figure 
2.1). The principal features of these plasmids are: the presence of a promoter driving the 
transcription, a polylinker sequence containing the DNA recognition sequence for many 
restriction enzymes to facilitate the subcloning of the gene of interest, also called MCS 
(multiple cloning site), a bacterial resistance gene (ampicillin) for selection of 
recombinants and an eukaryotic resistance gene (neomycin, blasticidin, zeocin or 
puromycin) for selection of cells containing the plasmid. To test the promoter activity of 
Chkl, the different genomic fragments were subcloned in the pGL2 enhancer vector 
lacking the promoter and with the MCS upstream to the reporter gene luciferase. To 
subclone the gene of interest, the general molecular biology techniques reported in 
Sambrook et al. (1989) were used. In summary, the gene of interest is excised from the 
plasmid of origin by digestion with the appropriate restriction enzymes for 1 hour at
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Figure 2.1 pcDNA3 expression vector
Circular plasmid for stable or transient over-expression of the cDNA of interest in 
eukaryotic cells.
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37°C in a buffer supplied with the enzyme. The entire reaction is loaded onto a 1% 
agarose gel to separate the exogenous DNA fragment from the plasmid by 
electrophoresis (gel preparation as described in paragraph 2.3.2.2). When the expected 
bands were present, the appropriate band containing the cDNA was excised from the gel 
and the DNA extracted from the agarose slice using the QIAgel kit (Qiagen) exactly 
following the manufacturer’s instruction. The cDNA so obtained was stored at 4°C. The 
host plasmid was digested with the same restriction enzymes used to excise the cDNA 
from the original plasmid. In case of restriction digestion with a single enzyme, after 
digestion, the plasmid was treated with shrimp alkaline phosphatase at 37°C for 60 
minutes to remove the 5’ phosphates and to reduce the probability of the plasmid to 
recirculate without insert. The reaction was then heated at 70 °C to inactivate the 
phosphatase. The linearized host plasmid was ligated with the excised cDNA insert in 20 
microliters of a solution containing 1U of T4 DNA ligase (Promega) and IX ligase 
buffer (30 mM Tris-HCl, pH 7.8, 10 mM MgCk, 10 mM DTT and 1 mM ATP, supplied 
with the ligase) for 4 hours at room temperature. Half of the volume of this solution was 
then used to transform competent bacteria. The second possibility o f cloning a sequence 
of DNA was to amplify by PCR the target sequence and to use the TA strategy to clone 
the amplified fragment.This technique provides a one step cloning strategy for a direct 
insertion of PCR product into a vector (T-vector). Basically, Taq enzyme has a non­
template dependent activity, which adds a set of deoxyadenosines to the 3’ ends of PCR 
products. The T-vector contains in its multi cloning site (MCS) complementary unpaired 
3’ thymidyl residues. This allows the PCR products to ligate efficiently with the vector. 
PCR products were ligated to the vector at a ratio o f 1:1 or 3:1 following the
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manufacturer’s instructions. pGEM®-T easy vector was purchased ready made as a 
component of a cloning kit (Promega, Milan-Italy).
In my work this second possibility was applied to generate the two recombinant Chkl 
KO construct. As I will further describe in paragraph 2.8 of this chapter to clone the 3’ 
and 5’ arms of the constructs I had to amplify definite genomic regions by PCR strategy 
using as a template the 53pl3 PAC clone, 5’ Chkl gene positive, previously isolated 
after the screening of a genomic library.
2.4.2 PREPARATION OF COMPETENT BACTERIAL CELLS FOR 
TRANSFORMATION
Fifty ml of sterile bacterial cellular suspension (XL 1-blue, Stratagene) were mixed, in a 
sterile 50 ml conical tube, with 10 ml of sterile LB medium:
Luria-Bertani Broth (LB) final concentration
10 g  bacto-tryptone 1 % (w/v)
5 g  bacto-yeast extract 0.5% (w/v)
lO gN aCl l% (w/v)
to a final volume o f 1 I with deionised water. The medium was then autoclaved for 15 
min and the antibiotic o f selection (for pcDNAS derived plasmids, ampicillin at the final 
concentration o f 50/ug/ml) was added once it had cooled to 55°C.
and allowed to grow in a 37°C heated shaking incubator (Folabo) at 225 rpm overnight. 
One ml of such liquid bacterial culture was then transferred into a sterile 500 ml bottle 
containing 100 ml of sterile LB medium and the bottle was placed into the 37°C heated
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shaking incubator at 225 rpm. To harvest bacterial cells in logarithmic growth phase, 2 
hours later, 1 ml of liquid culture was transferred, under a laminar flow in a disposable 
cuvette and the absorbance at 600 nm wave-length was read on the spectrophotometer. 
E. coli concentration in the liquid culture was calculated by considering that 1 A6oo nm 
unit corresponds to about 8x log bacterial cells/ml. When the 600 nm absorbance 
reached A 0.3 units (corresponding to roughly 2.4 x 108 cells/ml) the bacterial 
suspension was transferred in two ice-cold sterile 50 ml conical tubes and the cell 
growth was stopped by placing the tubes on ice for 15 minutes. E. coli cells were 
pelleted by centrifugation at 3,000 rpm for 10 minutes at 4°C and, after the removal of 
LB medium, cell pellets were pooled in the same tube by gentle resuspension in 10 ml of 
ice-cold sterile 0.1 M CaCU solution. After addition of 40 ml of ice-cold sterile 0.1 M 
CaCl2 solution, bacterial suspension was incubated on ice for 30 minutes and 
subsequently centrifuged at 3,000 rpm for 10 minutes at 4°C. The supernatant was then 
removed and the cell pellet was carefully resuspended in 5 ml of an ice-cold sterile 0.1 
M CaC12 containing 15% (v/v) glycerol (Sigma). This bacterial suspension was 
dispensed in 1.5 ml eppendorf tubes (400-500 pi aliquots for each tube) and kept at 4°C 
for 24 hours after which the tubes were quickly frozen in liquid nitrogen and stored at -  
80°C. The cells maintained their competence for transfection for 1-2 months when kept 
at -80°C. Fifty pi of freshly prepared competent cells were transformed with 50 ng of a 
DNA vector able to confer ampicillin resistance and 1/100,000 (dilution factor, 105) of 
the bacterial suspension was plated as described in agar plates. Transformation 
efficiency, calculated on the basis of the formula (NUMBER OF COLONIES) x (103) X 
(DILUTION FACTOR) / 50 ng, was expressed as the number of colony forming units
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(CFU) per pg of plasmide DNA. Generally, 106-108 CFU per pg of plasmid DNA were 
indicative of a good preparation of competent bacterial cells.
2.4.3 TRANSFORMATION OF BACTERIA
In an ice-cold 10 ml Falcon tube (Falcon, Becton Dickinson), 50 microliters of 
competent bacterial cells were diluted to a final volume of 100 ml with 0.1 M CaCh and 
20 microliters of the ligation reaction (reported in paragraph 2.4.1) were then added. The 
mixture was gently mixed by tapping and the tube was chilled on ice for 30-40 minutes, 
incubated for 90 seconds at 42°C in a water bath and for 2 minutes again on ice. After a 
5 minute incubation at room temperature, 900 ml of LB medium were added and tube 
was placed into a 37°C heated shaking incubator at 225 rpm for 1 hour. The tube was 
then centrifuged at 3,000 rpm for 5 minutes at room temperature, most of the 
supernatant LB removed and the bacterial cell pellet resuspended in the remaining fluid 
and spreaded into 90-mm dish (Coming-Costar Italia-Milan, Italy) containing LB agar 
medium plus the antibiotic of selection: (LB medium was prepared as previously 
described. Agar (1.5% w/v) (Life Technologies) was added before autoclaving and the 
solution poured on 90-mm dish (Coming-Costar, Milan-Italy) and allowed to dry under 
sterile hood) and incubated overnight at 37°C without agitation.
2.4.4 IDENTIFICATION OF RECOMBINANT CLONES
Plasmidic DNA was purified from bacterial suspension using the Quiagen mini-prep kit 
(Quiagen, Milan-Italy). The procedure, starting from 1.5 ml of bacterial suspension was
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exactly as described by the manufacturer. The recovered DNA, in 50 pi of water, was 
subjected to restriction digestion with appropriate restriction enzymes to verify that the 
insert was indeed present in the colony isolated. After digestion and separation on 
agarose gel, the fragments of DNA were visualised by using an UV transilluminator. 
The positive colonies containing the right insert were stored at -80  °C after the addition 
of 0.5 ml o f 50% sterile ultra pure glycerol (Sigma) to 0.5 ml of the bacterial suspension 
used for the enzyme digestion. When necessary, the remaining DNA was used for 
confirmation by DNA sequencing, which was performed through custom sequencing 
services (through a core facility available at Mario Negri Bergamo, Bergamo, Italy and 
more recently through PRIMM facility, Milan, Itay).
To obtain sufficient DNA to transfect cells, a midi prep purification was set up. Using a 
sterile spatula, frozen bacterial cells were scraped from the 2 ml sterile Nalgene tube and 
dissolved in 10 ml of 50 fag/ml ampicillin containing LB medium (contained in a 50 ml 
conical tube), and allowed to grow at 37°C in a shaking incubator at 220 rpm. After 8 h, 
1 ml of liquid culture was mixed with 100 ml of a fresh solution of 50 pg/ml ampicillin 
in LB medium in a 250 ml glass bottle, and cells were left to grow o/n at 37°C and 220 
rpm. Bacterial cells were then pelleted by a 30 min centrifugation at l,700xg at 4°C. 
After removal of LB medium, plasmid DNA was purified with the Qiagen Plasmid Midi 
Kit (Qiagen) according to the manufacturer's instructions. The DNA recovered from the 
midi preparation was quantified using a spectrophotometer, by reading the absorbance at 
260 nm and 280 nm. The quality of the DNA prepared was determined by the ratio 
between 260 nm and 280 nm absorbances, which should be 1.8.
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For quantification the extinction coefficient was used. The amount of DNA was 
calculated considering that a solution of 50 micrograms of DNA/ml would give an 
absorbance reading of 1.0 at 260 nm.
2.4.5 TRANSFECTION OF DNA IN  EUKARYOTIC CELLS
To transfect DNA into the different cell lines two different techniques were performed: 
the calcium phosphate precipitate method and liposome method.
2.4.5.1 CALCIUM PHOSPHATE PRECIPITATE METHOD
One day prior the transfection, cells were plated in order to be logarithmically growing 
on the day of transfection (i.e. 50-60% confluent at the time of transfection). Before 
transfection, exponentially growing cells were washed twice with ice-cold sterile PBS, 
and allowed to grow in 4.5 ml of D-MEM medium supplemented with 10% FCS and 2 
mM glutamine. DNA was dissolved in sterile water and was mixed with a solution of 2 
M CaCl2 {prepared by dissolving 14.7 g  o f CaCh in 100 ml H2O and filtering the 
solution with a syringe equipped with a 0.2 pm filter) to give a final concentration of 
0.25 M CaCl2 in a volume of 250 pi. In the meantime, for each transfection to be 
performed a 4 ml transparent tube (Falcon) was prepared by adding 250 pi o f a 2X 
HEPES-Buffered Saline (HEBS 2X):
HEBS 2X final concentration
1.6gNaCl 280 mM
0.074gKCl 10 mM
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0.027g NCI2HPO4 *H20  1.5 mM
0.02g Dextrose 12 mM
IgHEPES 50 mM
The salts are dissolved in 50-70 ml o f distilled water and the pH  o f the solution is then 
adjusted to 7.2 with 0.5 N  NaOH and then brought to 100 ml with sterile water.
Then a 1 ml sterile pipette fixed to an automatic pipettor was placed at the bottom of the 
tube containing the HEBS solution and the air forced inside the tube. While the solution
was bubbling, the DNA-CaCE solution was added drop-wise. When the DNA has been
added, the tube was vortexed for 20 seconds and kept in a tube holder for 30 minutes. 
The solution was then added drop wise to the cells seeded in a 25 cm2 flask and 
incubated 16 hours at 37°C.
The cells with the DNA-CaPC>4 solution were then visualized under the microscope to 
verify the presence of small precipitates of Ca2(HP0 4 ) on all the surface of the flask. 
Once this was verified, the medium was removed and the cells extensively washed with 
PBS (three four times, with the PBS left on the cells for 5 minutes to help in remove as 
much of the crystals as possible). After washing, the cells were incubated in complete 
medium.
2.4.5.2 LIPOSOME METHOD
The Lipofectamine 2000 reagent (Invitrogen) was mostly used to transfect DNA by 
liposome method and the manifacturere’s instructions were followed. Briefly, the ratio 
of DNA (pg) / lipofectamine 2000 (pi) in the transfection mixture prepared were 
comprised between 1:2 and 1:3 for most of the cell lines utilized. Cells were seeded at
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high density one day before trasfection in order to have a 90-95% confluence at the time 
of transfection. Both DNA and liposomes were diluted in Opti-MEM I Reduced Serum 
Medium (Invitrogen) without serum. After 5 minutes of incubation of Lipofectamine at 
room temperature, the diluted DNA was mixed with the diluted liposome solution and 
incubated for 20 minutes at room temperature. The mixture was then added to the cells 
which were incubated at 37 °C in the incubator till the day of the cells harvesting.
2.4.6 ISOLATION OF CELL CLONES STABLY EXPRESSING THE GENE OF 
INTEREST
When clones of cells stably expressing the gene of interest had to be isolated, 48 hours 
after the end of transfection the medium was removed and the cells detached with 
trypsin/EDTA solution. After counting, the cells were seeded in 9 mm plates at a density 
of 5,000 cells/ml in medium containing the selection antibiotic (500 micrograms/ml of 
G418 for neomycin resistance gene containing plasmids, 10 micrograms/ml of zeocin 
for zeocine resistance gene containing plasmids, 5 micrograms/ml of blasticidin for 
blasticidin resistance gene containing plasmids and 0,2 pg/ml of puromycin for 
puromycin resistance gene containing plasmids). At these antibiotic concentrations 
parental cells are killed and the only cells growing are likely to be those which have 
integrated in their DNA the transfected plasmid. The plates were then kept at 37°C and 
the medium renewed every two-three days. When colonies were formed, they were 
visualized under the microscope and isolated from the plate by using plastic rings which 
were attached to the plate with Vaseline. Once attached, 20 microliters of a trypsin 
EDTA solution was introduced into the cloning rings to detach the cells o f the single
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colony detached and transfer them in 24 wells plates containing 1 ml of medium plus 
selection antibiotic. The different clones picked up from the original plates are grown 
and passaged in duplicated in 6 well plates. One plate is used to verify the presence of 
the gene of interest and the other is used to maintain the clone for further studies and for 
long term storage. The positive clones could be screened by Western blotting analysis to 
verify either the downregulation (antisense strategy and siRNA strategy) or the inducible 
overexpression (dominant negative strategy) of the protein of interest.
The clones overexpressing the inserted gene were then expanded and stored in different 
aliquots in liquid nitrogen.
2.5 LUCIFERASE REPORTER ASSAY
Transient transfection experiments were performed following the calcium phosphate 
procedure described in the previous paragraph. These experiments were performed to 
evaluate the promoter activity of DNA fragments subcloned in appropriate vectors. The 
constructs used utilize the non mammalian gene luciferase, which is inserted in a 
promoterless plasmid. For this study pGL2 vector from Promega was used. This plasmid 
contains the fire fly luciferase gene followed by a viral enhancer and a multiple cloning 
site at its 5’ end. The transfection and transient expression of this plasmid in mammalian 
cells results in a very low level of luciferase (due to the absence of a promoter), which 
was detected in cell lysates using a commercially available kit (Dual luciferase system, 
Promega). The Chkl genomic fragments to be analyzed were subcloned in the multiple 
cloning sites of the pGL2 vector using appropriate restriction enzymes. Once the exact 
insertion and orientation of the fragment was verified using the procedures reported in
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paragraph 2.4, the plasmids were transiently transfected into mammalian cells growing 
in culture. At 48-72 hours following transfection, the medium was removed and the cells 
processed as reported in the instruction manual of the kit. The luciferase levels were 
measured in a luminometer and the values corrected for the expression of a control 
plasmid co-transfected with the plasmid under examination, which encodes a renilla 
luciferase distinguishable from the fire-fly luciferase utilized in these experiments.
2.6 ANTISENSE STRATEGY AND ANTISENSE CONSTRUCTS
Antisense mRNA is an mRNA transcript that is complementary to an endogenous 
target mRNA. It basically represents the non coding strand complementary to the 
coding sequence of mRNA. Introducing a transgene coding for antisense mRNA is a 
common strategy used to block the expression of a gene o f interest although in the 
last 5 years the more efficient small interfering RNA strategy in large part 
substituted the antisense strategy.
The availability of the pBluescript (BSSK) plasmid containing the full length human 
Chkl cDNA (kindly provided by Yolanda Sanchez) in the MCS, represented the 
starting point for the construction of three constructs containing fragments of 
different length cloned in an antisense orientation respect to the sense of 
transcription in the expression plasmid pcDNA3 (Invitrogen, fig 2.1). Briefly, the 
198 bp fragment was obtained by digestion of cDNA Chkl with the Xhol and Bglll 
restriction endonucleases, subsequently ligated in pcDNA3 previously digested with 
BamHI (protruding ends compatible with Bglll) and Xhol. The 675 bp fragment was 
obtained by digestion of the cDNA with Xhol and PvuII restriction enzymes and
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ligated in pcDNA3 digested with EcoRV (protruding ends compatible with PvuII) 
and Xhol. The 1,124 bp fragment was obtained by digestion of the cDNA with Xhol 
and BamHI restriction enzymes and ligated in pcDNA3 digested with Bam HI and 
Xhol. The subsequent steps o f cloning after the ligation were performed as described 
in paragraph 2.4.
2.7 GENERATION OF THE CONSTRUCT FOR THE INDUCIBLE 
EXPRESSION OF DOMINANT NEGATIVE CHK1 BY USING 
THE Trex SYSTEM
To get cellular clones inducibly expressing the Chkl dead kinase protein tetracycline 
inducible system (T-Rex System, Invitrogen) was employed. The T-REx System is a 
tetracycline-regulated mammalian expression system that uses regulatory elements from 
the E. coli TnlO-encoded tetracycline (Tet) resistance operon (Hillen and Berens, 1994; 
Hillen et al., 1983). Tetracycline regulation in the T-REx System is based on the binding 
of tetracycline to the Tet repressor and derepression of the promoter controlling 
expression of the gene of interest.
The major components of the T-REx System are:
an inducible expression plasmid (pcDNA4/TO) for expression of the gene of 
interest under the control of the strong human cytomegalovirus immediate-early (CMV) 
promoter and two tetracycline operator 2 (Tet02) sites (Figure 2.2A)
a regulatory plasmid, pcDNA6 /TR , which encodes the Tet repressor (TetR) 
under the control of the human CMV promoter (Figure 2.2B) 
tetracycline for inducing expression
100
pcDNA™4/T0
5078 bp
B pcDNA6/TR
6662 bp
Figure 2.2 Trex inducible expression system: vectors
A. pcDNA4/TO expressing the gene of interest under the control of a hybrid 
CMV/TetC>2 promoter.
B. pcDNA6 /TR expressing the Tet repressor under the control of the human CMV 
promoter.
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In the T-REx System, expression of the gene of interest is repressed in the absence of 
tetracycline and induced in the presence o f tetracycline.
In the absence o f tetracycline, the Tet repressor forms a homodimer that binds with 
extremely high affinity to each Tet02 sequence in the promoter of the inducible 
expression vector (Hillen and Berens, 1994). The 2 Tet02 sites in the promoter of the 
inducible expression vector serve as binding sites for 4 molecules (or 2 homodimers) of 
the Tet repressor. The affinity of the Tet repressor for the tet operator is KB = 2 x 1011 
M_1 (measured under physiological conditions), where KB is the binding constant 
(Hillen and Berens, 1994). Binding of the Tet repressor homodimers to the Tet02 
sequences represses transcription of your gene of interest. Upon addition, tetracycline 
binds with high affinity to each Tet repressor homodimer in a 1:1 stoichiometry and 
causes a conformational change in the repressor that renders it unable to bind to the Tet 
operator. The association constant, KA, of tetracycline for the Tet repressor is 3 x 109 M"
1 (Hillen and Berens, 1994). The Tet repressor:tetracycline complex then dissociates 
from the Tet operator and allows induction of transcription from the gene o f interest. 
Figure 2.3 shows how all system components work in the cellular contest.
2.7.1 CLONING OF THE DOMINANT NEGATIVE CHK1 CONSTRUCT IN  
PCDNA4/TO
The HCT-116 Trex positive clone transfected with pcDNA6 /TR was previously 
isolated in the laboratory, whereas according to what have been just described, the 
fusion protein HA-D130 cDNA (Chkl cDNA with a point mutation at the position 130 
in the protein kinase domain which substituted aspartic acid with alanine fused to the
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Figure 2.3 T-rex system
The repressor (tetR) protein is expressed from pcDNA6 /TR; a homodimer o f this protein 
binds to Tet operator2 (Tet0 2 ) in the inducible expression vector. Binding o f tet to tetR 
homodimers causes release from the Tet operator and induction of transcription of the 
gene of interest.
HA epitope) needed to be subcloned into the eukaryotic expressing vector pcDNA4/TO, 
in order to be transfected and expressed into eukaryotic cells after Tet induction.
Briefly HA-D130 cDNA prepared by a mini prep from the expression vector pcDNA3- 
HA-D130 kindly provided by Dr Ciro Mercurio (IEO, Milan) and the pcDNA4/TO were 
both digested with Hindlll and Notl restriction enzymes for 2 hours at 37 °C. This 
double digestion allowed the formation of sticky ends between the linearized 
pcDNA4/TO plasmid and the HA-D130 cDNA fragment. After digestion, the reaction 
products were loaded onto 1% agarose gel and the expected fragment purified as 
reported before.
The linearized pcDNA4/TO vector showed a molecular size of 5.4 Kb, HA-D130 cDNA 
of 1.9Kb and pcDNA3.1 of 5.5 Kb, as expected. pcDNA4/TO vector and HA-D130 
were then ligated and the procedures of cloning made as described in paragraph 2.4 of 
this chapter. A colony positive for the insert of the correct size after digestion with Notl 
and Hindlll was selected and the sequencing was performed (by PRIMM) to check 
whether the HA-D130 cDNA was ligated in frame for the correct “in vitro” synthesis of 
the HA-D130 protein.
2.8 KO CHK1 CONSTRUCTS
The construction of the two Chkl KO constructs was possible thanks to the availability 
of the previously isolated genomic clone 53P13 containing a large part of the Chkl gene 
(exons and introns) and by applying the PCR strategy which is herein described.
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2.8.1 PCR
The polymerase chain reaction (PCR) follows the principles in which a pair of primers 
(forward and reverse) defines the region to be amplified. After denaturation (generally at 
95 °C), primers are allowed to anneal to their complementary strand by lowering the 
temperature to their optimal annealing temperature (AT) which is specific for each set of 
primers and is linked to the oligonucleotides sequence. AT can be calculated on the basis 
of the following formula: AT=Tm-t, where Tm = 4x (G+C) +2x (A+T) is the melting 
temperature and 3 °C>t>5 °C. An elongation step allows the Taq DNA polymerase to 
start the polymerization reaction downstream of the 3’ ends of the primers (generally at 
a temperature of 72 °C). These three steps are then repeated for “n” (usually 30) cycles 
to allow exponential amplification of the target sequence. A final step, at 72 °C for 7-10 
minutes allows the Taq polymerase to conclude the polymerization step. Amplification 
is measured by resolving products through agarose gel electrophoresis. Whenever 
necessary, PCR products were then purified from gel. PCR reaction mix was made using 
as a Taq purchased from Takara (Gennevilliers, France) with which all the components 
necessary for the reaction (except for the primers and DNA template) are provided. PCR 
reaction mix was made following manufacturer's instructions. Generally, nucleotides 
(dNTPs) are used to a final concentration of 0.2 mM, MgCl2 to a final concentration of
1.5 mM, and 0.5 U of Taq. Forward and reverse primers were added to a final 
concentration of 500 nM. The “GeneFisher” software free available online (web address: 
http://bibiserv.techfak.uni-bielefeld.de/genefisher/) was used to design the best set of 
primers to be used for each region of the gene to be amplified. Synthesis of 
oligonucleotides used as primers was performed by Sigma.
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To the reaction mix, DMSO (dimethyl sulfoxide) was also added to a final concentration 
of 5%. To the final reaction mixture, a quantity of DNA template was added, (20 ng of 
plasmidic DNA, 50 ng of genomic DNA) then quickly spinned in a microfuge to recover 
all the fluids at the bottom of the tube and placed in PTC-200 thermal cycler (MJ 
research, Watertown, MA). Amplification conditions and cycle numbers were selected 
each time according to the AT of the pair of primers and the length o f the PCR product 
to be amplified.
2.8.2 CLONING OF THEKO CONSTRUCTS
As it is possible to observe from the picture in figure 4.5 of my results, NEO and 
HYGRO resistance cassettes (previously amplified by PCR) were inserted in between 
the 5’ arm and the 3’ arm of each construct with the aim to substitute exon2, intron 2 and 
exon 3 o f the Chkl gene by homologous recombination. Briefly, to amplify by PCR the 
5’ arm and the 3’ arm, specific primers were designed and specific restriction sites were 
inserted at the extremities so that the PCR products would have been subsequently 
cloned in the promoterless pBluescript vector (pBSSK). Before cloning in pBSSK, the 
PCR amplified fragments were subcloned in the pGEM T easy vector, (see paragraph 
2.4.1). Following subsequent step of cloning the entire 5’arm-NEO or HYGRO cassette- 
3’arm construct was obtainbed in the pBSSK. The recombinant plasmid was linearized 
with a unique restriction enzyme (Ahd) and transfected in the HCT-116 cell line, 
following steps of isolation of positive clones as described in paragraph 2.4.4.
To screen for the positive recombinant clones, genomic DNA was isolated by using the 
QIAamp DNA Blood Mini Kit (Qiagen) and the manifacturer’s instructions were
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followed. The screening of positive clones was performed by PCR by using specific 
primers designed at the extremity of the targeted region, taking advantage to the 
molecular weight difference between the wt allele and the recombinant allele with the 
neomycine cassette or the hygromycine cassette present in case of successful event of 
homologous recombination. The positive clones would show two distinct PCR products 
with a molecular weight difference of around 400bp.
2.9 RNA INTERFERENCE AND IDENTIFICATION OF A 
FUNCTIONAL CHK1 SPECIFIC siRNA
RNA interference (RNAi) is the process by which dsRNA (double strand RNA) silences 
gene expression by inducing the sequence specific degradation of complementary 
mRNA (siRNA). Long dsRNA is routinely used in non mammalian systems to effect 
gene silencing. Mammalian cells however have a potent antiviral response pathway that 
induces global changes in gene expression when dsRNA molecules longer than 30 nt are 
introduced in the cells (Hammond et al., 2001). A crucial insight came from Tushl and 
his group in 2001 (Elbashir et al., 2001) by showing that chemically synthesized short 
dsRNA molecules of 21-22 nucleotides known as small interfering RNA (siRNA) could 
be used to target mammalian genes by RNAi without activating the interferone response. 
Briefly the siRNA duplexes are composed of 21-nt sense and 21-nt antisense strands, 
paired in a manner to have a 2-nt 3’ overhang of uridine and a 5’- phosphate and 3’ 
hydroxyl groups. Once transfected in the cells, the siRNAs are incorporated into a 
multiprotein RNA-inducing silencing complex (RISC) containing a helicase which
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unwinds the duplex leaving the antisense strand to guide RISC to its homologous target 
mRNA for endonucleolytic cleavage as it is shown in figure 2.4.
Subsequent steps were performed to find a working siRNA direcetd against Chkl.
2.9.1 IN  VITRO SYNTHESIS OF siRNA CHK1
At first to choose a working siRNA Chkl I designed different siRNA specific for 
different Chkl cDNA targets which were in vitro transcribed using the Silencer 
siRNA construction kit (Ambion). The sequences were chosen following the criteria 
described in the kit datasheet which had to meet the requirements for the in vitro 
transcription by the T7 RNA polymerase. Briefly the first two nucleotides o f the 
RNA transcript at the 5’ ends had to be either GG or GA to ensure efficient synthesis 
while the two nucleotides at the 3’ ends had to be UU. In figure 2.5 the 4 sequences 
picked up to be in vitro transcribed on the Chkl cDNA are underlined and in 
particular the working one is outlined in yellow. Before picking up the sequences, 
the BLAST against EST libraries was performed to ensure that only the gene o f  
interest was targeted. To perform the in vitro transcription o f the siRNA Chkl the 
following steps were carried out.
• siRNA oligonucleotides sense and antisense were designed with a 3’ 8 -nt 
sequence complementary to the T7 Promoter Primer provided with the kit in 
order to ensure the hybridization of the siRNA oligonucleotides to the T7 
primer.
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Figure 2.4 mRNA specific degradation by siRNA in mammalian cells
Schematic representation o f the mechanism by which siRNAs once transfected in the 
cells specifically recognize the mRNA target. The RISC complex guides the 
unwound siRNA to its homologous mRNA target leading to endo and exonucleolytic 
cleavage and then to mRNA degradation. (Modified by Hammond S.M et al. 2001)
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• Oligonucleotides were prepared following the kit instructions and the 
hybridization reaction with the T7 primer was performed at 70 °C for 5 
minutes.
• The 3’ ends of the hybridized oligonucleotides were extended by the klenow 
fragment of DNA polymerase to create double stranded siRNA transcription 
templates. The reaction occurred at 37 °C for 30 minutes.
•  The sense and antisense siRNA templates were transcribed by the T7 RNA 
polymerase (37 °C for 2 hours) and the resulting RNA transcripts were 
hybridized to create dsRNA (37 °C overnight).
• The leader sequences were removed by digesting the dsRNA with a single 
strand specific ribonuclease. Overhanging UU dinucleotides remained on the 
siRNA because the RNAse does not cleave U residues. The DNA template 
was removed at the same time by a deoxyribonuclease.
• The resulting siRNA had been purified by glass fiber filter binding, following 
elution which removes excess of nucleotides, short oligomers, proteins and 
salts in the reaction.
• After quantification by the UV spectrophotometer and before proceding to 
transfect the cells, an aliquot of the siRNA product was loaded on a 2% 
agarose gel in order to test the quality of the 21-nt siRNA isolated.
Figure 2.6 summaries the principal steps of the procedure performed by using the 
Silencer™ siRNA construction kit (Ambion).
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Figure 2.5 Chkl cDNA targets for the siRNAs in vitro transcription
In figure the four cDNA target sequences chosen for the siRNA in vitro transcription 
are represented in blue. Yellow box shows the cDNA target o f the siRNA that most 
efficiently inhibits the Chkl expression.
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Figure 2.6 siRNA in vitro transcription procedure
Schematic representation o f the principal steps performed to in vitro transcribes the 
siRNAs by using a T7 RNA polymerase. More details in the text.
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2.9.2 SYNTHETIC siRNAs AND TRANSFECTION PROCEDURES
The cDNA Chkl target sequence comprising nucleotides 420-440 from starting ATG 
of Chkl cDNA was found to efficiently inhibit the Chkl expression and was chosen to 
be chemically synthesized in a larger scale and used to perform siRNA transfection 
experiments in the cells. The best siRNA transfection reagent was found to be 
Lipofectamine 2000 (Invitrogen). At first different concentrations of siRNA were tested. 
The 60 nM concentration was then found to be the lowest concentration used which 
ensured a good downregulation of the protein and was subsequently used to perform all 
the siRNA transfection experiments which were set up in the 24 well plates. Briefly, 
60nM of siRNA was mixed with 50 pi of OPTI-MEM each sample. The solution was 
subsequently mixed with 1 pi + 50 pi o f OPTI-MEM, previously incubated at RT for 5 
minutes. (NOTE: the amount of lipofectamine in each sample changed depending on the 
cellular line to be transfected ranging from 1-to 1,3 pi). The mixture was then incubated 
for 20 minutes at room temperature and 100 pi of transfection reaction was added to 500 
pi of media present in the well. The incubation with the transfected solution continued 
till the end of the experiment.
The synthetic siRNA Chkl was purchased from Proligo-SIGMA while the validated 
siRNA Chk2 was purchased from Xeragon oligoribonucleotides (Qiagen). The siRNA 
Chkl transient transfection experiments described in chapter 5 were performed by using 
a modified siRNA sequence directed against the same target sequence previously 
identified. I introduced an asymmetry in 5’ of the antisense strand by introducing a 
mismatch (nucleotide substitution in 3’ of the sense sequence). According to what 
Zamore and his group have reported in a recent paper, small changes in siRNA sequence
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5 ’ GGGAUAACCUCAAAAUCUCUU 3 ’ siRNA Chkl
3 ’UUCCCUAUUGGAGUUUUAGAG 5 ’ .......... ► personally validated (1)
5 ’ GGGAUAACCUCAAAAUCUAUU 3 ’ si* NA <T.l’kl
3 ’ UUCCCUAUUGGAGUUUUAGAG 5 ’ .......... *  P6rT ith  mismatch
5 ’ GCGUGCCGUAGACUGUCCAUU 3 ’   ^ siRNA Chkl validated
3 ’ UUCGCACGGCAUCUGACAGGU 5 ’ by Zhao et al. (2)
5 ’ ACUAUAAGGGUCAACACCUUU 3 ’ , ,  ,nxT
3 ’ UUUGAUAUUCCCAGUUGUGGA 5 ’  *  scramble siRNA ( )
5 ’ GCUUCCCAGUGGCAGGUCAUU 3 ’ ..........  ^ scramble siRNA (2)
3 ’ UUCGAAGGGUCACCGUCCAGU 5 ’
5 ’ CGCCGUCCUUUGAAUAACAUU 3 ’ .......... ^ siRNA chk2 validated
3 ’ UU GCGGC AGGAAACUU AUU GU 5 ’ by Xera8on
Figure 2.7 siRNA duplex sequences
A list o f the sequences o f siRNAs used in this thesis is provided in the figure. In the 
second duplex the mismatch introduced is marked with red colour.
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should have big effects on the participation of each individual strand of a siRNA duplex 
in entering the RNAi pathway. The RISC assembly is guided by an enzyme that selects 
which strand of siRNA is loaded into the RISC whereas the other one is degraded. This 
strand is usually the one whose 5’ end is less paired to its complementary. Thus the 
mismatch in 5’ of the antisense was designed to meet the biological requirements for the 
entry of the antisense strand into the RISC in order to render more efficient the 
downregulation (Schwarz et al., 2003). The second Chkl cDNA target sequence used in 
the siRNA double trasfection system was the validated one by Piwnica-Worms and her 
group (Zhao et al., 2002) and the cDNA target sequence comprises nucleotides 127-147 
from starting ATG. The control scramble siRNAs directed against the two siRNA Chkl 
sequences were designed by using a proligo database.
In figure 2.7 the siRNA duplexes sequences used in this thesis are listed.
2.9.3 siRNA CHK1 INDUCIBLE EXPRESSION
To get cellular clones inducibly expressing the siRNAs against Chkl the pSuperior 
plasmid (Oligoengine) was used (figure 2.8A). This plasmid basically has the same role 
that the pcDNA4/TO has in the inducible over-expression of a protein of interest. 
Briefly, the siRNA target was subcloned in the pSuperior plasmid downstream to an HI 
promoter which is responsive to the Tet repressor expressed by the second plasmid, 
pcDNA6 /TR. In the absence of tetracycline in the culture media, the Tet repressor binds 
to the promoter avoiding the expression of the siRNA. In the presence of tetracycline the 
Tet repressor detaches and the HI promoter gets activated expressing the siRNA of 
interest at first in a structure of a hairpin which permits the annealing of the sense and
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antisense sequences and then leading to the formation of the double strand RNA once 
the loop is cut by intracellular specific enzymes (figure 2.8B).
To clone the single cDNA target for the siRNA of interest in the pSuperior plasmid the 
following steps were perofined:
• 59-nt forward and reverse oligonucleotides were designed with the following 
structure each:
- Bglll (forward) and Hindlll (reverse) restriction site in 5’
- Target sense of 19-nt
- Hairpin o f 9-nt
- Target antisense of 19-nt
- Termination signal consisting of five thymidines in a row (T5) (the
cleavage of the transcript at the termination site is after the second
uridine so that the two 3’ overhanging U nucleotides are present as in 
the synthetic siRNAs. This region is inserted in 3 ’ o f the forward 
oligonucleotide and in 5’ immediately after the Hindlll site o f the 
reverse oligonucleotide.
•  The forward and reverse siRNA oligonucleotides were annealed in Universal 
Buffer (100 mM NaCl, 50 mM Hepes pH 7.4) by incubating 4 minutes at 94 °C 
and then at 70 °C for 10 minutes following a progressive cooling step (37 °C for 
15-20 minutes and at room temperature before using). In the mean time the 
pSuperior vector was cut with Bglll and Hindlll
•  The annealed oligonucleotides were cloned into the linearized vector and the
subsequent cloning steps were performed as described in paragraph 2.4.
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Figure 2.8 siRNA inducible expression system
A. pSuperior/puro vector. The two restriction enzymes chosen for cloning, Bglll
and Hindlll are underlined in the MCS. EcoRI restriction site (used for the
double siRNA cloning) in 5’ o f the HI promoter is also underlined.
B. Schematic representation of the siRNA duplex formation in the cells from the
DNA of 59bp cloned in the pSuperior vector.
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To clone the second cDNA target for the siRNA of Chkl in the pSuperior already 
containing the first cDNA Chkl target, the forward and reverse oligonucleotides of this 
second target had to be designed by adding downstream to the termination sequence, the 
EcoRI restriction site, so that after the first step of cloning by following the same 
cloning procedures just described, the target sequence inserted together with the HI 
promoter could be excised by cutting with the EcoRI restriction enzyme and then ligated 
in the first pSuperior containing one cDNA Chkl target and previously linearized with 
EcoRI (single site in the vector).
To clone the siRNA scramble sequences the same procedures just described were 
followed.
2.10 IDENTIFICATION OF TRANSCRIPTIONAL STARTING SITES
To identify the Chkl gene transcriptional starting sites the primer extension assay was 
performed. The first necessary step was the isolation of mRNA from the total RNA. The 
total RNA was isolated from the HCT-116 cell line as previous data in literature (Damia 
et al., 2001) had attested to have the two different length transcripts of Chkl.
2.10.1 TOTAL RNA EXTRACTION
The SV total RNA isolation kit (Promega) was used for isolating total RNA. By using 
this method it is possible to isolate pure RNA from relatively few cells (106) in a limited 
time (1-2 hours). The cells are lysed in a guanidine thiocyanate containing solution 
which maintains the integrity of RNA while disrupting cells and dissolving cell
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components. RNA was then prepared following exactly the manufacture’s instructions. 
The purified RNA is then eluted with a small volume of water (generally 50 microliters). 
An aliquot (2 pi) of this solution was diluted in sterile water to a final volume of 200 pi, 
and the RNA concentration was measured spectrophotometrically following the formula 
RNA (mg/ml) = OD260 nm x 40 x dilution factor. The amount o f RNA is calculated 
considering that a solution of 40 pg of RNA in one ml would give an absorbance reading 
of 1.0 at 260 nm. The260/280 assorbance ratio must be between 1.8 and 2.0 for a sample 
of reasonable purity. Samples were stored at -80°C until used.
2.10.2 PURIFICATION OF POLY A* RNA FROM TOTAL RNA PREPARATIONS
To isolate mRNA from the total RNA previously extracted, the Dynabeads Oligo 
(dT)25 Kit from Dynal (Invitrogen) was used and the procedure followed is herein 
described. Briefly, the use of Dynabeads Oligo (dT) 2 5 relies on base pairing between the 
poly(A+) residues at the 3’ end of most messenger and the oligo d(T) residues 
covalently coupled to the surface of the Dynabeads Oligo (dT)25 .
Around 75pg of total RNA was adjusted to a total volume of lOOpl with distilled DEPC 
treated water. The same total volume of 2X Binding Buffer (solution B) was then added 
to the Dynabeads 0 1 igo(dT) 25 to obtain a IX binding buffer concentration in order to get 
the most optimal binding concentration.
2X Binding Buffer (solution B):
20mMTris-HCl (pH 7.5)
lM LiCl
2mMEDTA
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2 0 0 pl of resuspended Dynabeads 01igo(dT)25 were then transferred from the stock tube 
suspension to an RNAse free Eppendorf tube placed in a Dynal MPC which is an 
apposite magnetic particle concentrator rack. After 30 seconds or when the suspension 
was clear the supernatant was removed and the dynabeads were washed by resuspension 
with lOOjul of 2X binding buffer. The 2X binding buffer was then removed from the 
dynabeads while the vial is placed in the dynal MPC then the vials were removed from 
the Dynal MPC. The dynabeads were resuspended again with lOOpl o f 2X Binding 
buffer. The total RNA suspension which was previously heated at 65 °C for 2 minutes to 
disrupt secondaries structures, was then added to the Dynabeads suspension. The 
mixture was mixed gently and the annealing was assured by rotating on a roller for 3-5 
minutes at room temperature. The vials were then placed in the Dynal MPC for 30 
seconds and the supernatant then removed. The vials were transferred to another rack 
and washed with 200 pi o f Washing buffer (solution E) using the Dynal MPC. The 
mRNA was then eluted from the Dynabeads by adding 10-20 pi of Elution Buffer 
(solution F) and by keeping them at 65 °C for 2 minutes. The tubes were then 
immediately placed in the Dynal MPC and the supernatant containing the mRNA was 
transferred in a new RNAse free tube. It was possible to calculate the concentration of 
the isolated mRNA by aliquoting 2 pi of the total solution in sterile water to a final 
volume of 200 pi, and the mRNA concentration was measured spectrophotometrically 
following the formula RNA (mg/ml) = OD260 nm x 40 x dilution factor. The amount of 
mRNA is calculated considering that a solution of 40 pg of RNA in one ml would give 
an assorbance reading of 1.0 at 260 nm. The260/280 assorbance ratio must be between
1.8 and 2.0 for a sample of reasonable purity. Samples were stored at -80°C until used.
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Washing buffer (solution E) 
lOmM Tris HCl (pH 8.0)
0.15MLiCl
ImMEDTA
Elution Solution (solution F) 
lOmMTris pH  7.5
2.10.3 PRIMER EXTENSION REACTION
Briefly, the primer extension analysis is used to determine the location and to quantitate 
the amount of 5’-end of specific RNAs. An end labeled oligonucleotide is hybridized to 
RNA and is utilized as a primer by reverse transcriptase in the presence of 
deoxynucleotides. The RNA is reverse transcribed into cDNA and is analyzed on a 
denaturing polyacrylamide gel. The length of the cDNA reflects the number of bases 
between the labeled nucleotide of the primer and the 5’ -end of the RNA whose length in 
our experiment was calculated thanks to the DNA sequence loaded close to the primer 
extension reaction in the same denaturing polyacrylamide gel. In our specific 
investigation the transcriptional starting site upstream to the second exon was found 
thanks to the utilization of a specific primer located in the second exon, called CHP2 
(figure 2.9).
2.10.3.1 OLIGONUCLEOTIDE LABELING B Y PHOSPHORYLATION
The following components were mixed to a 1,5 ml microcentrifuge tube:
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Exon 2
C H P 2
B
C H P 2 specific sequence: 5 ’A T T C A C A G C A A G T T G A A C T T C T C C A T A  V
Figure 2.9 CHP2 primer used for primer extension reaction
A. Schematic representation of the primer’s position in the Chkl gene.
B. Specific CHP2 primer sequence.
122
Oligonucleotide primer (lpM) 5pi (5pmol)
10X T4 Polinucleotide Kinase Buffer 2 pi
[y- 32P] ATP(10mCi/ml) 3 |il (30|iCi)
T4 Polynucleotide Kinase 1 jj.1
H20 9 p i
Total 20 pi
The mixture was incubated at 37 °C for 45-60 minutes, following the inactivation of the 
kinase for 10 minutes at 6 8  °C .
Purification of the oligonucleotide from unlabelled nucleotide was performed using 
Sephadex G50 columns (Boheringher-Mannheim) exactly following the manufacturer’s 
instructions. Briefly the column was at first equilibrated by centrifuging for 2 minutes at 
3,000 rpm; then the 20 pi of reaction were entirely loaded in the column and centrifuged 
for 4 minutes at 3,000 rpm. The incorporated radioactivity was detected by Cherenkov 
counting. The saved oligonucleotide could be stored at -  20 °C, being stable for up to 1 
month.
2.10.3.2 HYBRIDIZATION OLIGO/RNA
The following components were mixed to a 1,5 ml microcentrifuge tube: 
mRNA lpg/pl 3 pi
Buffer 10X 1,5 pi
Probed oligonucleotide at least 50,000 cpm
H20 to 15 pi
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The mixture was incubated at 60 °C for 90 minutes then it was cool down at room 
temperature for at least 15 minutes.
2.10.3.3 PRIMER EXTENSION REACTION
To each previous oligo/RNA annealed mixture the following components were 
added:
Tris HCl p H  8.3 1M 0,9pl
MgCl2 0,5M 0,9p i
DTT1M  0,25pl
Actinomicin D 6,75 pi
dNTP 2,5mM 2,66 pi
superscript (25U/ pi) 0,2 pi
H2O to 30 pi
The mixture was incubated at 42 °C for 1 hour then 1/10 volume of sodium acetate 3M 
and 2-3 volumes of ethanole 100% was added for precipitation by incubating 15-30 
minutes in dry ice and ethanole 100%, following a 30 minutes centrifugation at 13,000 
rpm. The samples were desiccated by speed vacuum and then resuspended in 5 pi of  
loading dye buffer, following boiling for 2 minutes to denature DNA-RNA hybrids 
and then loading on the denaturing polyacrylamide gel together with a DNA 
sequenced sample to detect the product’s length.
2.10.3.4 DENATURING GEL PREPARATION 
Denaturing gel recipe:
final concentration
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15 ml 30% acrylamide/bis 37.5:1 6%
18 ml TBE 5x Ix
37.8 g  urea 7M
Basically, urea was dissolved in the acrylamide solution with TBE lx  and the final 
volume made up to 90 ml with distilled water. The solution was placed on ice to cool 
before the addition of 10% of ammonium persulphate (450 pi) and TEMED (15 pi) just 
before pouring to give a gel of dimensions 30x40 cm. Sharks tooth (14 cm) combs were 
put in upside down and the gel was left to polymerise for about 2 h. The gel was placed 
in a model S2 sequencing gel electrophoresis apparatus (Gibco-BRL-Life Technologies, 
Milan-Italy). lx  TBE buffer was used as the running buffer. The gel was pre- 
electrophoresed for 30 min at 60 W, using a LKB power pack (Hoefer, Life 
Technologies).
TBE (5x) recipe:
final concentration 
54 g Tris base 446 mM
27.5 g boric acid 445 mM
4.65 g EDTA 12 mM
to a final volume of 11 with distilled water. Solution was stored at room temperature.
2.10.3.5 DNA SEQUENCING
125
To find out the length of the band obtained by the primer extension reaction a DNA 
sequence ladder was loaded in parallel on the acrylamide denaturing gel and was 
prepared following the Sanger sequencing protocol. The Sanger sequencing protocol is 
generally known as the chain termination method (Sanger et al., 1992). Chain 
termination is achieved by incorporating a nucleotide analogue at the end o f the growing 
DNA strand that lacks a 3'-hydroxyl group for attachment of the next nucleotide. This is 
done by individually introducing a small amount of the 2', 3'-dideoxyribonucleotide-5'- 
triphosphate (ddNTP) for one of the four DNA bases into each o f the four DNA 
synthesis reaction mixtures described above. The dideoxy analogs are incorporated onto 
the 3’-ends of the growing chains like normal deoxynucleotides, but they lack the 3'- 
hydroxyl group needed for addition of the next nucleotide. Thus, whenever one of them 
is randomly incorporated, growth of the chain is irreversibly terminated at that point. In 
the Sanger protocol, a purified DNA polymerase with no primase activity is used, thus 
preventing any possible spontaneous initiation of synthesis at unwanted locations. 
Priming is done with a synthetic oligonucleotide that is complementary to a specific 
sequence on the template strand. Plasmid DNA was denatured with NaOH (2 M) for 30 
min at 37°C. DNA was precipitated by addition of 2.5 volumes of 100% ice-cold ethanol 
and 10% 3 M NaAc, and left on dry ice for 30 min and then centrifuged for 30 min at 
15,000xg. The pellet was washed with 200 pi of 75% ethanol and centrifuged as before 
for additional 4 min. The pellet was air dried and resuspended in 8  pi of sterile water. T7 
(5 pmol) primer was added and the final preparation of the sample was accomplished 
using a - ( 35S) dATP and “Sequenase Version 2” sequencing kit (Amersham-Life 
Science). A radioactive labelled nucleotide was included in the synthesis so that labelled
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chains of various lengths can be visualised by autoradiography after separation by high- 
resolution electrophoresis.
2.11 PROTEIN ANALYSIS: WESTERN BLOTTING
Western blot analysis ensures separation of proteins according to size using sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS/PAGE), transferring them to 
nitro-cellulose electrophoretically and then using specific antibodies to detect the protein 
of interest.
2.11.1 PROTEIN EXTRACTS PREPARATION
Total proteins were extracted from cells growing in culture by a lysis method. Basically 
cell cultures were washed twice with ice-cold PBS and then detached with a disposable 
scraper in 500 pi o f PBS. The suspension was then centrifuged at 1,200 rpm for 10 
minutes and after centrifugation, the pellet was resuspended in an amount of lysis buffer 
dependent on the size of cell pellet
Lysis Buffer final concentration
20 p i Triton X-100 1%
20 /A Tris 1M, pH  7.4 10 mM
60 filNaCl 5 M 150 mM
8 fil leupeptin 5 mg/ml 20 pg/ml
5 p i aprotinin 2 mg/ml 5 pg/ml
20 p i PMSF100 mM 1 mM
to a final volume o f 2 ml with sterile water.
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and incubated on ice for 30 minutes in an orbital shaker. After 10 min of centrifugation 
at 12,000 x g at 4°C, cellular debris were pelleted and the total protein present in the 
supernatant was recovered and placed in a fresh Eppendorf tube (1.5 ml). An aliquot (2 
pi) was used for determination of protein concentration.
2,11.2 CALIBRATION CURVE PREPARATION
Solutions of bovine serum albumin (BSA) (ranging between 1 and 20 pg/200 pi) were 
prepared from a stock solution of BSA obtained by dissolving powdered BSA (Sigma) 
in water. In a 1.5 ml tube, 200 pi of each BSA solution were mixed with 600 pi of  
distilled water and 200 pi of BioRad protein assay dye (BioRad). In the blank sample 
800 pi of distilled water was mixed with 200 pi of BioRad protein assay dye. Samples 
were rapidly transferred into disposable cuvettes (PBI International, Milan-Italy) and the 
absorbance at 595 nm was measured in the spectrophotometer. The absorbance value 
corresponding to the blank sample was subtracted from the values obtained in the BSA- 
containing samples. Each calibration sample was run in triplicate. The calibration curve 
obtained in such a way, allows extrapolation of the exact absorbance value 
corresponding to 1 pg of proteins present in the solution.
2.11.3 DETERMINATION OF PROTEIN CONCENTRATION IN  CELLULAR 
EXTRACTS
Protein concentration in the cellular extract was determined according to the Bradford 
protocol. The concentration of proteins in the samples was determined by mixing in a
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1.5 ml tube 2 pi of protein extract with 200 pi of BioRad protein assay dye and distilled 
water in a final volume of 1 ml. Samples were processed as for the calibration curve and 
the amount of proteins calculated from the absorbance value corresponding to 1 pg of 
proteins (obtained from the calibration curve).
2.11.4 SDS-PAGE
An aliquot (typically 30 pg) of protein of each sample was mixed with the same amount 
of 2X SDS loading buffer:
SDS Loading Buffer (2X)
200 pi Tris 1 M, p H 8.8 
400 p i D T T 1 M  
800 jul SDS 10%
400 p i glycerol 
40 p i bromophenol blue 10% 
to a final volume o f 2 ml with sterile water
and the mixture was boiled for 5 min. Samples were loaded onto a 5% stacking gel and a 
range of 6-15% separating gel:
Stacking Gel final concentration
2.5 ml Tris-HCl 0.5 M, p H  6.8 125 mM
0.1 ml SDS 10% (w/v) 0.1% (w/v)
final concentration 
100 mM 
200 mM 
4%>
20%
0.2 %
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1.62 ml 30% acrylamide/bis 37.5:1 5% (w/v)
To a final volume o f 10 ml with deionised water.
50 p i ammonium persulphate 10% (w/v) 0.05% (w/v)
5 p i TEMED
Separating Gel final concentration
5.0 ml Tris-HCl 1.5 M, p H 8.8 750 mM
0.2 ml SDS 10% (w/v) 0.1% (w/v)
X m l 30% acrylamide/bis 37.5:1 X%> (w/v)
To a final volume o f 10 ml with deionised water.
100 p i ammonium persulphate 10%> (w/v) 0.05% (w/v)
7.5 p i TEMED
Stacking and separating gels were prepared shortly before pouring. Ammonium 
persulphate catalyses polymerization and TEMED accelerates the reaction and so these 
two reagents were added last.
Proteins were resolved on a minigel apparatus (BioRad) and run for 2 h at 100V in IX 
TGE buffer:
Running Buffer (TGE IX) final concentration
15.15 g Tris base 25 mM
72 S glycine 192 mM
5 g  SDS 0.1% (w/v)
to a final volume o f 5 1 with deionised water. The buffer was stored at room temperature.
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Electrophoresis progress was followed using pre-stained molecular weight markers (11- 
170 Kda, Page Ruler Prestained Protein Ladder, FERMENTAS)
2.11.5 PROTEIN TRANSFER AND DETECTION
The separated proteins were transferred onto nitro-cellulose (at 60V for 2 h) using 
BioRad Mini transfer blot equipment in IX transfer buffer:
Transfer Buffer IX  final concentration
24.2 g  Tris Base 50 mM
28.5 g  glycine 100 mM
4 ml SDS 10% 0.01%
800 ml methanol 20%
to a final volume o f 4 I with deionised water. The solution was stored at room 
temperature.
Filters were stained with Ponceau red solution (Sigma) to check sample loading and 
transfer. Blots were placed in a bag with 5% non-fat dried milk dissolved TBS-T 0.1%
TBS-T 0.1% final concentration
2.42 g  Tris base 20 mM
8gNaCl 137 mM
1 g  Tween 20% 0.1% (w/v)
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to a final volume o f 1 I with deionised water. The pH  was adjusted to 7.6 with 
concentrated HCl and stored at 4°C.
and shaken o/n at 4°C to block non-specific binding. All the following procedures were 
carried out at room temperature on a shaker. Blots were exposed for 2 h at room 
temperature to the desired primary antibodies diluted to the optimal working solution in 
TBS-T 0.1%. After incubation, the blots were washed twice with TBS-T 0.1% and 
incubated with the appropriate horseradish-peroxidase linked anti-mouse or anti-rabbit 
IgG secondary antibody (Amersham) for 1 h using appropriate dilutions. Blots were 
washed as previously described, and detection was performed with an enhanced 
chemiluminescent detection system (ECL, Amersham-Life Science). Briefly, the 
horseradish peroxidase acts as a catalyst for the oxidation of a luminol substrate, which 
subsequently emits small but sustained quantities of light. This chemiluminescence is 
specifically enhanced allowing an image to be recorded on photosensitive film. The 
blots were exposed to film for different time ranging from 15” to 3 min and developed 
using an X-o graph compact x-2 developer with Kodak GBX developer and fixer.
The antibodies used for Western blot analysis in this study were:
• Chkl, Chk2, E2F1, cyclin B l, caspase-3, actin and P-tubulin antibodies.
Mouse monoclonal IgG for Chkl, cyclin B l and caspase-3, rabbit polyclonal IgG for 
E2F1, Chk2 and p-tubulin and goat polyclonal IgG for actin detection were supplied by 
Santa Cruz Biotechnology. Stock solutions were stored at 4°C and working solutions 
were prepared by diluting the antibody 1:500 in 5% non-fat dried milk dissolved in 
TBS-T 0.1%. Goat anti-mouse for Chkl, cyclin B l and caspase-3, goat anti-rabbit for
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E2F1, Chk2 and p-tubulin and donkey anti-goat for actin IgGs horseradish peroxidase 
secondary antibodies were supplied by Santa Cruz and diluted 1:3,000 in 5% non-fat 
dried milk dissolved in TBS-T 0.1%.
2.12 KINASE ASSAY
Chkl kinase activity was determined after immunoprecipitation with anti Chkl antibody 
(G4, Santa Cruz biotechnology). Briefly 100 pg of protein extracts (prepared as just 
described) were incubated at 4°C with 1 pg of anti Chkl antibody (SantaCruz 
Biotechnology) overnight with continuous, gentle rocking. To this solution, 50 pi of 
agarose beads (protein A/G Santa Cruz Biotechnology) were added and the incubation 
continued for 1 hour. Agarose bound kinase was collected by centrifugation at 2,000 
rpm in an eppendorf tube for 5 min and washed twice with 500 pi of PBS.
Kinase reaction was performed in 25 pi reaction containing: 1.5 pg o f recombinant 
GST-Cdc25C (aa 250-256) previously exratced from bacteria as I will describe in the 
next paragraph 5pCi of 32P-yATP (Amersham), 1 pM ATP, 0.5 mM DTT, 50mM Tris 
HC1, 10 mM MgCl2 . After 20 minutes incubation at 30°C, 25 pi of 2x loading buffer are 
added and the mixture heated at 90°C for 5 minutes, cooled on ice and loaded on 10% 
SDS-PAGE gels.
The gel was run for 16 hours at 30 V after which the gel is removed and directly 
exposed to autopradiographic films to detect phosphorylated Cdc25C.
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2.12.1 PURIFICATION OF GST-FUSION PROTEIN GST-CDC25C FROM  
BACTERIA
To recover GST fusion proteins produced in E. coli cells containing a recombinant 
pGEX-3X plasmid the GST Gene Fusion System, purchased from Pharmacia Biotech, 
was used, following the procedure suggested by the manufacturer’s instruction manual. 
From a glycerol stock stored at -80 °C, E. coli containing pGEX-3X /GST-Cdc25C (aa 
250-56) recombinant was streaked onto a LB medium agar plate in sterility and 
incubated overnight at 37 °C. One colony was picked up and inoculated into 5 ml of LB 
medium containing the antibiotic of selection then incubated for 12-15 hours at 37 °C 
with vigorous shaking. The grown culture was then diluted 1:100 into fresh pre-warmed 
LB medium with the antibiotic and let grow at 37 °C with shaking. Then the steps 
followed were exactly the same described in the instruction manual provided with the 
purification system previously mentioned. Briefly, the bacterial culture was grown until 
the A6oo reached 0.5-0.6, then by the addition of 0.1 mM of IPTG to the culture induced 
to produce fusion protein with a 2-6 hour-incubation. The bacterial culture was 
centrifuged to sediment the cells and the pellet resuspended in a final volume o f ice-cold 
PBS corresponding to 1/20 of volume of the starting bacterial culture. The cells were 
disrupted with a sonicator on ice and fusion proteins were solubilised by addition o f 1% 
Triton X-100 to the sonicated cells and gently rotated for 30 minutes. Then the solution 
was centrifuged and the supernatant was loaded the Glutathione Sepharose 4B and 
shaken for 2 hours in the cold room. This agarose matrix carried glutathione molecules 
which bound to the fusion protein through the GST-tag. After washes to remove un­
bound proteins, the fusion protein was eluted with 10 mM of GSH from the matrix. The
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eluted material was monitored for GST-fusions protein by SDS-PAGE. The 
polyacrylamide gel was subsequently stained with Coomassie Blue R250.
Coomassie Blue R250:
0.25 g  Coomassie Blue
45 ml methanol
45 ml glacial acetic acid
to a final volume o f 100 ml with deionised water. Filter the solution through paper
The gel was immersed in the coomassie solution for 60 minutes and washed overnight in 
a de-staining solution (30 ml methanol, 5 ml glacial acetic acid, to a final volume o f 50 
ml with deionised water).
2.13 IN  VIVO TUMOR GROWTH
Four week-old female Athymic Swiss NCr-nu/nu mice were obtained from Charles 
River (Calco, Italy). Mice were maintained under pathogen-free conditions, and 
provided with food and water ad libitum. Procedures involving animals and their care 
were conducted in conformity with the institutional guidelines that are in compliance 
with national (D.L. n.ll6,G.U., suppl.40, 18 febbraio 1992, Circolare No. 8, G.U., 14 
luglio 1994) and international laws and policies (EEC Council Directive 86/609, OJ L 
358,1, Dec 12, 1987; Guide for the use of Laboratory Animals, United States National 
Research Council, 1996). The clones, (HCT-116 p53 +/+ and p53 -/-) stably transfected 
with the pSuperior-siRNA Chkl plasmids, were allowed to grow in vitro and then 5xl06 
cells of each clone were implanted subcutaneously in each flank of nude mice. The day
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after transplant, mice were randomized to receive or not tetracycline in the drinking 
water. Tetracycline was provided with drinking water (2pg/ml) throughout the period of 
the experiment and was replaced every other day. The length (L) and the width (W) of 
the tumor mass were measured by caliper twice weekly, and the tumor volume (TV) was 
calculated as: TV= (LxW2)/2 being W<L. At the end of the experiment animals were 
sacrified and tumor tissue excised. Fragments o f the tumors were immediately frozen in 
liquid nitrogen for protein extraction and other pieces were fixed in formalin 4% for IHC 
analysis.
2.14 FLOW CYTOMETRIC ANALYSIS OF CELL CYCLE 
DISTRIBUTION
Cells (about 5xl05) were fixed 24 after the end of DDP and IR treatments in the siRNA 
transfection experiments described in chapter 4, while as regarding the experiments 
described in chapter 5 the cells were fixed at 72 hours after siRNA transfection. Cells 
were washed twice in ice-cold PBS, fixed in ice-cold 70% ethanol, washed in PBS, 
resuspended in 2 ml of a solution containing 25 pg/ml of propidium iodide in PBS and 
25pi of RNAse 1 mg/ml in water and stained overnight at 4°C in the dark. Cell cycle 
analysis was done on at least 10,000 cells for each sample using the FACSCALIBUR 
instrument (Becton Dickinson, HO, USA). The percentage of cell cycle phase 
distribution was calculated as previously described (Broggini et al., 1991). In Chapter 4 
the G2 abrogation of the cell cycle was calculated following the formula: 1 - % o f cells 
in the G2 phase in siRNA transfected treated cells/ % of cells in the G2 phase in mock 
treated cells.
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2.14.1 CYCLINB1 LEVELS DETECTION B Y  FACS ANALYSIS
To detect cyclin B1 levels by FACS, cells were again fixed in ethanol 70% and 
stored at +4 °C for at least one night. The fixed cells were washed in cold PBS, 
following permeabilization with 0,25% of Triton X-100 in PBS for 5 minutes on ice. 
Cells were then washed in PBS and incubated with 200 pi o f the anti cyclin B1 
antibody (0,5 pg/sample, clone GNS1 from Pharmingen) diluted in rinsing buffer 
(1% BSA in PBS) overnight at 4 °C by gentle agitation. A blank sample was prepared 
by incubation of cells with 200 pi of isotype IgG instead of cyclin B l. Cells were then 
washed once before the incubation with 200 pi of Alexa Fluor 488 F(ab’)2 goat anti 
mouse IgG (Molecular Probes, Eugene, Oregon, USA) diluted 1:500 in 0,5% (v/v) 
Tween-20 in PBS for one hour and incubated at room temperature in the dark by 
gentle agitation. Cells were washed in PBS and subsequently resuspended in a 
solution containing 5 pg/ml of propidium iodide + 25 pg/ml o f RNAse A in water to 
stain the DNA, for one hour at room temperature in the dark. Bi-parametric 
CyclinBl/DNA flow cytometric analysis was performed on at least 20,000 cells for each 
sample using the Coulter Epics XL (Beckman Coulter, Miami, FL) and the data 
analyzed with System II software (Beckman Coulter). The fluorescence pulse was 
detected using a bandpass filter, 530±30 nm and 620 ± 35 nm for green (cyclinBl) and 
red (DNA) fluorescence respectively, in combination of a 570 nm dichroic mirror. This 
was the procedure I used in US to detect cyclinBl and DNA by FACS. In Mario 
Negri laboratory, the procedure I followed was similar but to reduce the interference 
between propidium and FITC emission spectra, the DNA was stained with TO-PRO- 
3 iodide (TP3). After removing the Alexa 488 the cells were washed in PBS and
137
stained for 30 minutes at room temperature in the dark with a TP3 solution 
containing 0.5 pM TO-PRO-3 in PBS and 25 pi RNAse 1% in PBS and the cell cycle 
analysis was performed by using a FACSCALIBUR instrument (Beckton Dickinson) 
equipped by a second red iodide laser emitting at 635 nm and a band pass filter 661± 
16 nm for TP3 detection.
2.15 IMMUNOFLUORESCENCE ANALYSIS
To perform immunofluorescence analysis the cells were seeded and grown directly 
on round glass coverslips in 24 well plates. Depending on the kind o f staining 
performed, the procedure followed is reported below.
2.15.1 DETECTION OF CHK1 INpSUPERIOR DOUBLE INDUCIBLE CLONES
Cells seeded in 24 well plates on coverslips at approximately 15,000 cells/ml of 
density were subsequently induced or non induced with doxycycline 2pg/ml. The 
inducer was added each 48 hours. The cells either induced or not, after 48,72 and 96 
hours from the first induction were washed in PBS once and fixed with 4% 
paraformaldehyde (PBS solution) for 20 minutes, following two washes in PBS. 
Cells were permeabilized with Triton X-100 (0.5% in PBS) for 5 minutes and then 
blocked in Blocking Buffer (2% BSA, 0,2% triton X-100 in PBS) for one hour. The 
cells were subsequently incubated for one hour with the anti Chkl primary antibody 
(clone DCS310 from SIGMA) diluted 1:500 in blocking buffer, following 3 washes 
in PBS, 5 minutes each. The FITC conjugated secondary antibody Alexa Fluor 488
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donkey anti-mouse (Molecular Probes) was added to the cells diluted 1:500 in 
blocking buffer for one hour in the dark. After 3 washes o f 15 minutes each in PBS, 
cells were incubated with Hoechst 33342 (trihydrochloride, tritydrate, Invitrogen) 
solution (final concentration: 1 pg/ml) for 20 minutes, following two washes in PBS 
and one wash in distilled water. The cells were mounted with the mounting media 
Fluor Save (Calbiochem) observed in a Zeiss Axiophot photomicroscopy equipped for 
epifluorescence (Carl Zeiss, Oberkochen, Germany) and pictures were taken. If not 
otherwise specified, both the primary and the secondary antibodies used in the 
immunofluorescence analysis herein described were diluted in blocking buffer.
2.15.2 MITOTIC PHENOTYPE DETECTION IN  HeLa CELLS
To study the mitotic phenotype in HeLa cells different staining and costaining 
strategies were used.
2.15.2.1 MITOTIC SPINDLE STAINING
HeLa cells transfected with either siRNA scramble or siRNA Chkl were fixed at 48 
and 72 hours post transfection with 4% paraformaldehyde (in PBS solution) for 20 
minutes at room temperature, washed in PBS twice and stored at 4 °C until staining. 
Before staining cells were permeabilized for 5 minutes with Triton X-100 (0.5% in 
PBS) for 5 minutes then blocked in Blocking Buffer (2% BSA, 0,2% triton X-100 in 
PBS) for one hour. The cells were then incubated with anti a-tubulin (Harlan, anti 
rat) diluted 1:100. After over night incubation, cells were washed 3 times in PBS (5 
minutes each) and the anti-rat antibody conjugated FITC (from Sigma) was used as
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secondary antibody for one hour at room temperature, 1:100 dilution, following 3 
washes in PBS (10 minutes each). To stain nuclei, before mounting, cells were 
incubated with DAPI (final concentration: 30 ng/ml in PBS) for one minute and 
subsequently mounted with 7|il o f Vectashield solution (VectorLab). Slides were 
then observed at the microscope (Zeiss Axioscope, with a Zeiss color camera and the 
Axiovision software).
Basically the same procedure and the same material were used to observe the mitotic 
spindle in U20S cells, but the cells were observed in a Zeiss Axiophot 
photomicroscopy equipped for epifluorescence (Carl Zeiss, Oberkochen, Germany) as 
this part was performed in Mario Negri Institute.
2.15.2.2 MITOTIC SPECIFIC CO-STAINING WITH ALPHA TUBULIN AND HISTONE H3 
PHOSPHORYLATED A T  SERINE 10 
To perform the costaining with the two mitotic markers a -tubulin and histone H3 
phosphorylated at serine 10, the cells were basically treated exactly as in the previous 
staining with only a-tubulin and the subsequent staining with the second marker. After 
the washes from the secondary FITC conjugated anti rat antibody, the slides were 
incubated with anti histone H3 phosphorylated at serine 10 (anti mouse, Cell signal) 
diluted 1:50 overnight at 4 °C. Slides were washed 3 times in PBS (5 minutes each) and 
then incubated with secondary antibody, donkey anti mouse Alexa Fluor 594 (Molecular 
Probes), diluted 1:800, for one hour at roome temperature, following three washes in 
PBS (10 min. each). DAPI staining and mounting of the slides were performed as 
previously described.
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2.15.2.3 MITOTIC SPINDLE AND CENTROSOMES CO-STAINING
To detect both mitotic spindle and centrosomes in HeLa cells, the following 
procedure was performed. After the standard fixation with paraformaldehyde 4%, 
slides were additionally fixed with ice cold methanol for 3 minutes at room 
temperature, following a PBS wash for 5 minutes. The permeabilization occurred for 
30 minutes by gentle shaking at roome temperature in 0,5% Triton X-100 (in PBS). 
The slides were then incubated with anti y-tubulin (anti mouse, clone GTU-88 from 
Sigma) diluted 1:6,000 in Blocking Buffer for one hour at room temperature, 
following three washes in PBS (5 minutes each). The secondary donkey anti mouse 
Alexa Fluor 594 was then used as secondary antibody (Molecular Probes), at a 1:800 
dilution in blocking buffer, following three washes in PBS (15 minutes each). The 
subsequent incubation with anti a-tubulin and DAPI was performed as previously 
described.
2.15.3 DAPI-SULFORODAMINE STAINING
U20S cells seeded on round glass coverslips and transfected with either siRNA 
scramble or siRNA Chkl were fixed at 72 hours post transfection with 4% 
paraformaldehyde (in PBS solution) for 20 minutes at room temperature, then 
washed in PBS twice and stored at 4 °C until staining. Cells were incubated with a 
DAPI/sulphorhodamine solution for 15-30 minutes in the dark (3.5 mg DAPI was 
dissolved in 100 ml in deionised water; to 0.5 ml o f DAPI solution diluted in 100 ml o f  
PBS, 3 mg o f sulphorhodamine was added. The volume was brought to 300 ml by adding 
the Na-Tris HCl pH8 solution:
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Tris base 12 g  
NaCl 6g
HC11M 54 ml
H2O to a final volume o f lL .
After further washes with deionised water, glass coverslips were mounted in Entellan 
(Merck, Milan-Italy) and observed in a Zeiss Axiophot photomicroscopy equipped for 
epifluorescence (Carl Zeiss, Oberkochen, Germany).
2.15.4 LAMINB STAINING
U20S cells seeded on round coverslips and transfected with either siRNA scramble 
or siRNA Chkl were fixed at 72 hours post transfection with paraformaldehyde 4% 
and then after usual permeabilization with Triton X-100 0,5% in PBS for 5 minutes 
and a 1 hour incubation with blocking buffer, were stained with anti lamin B (goat, 
Santa Cruz Bitechnology) diluted 1:500, overnight at 4 °C, following three washes in 
PBS (5 minutes each). Cells were incubated with FITC conjugated goat secondary 
antibody (molecular probes) for one hour at room temperature, following three 
washes in PBS (15 minutes each). DAPI staining and mounting procedures were the 
same just described for the other immunofluorescence staining.
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RESULTS
CHAPTER 3
CHARACTERIZATION OF THE 5 ’ FLANKING REGION 
OF THE HUMAN CHK1 GENE
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3.1 INTRODUCTION
As I largely mentioned in my introduction, following DNA damage a very well 
organized signal transduction pathway is activated in the cell to prevent genomic 
instability. The different checkpoint proteins participating in the checkpoint pathways 
have to be considered as interconnected in exerting their function. In fact, for example, 
the main player of the G1 checkpoint, p53, also plays a role in regulating the G2-M 
transition by transactivating some genes involved in the regulation of the Cdkl/CyclinB 
complex. On the other hand the two main G2 checkpoint regulators, Chkl and Chk2, 
play a role in G1 and S phase checkpoint by phosphorylating and leading to degradation 
of the Cdc25A phosphatase. It has been recently shown by our group and another group 
(Damia et al., 2001; Gottiffedi et al., 2001) how Chkl and p53 can be interconnected 
following DNA damage. Chkl can contribute to the phosphorylation and activation of 
p53 and at later time points from the introduction of the damage, Chkl would be 
downregulated in a p53 dependent manner. This is likely to be the way the cells abrogate 
the G2 block once the damage has been repaired (figure 3.1). In order to further 
investigate on the p53-dependent downregulation of Chkl and more in general to deeply 
study the way Chkl is transcriptionally regulated, the human Chkl gene promoter was 
isolated and characterized.
3.2 ISOLATION OF THE 5 ’ FLANKING REGION OF THE CHK1 
GENE
To isolate the genomic sequences involved in the transcriptional regulation of the Chkl 
gene, a human genomic library spotted in duplicate in seven different filters by the UK
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DNA
DAMAGE
G2 BLOCK ABROGATED
Figure 3.1 p53-Chkl crosstalk following DNA damage
Schematic representation showing how p53 and Chkl are interconnected each other after 
DNA damage. Further explanations in the text.
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Human Genome Mapping Project Resource Centre (UK-HGMP-RC) was screened. The 
filters were screened by using a 5’ specific Chkl cDNA probe to allow the isolation of 
the promoter region of Chkl. Two positive clones were isolated after the screening 
which were identified through the coordinates o f the filters and then requested to the 
UK-HGMP-RC (figure 3.2). The two positive clones (53P13 and 253) obtained were 
grown in LB media and the DNA was isolated from the overnight culture as described in 
materials and methods. Both the clones contained approximately 100 Kb of DNA, so in 
order to further characterize the putative Chkl promoter the first necessary step was to 
get smaller DNA fragments again probed by the Chkl gene. A Southern blot analysis, 
represented in figure 3.3, was then performed on the two clones. The DNA was digested 
over night with different appropriate restriction enzymes (BamHI, EcoRI, Hindll) and 
half of it was loaded on a 0,8% agarose gel to separate the fragments o f different length. 
At the end of the run the gel was stained with ethidium bromide and the bands visualized 
by the UV light. The gel was then transferred to nylon filter and hybridized with a small 
cDNA probe in order to identify the fragments in the genomic sequences of the two 
positive clones isolated, containing the Chkl gene. As it can be observed in figure 3.3, 
panel B, a certain number of digested fragments gave positive hybridization thus 
containing the sequence of Chkl used to hybridize the filter. A fragment of 
approximately 10 Kb, resulted from clone 53P13 after digestion with EcoRI was picked 
up for the following steps of characterization. First o f all this fragment was subcloned in 
the pBluescript plasmid by the EcoRI site contained in the MCS of this plasmid. The 
recombinant plasmid obtained permitted the sequencing of the inserted DNA, initially 
by using the specific plasmid primers contained just near by the MCS, then departing
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Figure 3.2 Screening of a genomic library
The figure represents an autoradiography resulted from a filter containing genomic DNA
T9probed with a P-labeled Chkl cDNA fragment. Each clone is spotted in double on the 
filter. The arrow points to one of the two Chkl positive clones which have been selected 
from this screening.
147
53P13 253
Figure 3.3 Southern blot analysis of two genomic clones isolated from the screening 
of the genomic library
DNA isolated from the clones was digested with different restriction enzymes and 
separated on agarose gel.
Panel A. Ethidium bromide staining of the gel. The two clones (53P13 and 253) have 
been digested with BamHI (B), EcoRI (E) or Hind III (H). M is the molecular weight 
marker.
Panel B. Autoradiography of the gel transferred to a nylon membrane and hybridized
T9with a P-labelled Chkl probe. Numbers on the left are derived from molecular weight 
markers. An arrow indicates the lOkb EcoRI fragment chosen for the following studies.
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from the first sequences, other oligonucleotides primers were synthesized and used to 
further sequence the entire inserted clone. The obtained sequence was then aligned and 
matched with the human genomic sequences present in the NCBI gene bank database 
revealing sequence homology to a known sequence (PAC clone no 7622324) and 
contained the Chkl second exon, the first intron, the sequence of the first 5’ UTR exon, 
region of the gene transcribed but not translated and a further 5’genomic region as it is 
represented in figure 3.4.
5 ’UTR exon2
EcoRI EcoRI
-3.000 -1 ,394  - 759 - 20 +65
Figure 3.4 5’ Chkl genomic fragment of 10 Kb subcloned in pBluescript
Schematic representation o f the genomic Chkl region comprised in the fragment o f 10 
Kb previously isolated after the Southern blot Analysis and subsequently subcloned in 
pBluescript plasmid. The blast o f the sequenced fragment with the human genomic 
sequences deposited in the NCBI gene bank database revealed complete homology with 
the PAC clone no 7622324 containing the exon 2 (-20;+65), the entire intron 1 (-759;- 
20), the first untranslated 5’ UTR exon (-1,394;-759) and a large 5’ genomic region o f 
Chkl (-3,000;-1,394).
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3.3 IDENTIFICATION OF THE CHK1 GENE TRANSCRIPTIONAL  
STARTING SITES
As it has been already shown that Chkl generates two transcripts of different length, the 
presence o f two different transcriptional starting sites was hypothesized. I tried to detect 
the transcriptional starting sites both upstream of the second exon which contain the 
ATG of the 54 kDa Chkl protein and upstream of the 5’UTR not translated exon also 
included in the DNA fragment isolated. I extracted PolyA+ RNA from the colon 
carcinoma cell line HCT-116 which was already ascribed carrying both the Chkl 
transcripts (Damia et al., 2001) and two different approaches were at first used to search 
for the transcriptional starting site: primer extension and race marathon. By primer 
extension using specific primers located in the second exon, it was possible to locate 
precisely the starting site at the beginning of the published Chkl cDNA which was 
found to be at base -20 from the ATG coding for the first methionine of the Chkl 
protein. As it can be observed in figure 3.5, it was possible to count precisely the 
position of the starting site as a nucleotidic sequence run next to the primer extension 
reaction. It was possible to calculate the length of the fragment obtained from the primer 
extension and then predicting the precise transcriptional starting site by counting the 
nucleotides departing from the known primer used for the specific primer extension 
reaction (as described in materials and methods). Unfortunately, despite several attempts 
by using the primer extension strategy and the race marathon stategy, it was not possible 
to precisely identify the other transcriptional starting site upstream to the 5’UTR region.
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A T G C
CHP2
PRIMER
Figure 3.5 Primer extension reaction to detect the transcriptional starting sites of 
the Chkl gene
Autoradiography representing the primer extension reaction result by using the primer 
CHP2 located in the second exon. The arrow points to the band obtained due to the stop 
o f the reaction at the level of the putative transcription initiation site which thanks to the 
DNA sequence reaction loaded on the gel (left side) was calculated being at -84 bp from 
the CHP2 primer and at -20 bp from the starting ATG located at the beginning o f the 
second exon.
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3.4 PRIM ARY STRUCTURE AND FUNCTIONAL ANALYSIS OF  
THE CHK1 PROM OTER
The 5’ Chkl flanking region between +1 (A of the ATG coding for the first methionine 
of the Chkl protein) located in the exon 2, and -2,240 was examined for potential 
transcription binding sites using Matlnspector V2.2 and TFSearch ver 1.3. In figure 3.6 
is represented the primary structure of the 5’flanking region of the human Chkl gene. 
Regions upstream the first methionine are indicated by negative numbers. The results of 
the analysis revealed that this putative promoter region did not contain TATA box while 
four GC boxes could be detected in a region spanning from -1,061 to -590. Several 
consensus E2F sites as well as potential sites for Spl, GATA-1,2,3, MZF1 could be 
detected as shown in the figure 3.6. The GC content in the sequence was determined 
using an EMBL-EBL program. Whereas the bulk genomic DNA had a GC content of 
44%, two CpG islands (defined as areas larger than 200bp that show a GC content o f at 
least 60% and an observed/expected CpG ratio above 0.6) were found located at -1,080 
and -698 and at -1,456 and -1,234 from the A coding for the first met o f the Chkl 
protein. To test the functionality of the isolated genomic sequence, fragments of 
different length of the genomic DNA isolated containing the 5’ region of the Chkl gene 
were subcloned in the multiple cloning site of the promoter less pGL2 enhancer vector 
upstream to the luciferase cDNA. This vector is generally used to determine the 
efficiency of putative genomic promoter regions to drive the transcription of the 
luciferase gene. Recombinant clones were selected and the DNAs were partially 
sequenced to further verify the presence of the right inserts and to determine the
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GTGTTGGGAT TACACGTGTG AGCCACCAGG CCCCGGCCTT GAGTAACATT TTATACTTGT TTCACTTTAC TATTATCATA -2161
ATAGCCAGTT ATGCTTAGTG TTTGTATGTG GCCCAGTCTT AAGGACTAAG AAAATATATA TGTATATATA TAAAATATAT -2081
HFH3
ACATATAAAA AAATATGTTT TTTTCCTACG GAATGATGCT GTTGCCCAGG CTGGAGTGCA GTAGTGCTCA CTAACCTCTA -2001
ACTCCTGGAC TCAAACGATT GTTCTGCTTA GGCCTCCCAA GTAGCTAGGG CTACAGGGAC ACACCACCAA GCCCGACTAA -1921
GATA
TTCCTAAATT TTTTTATTTG TAGAGATGGG GTCTCCCTAT GTTCCCCAGG CTGGTCCTGA ACTCCTGGCC TCAAGCCATT -1841
CTCCTGCCCT CGCCTTCCCA AAGTGCTGGA ATTACAGGCA GGAGCCACTG CGCCCGGCCA GTGCTGGAGA ATGTAATGGA -1761
GATGATCCTG CCTATCCCTG AGTTCCAGTC TAGTTTACTG TCAGAGAATA CTTATTTCCA TTTTTCCTAT TTTGTTCTTG -1681
-2  33UTR -22SOTR cd»A  ___
AGTCTCTTTC CTCAGAATTT ACTTTTCCAC TTAAATGACG TACGCAGCTT TTAAATTTGC GTTGTAAGAT TTATTltTGGC -1601
______ B rn -2 _______ GATA
TCh'CCCCGCC TGTTCTTTGC ACATTAAAAA TGAAAAAGTT TGTAGAACTA AGCTAAGCAG ATGGTCTTCC TGCAAAAAGA -1521
E2F
CCGGGCTGAA GTAAAGCATT GfrT'PTGGAvfc TG3TTCACAG AAAAAAGGCA AAACTGGTTA TCCTGACTTC AAGCTCCAAC -14  41
ATAAACTGCT CGCTTTCTCC GGGAAACTTG CCCCGCCACA TACACTTGAC TGCGTGGCCA GTTCTTTCGA AGCCTCTCGC -1361
________ Z I P
TCCCAACACG GAGTTCCTCC CATTTCTTCA CAGTCGGCTC TCAGCAGCTG CTGCTGGTTT CTCGGCTCCA GCACCACGAG -1281
TACCGCACTC TGAGGTTTAC AAAGCACTCT GCTTCACCGA CTGTGATCCT CACAGTCCTG TCCGCTGGCC TCACGCAGGT -1201
GGCGGTGCAG CCTTTCAGGC CCAGAGCGGC CAGGAGCGAA GCCCGCAGCC CCGCCTGGAA GCGCAGCGCG GTCGGTCGCG -1121
 c £ L    ^
CGCCCCTGAG GCTTGGAGGC CTGGGCTTCC CQ7AGCAGCG CTCGAGCACC GCCCAGTCGA GCCTCACACC GGATGCCACT -1041
E 2 F  GATA ,
TCATATTTGG GCCCAGAGCT CARTTCGCGC CGATGCGGTC CGCCGTCCTT AAATCTCTTC AGCCAGGATC TCTCCCCGAC -961
_____ CREB .  E2F
IS.CAAAGCAG...g.C.CTGGGCGG GAGCGGCAAC ATCTCCACGT CACCCTffTTG GAGCfcGCCGA CATTCAG&GG GGCAGGACAC -881
E 2 F     —--------
GGGAACGCGC GCTGTCTTGC ITTACGGCGC GGOTGCGCGA GTTTGCGGCA GCGTGACGCC CTCAAGfTljrT GGCGG^AAAA -801
GCGcflGCATT TGGATTCCTG CAGTGGTGGG CAAAGGACAG TCCGGTGAGG AAGGGCGGCC GGTAGAGTAG GGAAGGTTTC -7 2 1
TAAAGAAGGA GTTCGGGGTC TAGATTAGTG AGGGAGGGCA TGGTGGGAGA AAGTTAGCAT TGACTAGCGC AGGGGATTGG -641
AGAGACTCCT GCGGAGGGGC GGTTTCGGAG GGTGGAGGAA TGGTACCAGG AGGTTCCCGT TGTCGGGGCG GGGGCAGGAG -561
E2F
GGACTAACCC GCTGCTAGCT AAGAACCCCA AGSAAGAGTC CCAGCCCTTC CTTTCGCCTC TGGGGGCAClr TTGGCCbCGC -481
GATA -M U il IKAROS 2,
CCCGGCCTTT GGGACGGGTG GGGCTGTGGA TGGGGATGGG AATTGGAATT GAGCAATTGG GAGGAGGCGC TGCCGCAGGC -401
GTTTTCTGCC CCATACCGCT CCCTATATCC TCTTCCTCTC TTCCCCACAC CCCCACCTCT CCCTCCTCCT TCCCCAGTCG -321
E1K1
TTCGCCGGAA AGCATTTGTC TCCCACCTCT TCATAACAAC AATTAATTTC CTCTGGGGCC TGAGGAGGGC AGAATTTCAA -241
CCTTCGGTGT GCTTGGGAGT GGCGATTGTG ATTTACACGA CAAAATGGTC AGGTTTAGAA TAGTTGTTCG TGGTTGAAAG -161
M Z F 1 M Z F 1 ,
ACTTGGATAA ATGTGGATGA GATAGAAGGG GAAGGCAAGA GCTGTTAATT TTCGTGGGCA ATCCTGGGGA GAGGCGGGGC -81
- 2 0,
TCAGTGGCTT CACTGGTGAT CTTACACTCT ACATCTTTTC TGGATTCCTG CCTTTTACAG CCGAGGTGCT CGGTGGAGTC -1
;AXa3CAGTGCCCTTTGTGGAAGACTGGGACTTGGT0CAAACCCTG«GAGAAGGTGCCTATGGAGA. . . I n t r o n  2 +64
Figure 3.6 Primary structure of the 5’ flanking region of the human Chkl gene
The nucleotide of the first methionine codon located in the second exon is numbered +1 
while upstream regions are indicated by negative numbers. Outlined sequences represent 
the 5’UTR and the second exon while the boxes mark the E2F1 binding sites. No TATA 
regions are identified. Arrows above the sequence indicate consensus sequences for 
transcription factors.
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orientation. As it can be observed in figure 3.7, panel A, the generated constructs simply 
called A, C, E, H, I, covered the Chkl genomic region from -2,240 to +78 from the 
known ATG starting site. The different constructs were then transiently transfected in 
two different p53 null cell lines: the ovarian cancer cell line SKOV-3 and the 
osteosarcoma cell line SAOS-2. The luciferase activity assay was then performed 48h 
after transfection following the procedure described in chapter 2.5. As it is clearly 
depicted in figure 3.7, panel B, a 25 to 60 fold increase over the activity of the control 
vector pGL2-enhancer could be detected in all the constructs tested. Moreover the 
constructs subcloned in an antisense orientation yielded no luciferase activity thus 
confirming the specificity of the promoter activity o f the isolated region (data not 
shown). Various deletion constructs were also made trying to identify the minimal 
promoter region in the sequence upstream to both the 5’UTR and the exon2. As depicted 
in figure 3.8 panel A, shorter fragments were further subcloned both from the original A 
fragment (into the resulted A1,A2,A3, IR) and from the I fragment (into the so called II 
and 12). As it is possible to observe in figure 3.8, panel B, a substantial decrease in the 
promoter activity could be detected in the constructs harboring deletions of band A 
(upstream to the 5’UTR). A comparison of the promoter activity of the different 
constructs derived from A would suggest the presence of a negative regulatory region 
located between -1,830 and -  1,762. In fact no luciferase activity was associated with 
construct A l while the A2 construct, pretty similar to the A l construct, but lacking the 
region above mentioned, shows a significant luciferase activity, although much lower 
than the original A construct probably due to the lack o f the -1,843/1,830 and -1,381/976 
parts, with putative positive regulatory activity. As regarding the region upstream to the
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Figure 3.7 Functional characterization of the 5’ flanking region of the human Chkl 
gene
Panel A. Schematic representation o f the different constructs sub-cloned in the reporter 
plasmid pGL2 enhancer and used in the transient transfection experiments.
Panel B. The fold increase over the pGL2 enhancer vector o f luciferase activity is 
depicted, thus showing the effective promoter activity o f the Chkl genomic region 
isolated. The results are mean ± SD o f at least three different experiments done in 
triplicate.
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Figure 3.8 Analysis of the minimal promoter activity of the 5’ flanking region of the 
human Chkl gene
Panel A. Schematic representation of the different constructs subcloned in the reporter 
vector and used in the transient transfection experiments.
Panel B. Fold increase over the pGL2 enhancer vector luciferase activity.
The results of the luciferase activity assay are normalized by the internal control Renilla 
and are the mean± SD of at least three different experiments done in triplicate
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exon 2, a substantial decrease in luciferase activity was observed with the shortest 
construct 12, while the deletion from -1,394 to -604 did not alter the luciferase activity 
of the construct II thus revealing that most probably the minimal promoter region is 
represented by the 5’ part of the II fragment between -604 and -257 as the 12 fragment 
lacking this region showed a substantial decrease in luciferase activity.
3.5 MODULATION OF THE CHK1 PROMOTER ACTIVITY BY  
DIFFERENT TRANSCRIPTIONAL FACTORS
Once having identified a functional Chkl promoter I investigated on the possible 
modulation of the Chkl promoter activity by different transcription factors. In particular 
I focused on p53, p73 (belonging to p53 family) and E2F1.
3.5.1 CHK1 PROMOTER ANDp53
At first I focused on the possible negative modulation of the Chkl promoter by p53 as 
previous recent data from our laboratory and others have shown a p53 dependent 
downregulation of Chkl protein in HCT-116 colon carcinoma cell lines after DNA 
damaging agents (Damia et al., 2001; Gottifredi et al., 2001). The ability o f p53 to cause 
downregulation of the Chkl promoter was tested by cotransfecting in the human ovarian 
cancer cell line SKOV-3, p53 null, an expression vector containing the human p53 
cDNA with the different pGL2 promoter constructs whose characterization was just 
described (pGL2-A,-C,-E,-H). Figure 3.9 shows that in the presence of p53 a decrease in 
luciferase activity ranging from 30 to 65% was observed in all the constructs tested 
compared to the luciferase activity observed in the absence o f p53. The transcriptional
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Figure 3.9 p53 modulation of the 5’ flanking region of the human Chkl gene
SKOV-3 cells (p53 null) were transiently transfected with the different promoter 
constructs either alone (yellow bars) or with the human p53 expressing plasmid (blue 
bars). The fold increase over the pGL2 enhancer luciferase activity normalized by the 
internal Renilla control is depicted. As previously underlined these results are mean ± 
SD of at least three different experiments done in triplicate.
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Figure 3.10 Modulation of the 5’ flanking region of the human Chkl gene by p53 
either wt or mutated in the DNA binding domain
SKOV-3 cells p53 null were transfected with the pGL2-H construct, the most repressed 
fragment by p53, alone or in combination with p53 either wt or mutated. The relative 
luciferase activity over the value obtained by the pGL2-H construct transfection is 
represented in the figure showing an over 50% decrease in luciferase activity in the 
presence of both p53 wt and mutated. The results are mean ± SD o f at least three 
experiments done in triplicate.
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repression exerted by p53 on Chkl promoter fragments appeared more evident if 
compared with the transcriptional activation induced on the p53 responsive p21 
promoter fragment cloned in the pGL2 enhancer vector which represented the positive 
control of this experiment. The same constructs inserted in an antisense orientation were 
also co-transfected with the hp53 cDNA and used as negative control of this experiment 
confirming that their promoter activity (approximately close to 0) was not affected by 
p53 (data not shown).
The next following experiments were performed by using the pGL2-H construct which 
was the most repressed fragment by p53. This construct was co-transfected in the same 
cellular system, the SKOV-3 cell line p53 null, with the expression vector containing 
either hp53 cDNA wt or its mutated form in the DNA binding domain finding out a 
similar decrease in luciferase activity (of about 60%) compared to the luciferase activity 
observed in the absence of p53 (figure 3.10).
This result led to the hypothesis that probably the oncosuppressor p53 does not need to 
have an intact DNA binding domain to negatively regulate the Chkl gene but would 
probably exert its negative regulatory action on the Chkl promoter through the 
interaction with additional proteins.
3.5.2 CHK1 PROMOTER AND THE ANp73a ISOFORM
On the basis o f the just showed p53 dependent downregulation of the Chkl promoter,
I next asked how the AN form of p73 which has been previously reported to have a 
dominant negative function on the p53 transcriptional activity would possibly 
modulate the Chkl promoter. The osteosarcoma cell line SAOS-2 was transfected
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Figure 3.11 AN p73a modulation on the 5’ flanking region of the human Chkl gene
SAOS-2 cells were transfected with the pGL2-H construct alone or in combination with 
p53, AN p73 or both the expression plasmids. The fold increase over the pGL2-H 
luciferase activity is reported. The results are mean ± SD o f at least three different 
experiments done in triplicate.
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with either the pGL2-H construct alone or with the human ANp73a expression 
plasmid and as it is possible to observe in figure 3.11, the presence of the p73 
isoform induce a slight but reproducible upregulation (approximately 2 fold increase) 
of the promoter activity o f the pGL2-H construct. Furthermore when also the human 
p53 expression plasmid was cotransfected, no decrease in luciferase activity o f the 
pGL2-H construct was observed thus suggesting that probably the hANp73a isoform 
is able to revert the p53 dependent downregulation o f Chkl, acting as antagonist on 
the repressor transcriptional activity of p53.
3.5.3 CHK1 PROMOTER AND E2F1
The role of E2F1 in modulating the Chkl promoter activity was then evaluated as the 
analysis of the primary structure of the promoter region revealed the presence o f six 
E2F1 binding sites. Moreover indirect evidences recently underlined in literature linked 
E2F1 to Chkl (Gottifredi et al., 2001; Ren et al., 2002).
The pGL2-H construct containing the largest number of E2F1 binding sites (represented 
in figure 3.12) was chosen to perform the co-transfection experiments with the 
expression vector containing either the hE2Fl wt or the form of hE2Fl (132 mut) 
mutated in the DNA binding domain. The results obtained by co-transfecting the 
osteosarcoma cell line SAOS-2 are depicted in figure 3.13 and showed an over 20 fold 
increase respect to the pGL2-H luciferase activity when hE2Fl wt was co transfected 
with pGL2-H construct, while in the same experimental setting the co-transfection with 
the mutant form did not alter the pGL2-H basal luciferase activity. Similar results were 
obtained in the SKOV-3 cell line and led us to hypothesize that E2F1 has an effective
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E2F1 binding sites
-2,240 ST GTT GGGATT ACACGT ST GAGCCACCAGGCCCCGGCCTT GAGT A AC ATT TT AT ACTT G 
TTTCACTTT ACT ATT ATCAT AAT AGCCAGTT ATGCTT AGTGTTTGT ATGTGGCCCAGTC 
TT AAGGACT AAGAAAAT AT AT ATGT AT AT AT AT AA AAT AT AT ACAT AT AAAAAAAT 
ATSTTTT TTT CCT ACGGA ATCATGCTGTT GCCCAGGCT GS AST SC AST AGTGCTCACT A 
ACCTCT AACTCCTGGACTCAAACGATTGTTCTGCTT AGGCCTCCCAAGT AGCT AGGGCT 
ACAGGGACACACCACCAAGCCCGACT A ATT CCT A A ATTTTTTT ATTTGT AGAGATGGGG 
TCTCCCT ATSTT CCCCAGGCTGGTCCTGAACTCCTGGCCTCAAGCCATTCTCCTGCCCTCG 
CCnCCCAAAGTGCTGGAATTACAGGCAGGAGCCACTGCGCCCGGCCAGTGCTGGAGAAT 
GTAATGGAGATGATCCTGCCTATCCCTGAGTTCCAGTCTAGTTTACTGTCAGAGAATAC 
TT ATTT CC ATTTTTCCT ATT TTGT TCT TS ASTCTCTTT CCTCAG AA "CLU l£X I TTCCAC 
TT AAATGACGT ACGCAGCTTTT AAATTTGCGTTGT AAGATTT ATT"\  f CCCCGC
CTGTTCTTTGCACATTAAAAATGAAAAAGTTTGT iG i id  * t/jTT faSCTOATSGTCT 
TCCTGCAAAAAGAGGGGGCTGAAGT AAAGCATTGj <|TSSTT CACAGAAAAA
AGGCA A A ACTGGTT AT CCT G ACTT C A AGCTCCA ACXTXTffiCTGCTCGCTTT CTCCGGGA 
AACTTGCCCCGCCACATACACTTGACTGCGTGGCCAGTTCT TTCGA AGCCT CT CGCT CCC 
A ACACGGAGTT CCT CCC A TTTCTTCACAGT CGGCT CT CAGCAGCT GCT GCT GSTTT CT CG 
GCTCCAGCACCACGAGT ACCGCACT CT GAGGT TT AC A A AGCACTCTGCTT CACCG ACT GT 
GATCCTCACAGTCCTGTCCGGTGGCCT CACGCAGGT GGCGGT GCAGCCTT TCAGSCCCAG 
AGCGGCCAGGAGCGAAGCCCGCAGCCCCGCCT GGAAGCGCAGCGCGGT CGGT C&C&CGCCC 
CT GAGGCTT GGAGGCCT GGGCTT CCCCCAGCAGCGCf£GjkG£A£CGGCCAGT CG AGCCT CA 
CACCGGATGCCACTTCATATTTGGGCCCAGAGCTCJl qpGATGCGGTCCGCCGT
CCTTA AATCTCTTCAGCCAGA ATrjnrqCCGACT^ TAWAGCCCTGGGCGGGAGCGG 
CA AC ATCTCCACGTC ACCC\ fccC&ACATTCAGAGGGGCAGGACACGGGA AC
GfG T T S T ri|T GTT TT I SCGCGAGT TTGCGGCAGC&TGACGCCCT CA AGIS C  ATTTfiG A TTCCTGCAGTGGTGGGCA A AGGACAGT CCGG iEC^TOEECEECCSErrtSASTASSSAASSTTTCTAAAGAASSASTTQSGSSTCTAS 
ATT AGTGAGGGAGGGCATGGTGGGAGAAAGTT AGCATTGACT AGCGCAGGGGATTGGA 
GAG ACT CCT GCGGAGGGGCGGT TT CGGAGGGT GGAGGA AT SST ACCAGGAGGTT CCCGT 
TGTGGGGGCGGGGGCAGGAGGGACT AACCCGCLGGLAGCT AAGAACCCCAAGGAAGAGT 
CCCAGCCCTT CCTTTCGCCTCTGGGGGCAdl CfGCQCCGGCCTTTGGGACGGGTG
GGGCTGTGGATGGGGATGGGA ATTGGAA V I'E'A A T TGGGAGGAGGCGCTGCCGCAGG
CGTTTT CTGGCCCAT ACCGCT CCCT AT A TCCTCTTCCTCTCTTCCCCAGACCCCCACCTCT 
CCCTCCTCCTTCCCCAGTCGTTCGCCGGAAAGCATTTGTCTCCCACCTCTTCATAA - 2 8 4
Figure 3.12 E2F1 binding sites on H fragment
Nucleotidic sequence of the H fragment which comprises six E2F1 binding sites 
represented in yellow and circled by the blue boxes. The region in red represents the 
5’UTR sequence which is fully included in the H fragment used in the investigation.
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Figure 3.13 E2F1 transcriptional factor modulation on the 5’ flanking region of the 
Chkl gene
SAOS-2 cells were transfected with the pGL2-H construct alone or in combination with 
E2F1 expressing plasmid either wt or mutated in the DNA binding domain. The fold 
increase over the pGL2-H lucifearse activity, normalized by the internal Renilla control, 
is shown. The results are the mean± SD of at least three different experiments done in 
triplicate.
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Figure 3.14 E2F1 positive modulation on the Chkl promoter
Additional confirmation of the positive modulation of the 5’flanking region o f the Chkl 
gene by the E2F1 transcriptional factor.
Panel A. Luciferase activity o f the SAOS-2 cells and of the clone from it over­
expressing E2F1 both transfected with the pGL2-H construct. The results are expressed 
as fold increase over the pGL2-H luciferase actitvity.
Panel B. Western blot analysis showing hE2Fl expression levels in SAOS-2 and SAOS- 
E2F over-expressing clone.
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role in positively modulating the Chkl promoter and this positive regulation would most 
probably require the binding of this transcriptional factor directly on the DNA of the 
Chkl promoter. To further corroborate the positive role played by E2F1 on the Chkl 
promoter, SAOS-2 cells stably over expressing hE2Fl wt were transfected with the 
pGL2-H construct. A limited but reproducible increase in luciferase activity could be 
observed in cells overexpressing hE2Fl as compared to SAOS-2 cells with basal 
expression of hE2Fl (figure 3.14 panel A). As it can be observed in panel B of the same 
figure these cells do express higher levels of E2F1 compared to parental cells as the 
Western blot analysis revealed. It was also possible to study the Chkl promoter activity 
on a Retinoblastoma (Rb)-inducible H562 human small cell lung cancer cells (clone 
10D5) kindly provided by Dr. G.W. Kristal from Virginia. These cells were stably 
transfected with a tetracycline inducible expression vector for retinoblastoma protein. As 
it is possible to show in figure 3.15, a 50% of downregulation of the luciferase activity 
was observed in Rb-induced H526/10D5 cells when transfected with the pGL2-H 
construct thus suggesting that the increased Rb protein expression caused the 
sequestration of the E2F1 protein which can not exert its transcriptional activity on the 
Chkl promoter.
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Figure 3.15 Chkl promoter activity on a Retinoblastoma inducible human cancer 
cell line
Representation o f the relative luciferase activity over the pGL2-H construct on a 
Retinobastoma (Rb)-inducible H562 human small cell lung cancer cells (clone 10D5) 
either induced or non induced with doxycycline (2pg/ml) and transfected with the 
construct studied (pGL2-H). As in all the previous experiments described, the results are 
mean± SD of at least three different experiments done in triplicate.
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3.6 DISCUSSION
The investigation conducted in this chapter described for the first time a detailed and 
specific analysis of the 5’ flanking region of Chkl which was isolated and then 
structurally and functionally characterized. The 5’ region isolated comprised the 3,000 
bp upstream to the ATG corresponding to the first methionine translated of the Chkl 
protein. It was already previously reported the presence of a 5’UTR (first exon 
transcribed but not translated) respect to the initially sequenced cDNA (Yolanda 
Sanchez personal communication) which was also confirmed in the Chkl 5’ flanking 
region isolated and sequenced by our group. The Chkl gene codes for two different 
mRNAs (Sanchez et al., 1997) which then generate a single 54kDa polypeptide 
synthesized starting from the ATG located in the second exon. It was possible to locate 
by primer extension the transcriptional starting site upstream to the second exon which 
resulted at -20 from the ATG while I could not unequivocally identified the exact 
transcriptional starting site upstream the 5’ UTR even though I attempted several times 
by two different techniques (race marathon and primer extension). By applying the 
molecular cloning strategy, fragments of different length could be subcloned in a 
reporter plasmid upstream to a luciferase gene and the promoter activity of this region 
could be confirmed. Two distinct higher promoter activity regions were localized in a 
region upstream the second coding exon (between -257 and -604 bp from starting ATG) 
and in a region spanning part of the 5’UTR and its closely upstream region (between - 
978 and -1843 from starting ATG). This investigation was possible by studying the 
luciferase activity of different deleted constructs derived from the original longer DNA 
fragments (see figure 3.8). The Chkl promoter can be classified as a TATA less
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promoter, as by analyzing the primary structure of this region no TATA box near the 
transcription starting sites could be detected. Beside the accurate structural and 
functional analysis of the Chkl promoter, the most interesting aspect o f this study was to 
demonstrate the transcriptional negative regulation of Chkl by p53 as previous data 
obtained from our group and another group strongly suggested this hypothesis (Damia et 
al., 2001; Gottifredi et al., 2001). It was possible to show by co-transfection experiments 
of hp53 and all the different constructs harboring different fragments of Chkl promoter 
region that p53 possibly negatively regulates Chkl as a 50% decrease in luciferase 
activity was recorded in the presence of p53. As I already described, p53 is a sequence 
specific transcription factor that is usually activated in response to different kind of 
cellular stress, mediating either cell cycle arrest or apoptosis depending on the cell type 
and the consistence of the damage (Haupt et al., 2002). The mechanisms by which the 
p53 dependent transcriptional activation occurs have been already described in detail 
and requires the direct binding of p53 to consensus sequences in the promoter region (El 
Deiry et al., 1992). On the other hand the p53 dependent transcriptional repression is still 
poorly described and understood (Murphy et al., 1996). A particular consensus sequence 
for the putative repressor p53 activity has been previously described (Johnson et al., 
2001). This consensus sequence was not detected in the cloned Chkl promoter region. 
The p53 mutated in the DNA binding domain did not negatively regulate the Chkl 
promoter thus suggesting that, as for other p53 downregulated promoters, p53 effect is 
not linked to its direct binding to DNA but would most probably occur by the interaction 
with other additional proteins. Experimental evidence had attributed to the p21/Rb/E2Fl 
pathway an involvement in the regulation of the repression of the Chkl promoter
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(Gottifredi et al., 2001). Seven different E2F1 binding sites were actually detected on the 
DNA sequence of Chkl promoter and it was possible to show that those are functional 
sites since E2F1 wt but not the form mutated in the DNA binding domain can modulate, 
upregulating, the Chkl promoter region. The E2F1 dependent upregulation of the Chkl 
promoter can also indirectly explain the p53 dependent downregulation of the Chkl 
promoter previously observed following DNA damage. As it is summarized in figure 
3.16, in fact, after DNA damage, beside the direct repressor action exerted by p53 on the 
Chkl promoter, most probably through the action of other proteins, an additional 
indirect regulation would also explain the negative influence on the Chkl promoter. This 
indirect regulation is more related to the p53 intrinsic ability to transactivate, after DNA 
damage, the p21 inhibitor which through the direct inhibition of the cdk-cyclins 
complexes involved in the Gl-S transition, would maintain the Rb protein in a 
hypophosphorylated form thus avoiding the release and activation of the E2F1 
transcription factor. The sequestered E2F1 transcription factor would not exert any more 
its positive action on the Chkl promoter. The E2F1 positive regulation of the Chkl 
promoter could also possibly correlate with the cell cycle specific expression o f Chkl 
which appears restricted from S to G2-M phases (Kaneko et al., 1999). The expression 
of E2F target genes are regulated in a cell cycle dependent manner. In G1 phase E2F1 is 
sequestered by the pRb family members, as just described, and can not exert its 
transcriptional activity while during the progression of cells from G1 to S phase the G1 
cyclin dependent kinases phosphorylate and dissociate the pRb proteins from E2F, 
resulting in the activation of the genes required for progression into the S phase. The 
results obtained further supported the evidence that the different players of the
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Figure 3.16 p53 negative modulation on the Chkl promoter after DNA damage
Schematic representation of the possible mechanisms by which p53 negatively regulates 
the Chkl promoter after DNA damage.
The first hypothesis (1) would possibly claim the existence of a direct negative action on 
the Chkl promoter by p53 by a poorly defined mechanism.
The second hypothesis (2) would suggest an indirect action of p53 on the Chkl promoter 
through its ability to transactivate p21 which would lead to the inhibition o f the 
cdk/cyclins complexes involved in the G l-S transition. Thus the Rb factor is maintained 
in an unphosphorylated form avoiding the E2F1 release which can not exert its positive 
action on the Chkl promoter.
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checkpoint pathways have to be considered as interconnected each other in exerting their 
function. By studying the transcriptional regulation o f the Chkl promoter, in fact, it 
was possible to find out that this gene can be modulated by p53 and E2F1. 
Furthermore in our experimental system, it was also possible to detect a positive 
regulation o f the Chkl promoter by the AN isoform of p73a which was ascribed to 
have a dominant negative action on the p53 activity (Vossio et al., 2002), thus 
suggesting that upon damage a ANp73 upregulation o f Chkl protein levels would 
help in inducing the G2-M block and the repair of the damage at the early phase 
followed by a p53 dependent decrease in Chkl levels that would allow the re-entry 
of the cell cycle.
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CHAPTER 4
ABROGATION OF THE G2 CHECKPOINT BY  
INHIBITING CHK1 AS POSSIBLE CANCER THERAPY
STRATEGY
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4.1 INTRODUCTION
As it has been documented in the literature and as my previous observation on the 
Chkl transcriptional regulation revealed, an inter-relationship exists among proteins 
participating in the DNA damage checkpoint pathways and when one o f the players 
of this fine scenario is altered, incidence o f tumorigenesis and genetic instability 
increase. The oncosuppressor p53, which plays a relevant role in the DNA damage 
checkpoint has been found mutated in a high percentage o f human tumors thus 
inflicting on the functionality o f the G1 checkpoint. In these G1 checkpoint defective 
tumor cells, the sensitivity to different anticancer agents depends primarily on the G2 
checkpoint. A strategy to increase the sensitivity to these treatments in tumor cells 
more than in normal cells would be to try to abrogate the G2 checkpoint. By 
abrogating the G2 checkpoint, tumor cells, already harboring alterations in the G1 
checkpoint pathways would be more sensitive to DNA damaging agents than normal 
cells and this could lead to an increased therapeutic index. Starting from this 
assumption I attempted to inhibit the function of the most important player of the G2 
checkpoint: the protein kinase Chkl.
In this section I’ll describe the different strategies used to try to inhibit Chkl and the 
results obtained by using the siRNA strategy which was the most successful 
approach. To inhibit the Chkl function the human colon carcinoma cell line HCT116 
was chosen as experimental system, as isogenic subclones with a defective G1 
checkpoint due to either p53 or p21 inactivated by homologuous recombination were 
available in the laboratory.
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4.2 ANTISENSE STRATEGY
Fragments o f different length of the available Chkl cDNA kindly provided by 
Yolanda Sanchez were isolated by digestion with appropriate restriction enzymes 
and then sub-cloned in antisense orientation in a mammalian pCMV expression 
vector. The cloning strategy was used (as already described in materials and 
methods) to get the recombinant plasmids containing inserts o f 198 bp, 675 bp, 1,124 
bp correspondent to the different Chkl cDNA antisense fragments, as it is shown in 
figure 4.1. The recombinant plasmids were then stably transfected in the human 
colon carcinoma cell line HCT-116. Single colonies were isolated by seeding the 
cells at a low density and were selected in the media containing the selection brought 
by the pcDNA3 plasmid (G418) at the proper concentration. Protein extracts o f more 
than 200 clones were isolated and screened by detecting the Chkl protein levels by 
Western blot analysis. No antisense Chkl clone could be found as all the clones 
selected presented appreciable levels of Chkl protein. This negative result was 
initially attributed to the fundamental role played by Chkl not only in the G2 
checkpoint but also in the physiological growth of the cells. Indeed experimental 
evidence showed that Chkl -/- KO mice die early in the embryogenesis. However 
Zachos et al. have recently shown that the avian DT40 lymphoma cell line Chkl -/- 
is viable (Takai et al., 2000; Zachos et al., 2003), so that the effect o f the lack of 
Chkl in somatic cell lines could be cell line specific and maybe lethal for the 
experimental system chosen (HCT-116). On the other hand the unsuccessful results 
could be just related to the intrinsic limitation of this antisense strategy.
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Figure 4.1 Antisense Chkl constructs
Schematic representation of the Chkl cDNA fragments of different length subcloned in 
an antisense orientation in the pcDNA3 expression vector thanks to the availability of 
the Chkl cDNA full length expression vector. Briefly, the 198 bp fragment was 
subcloned between Xho I and Bglll restriction sites; the 675 bp fragment was subcloned 
between Xhol and PvuII and the 1,124 bp fragment was subcloned between Xhol and 
BamHI as described in materials and methods.
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4.3 DOMINANT NEGATIVE PHENOTYPE STRATEGY
The dominant negative phenotype strategy was actually studied in parallel with the 
antisense strategy in the HCT-116 cell line. A stable and a tetracycline inducible 
expression system (described in materials and methods) was used in the colon carcinoma 
cell line HCT-116 to generate a clone with a stable or inducible over-expression of the 
Chkl cDNA mutated in aminoacidic position 130 (aspartic acid replaced with the 
alanine) at the level of the protein kinase domain (D130, dead kinase Chkl). I deeply 
focused on the isolation and characterization of inducible clones overexpressing the dead 
kinase Chkl more than on the stable clones to avoid the problem of the lethal phenotype 
that the stable altered expression of the Chkl protein could cause in the cells, as it could 
be initially hypothesized by unsuccess to isolate antisense Chkl clones. Briefly, the 
recombinant plasmids were obtained by molecular cloning strategies. The Chkl dead 
kinase cDNA fused at 5’ to the cDNA correspondent to the HA epitope (coding for a 
viral protein) was cloned in a plasmid called pcDNA4/TO downstream to a pCMV 
promoter, responsive to a Tet repressor expressed by a second plasmid, pcDNA6/TR. In 
the absence of tetracycline in the culture media, the Tet repressor binds to the promoter 
avoiding the expression of the cDNA of interest. In the presence of tetracycline the Tet 
repressor detaches and the promoter gets activated expressing the dead kinase Chkl 
cDNA. The colon carcinoma cell line HCT-116 Trex 8A, previously obtained in the 
laboratory by stable transfection with the pcDNA6/TR plasmid was transfected with the 
pcDNA4/TO HA-D130 plasmid and colonies were isolated as previously described and 
kept in the appropriate selection media with the two antibiotics whose resistance genes 
are on the plasmids used. Positive clones were easily detected by Western blot analysis
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Figure 4.2 Characterization of one of the two positive clones inducibly expressing 
the dead kinase Chkl
Panel A. Western blot analysis showing the protein levels of both the endogenous Chkl 
and the exogenous catalytically inactive Chkl fused with the HA epitope. The 
exogenous form resulted at least three times more expressed in the presence of 
doxycycline (2pg/ml) in the culture media respect to the endogenous counterpart. The 
protein levels at 2,3 and 5 days from the first induction are represented. The inducer was 
added every 48 hours.
Panel B. Cell growth curve of the positive clone either induced or non induced with 
doxycycline. The cells were counted after 24,48,72 and 144 hours from the first 
induction. The values represent the mean o f three different experiments done in 
triplicate.
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thanks to the molecular weight difference between the endogenous Chkl protein and the 
exogenous one fused with the HA epitope. Two tetracycline inducible positive clones 
were isolated and both showed the same characteristics. I reported for convenience the 
results regarding just one of the two clones. In figure 4.2 panel A, it is reported the 
Western blot analysis showing a three times more expression of the catalytically inactive 
exogenous protein respect to the endogenous one in the presence of doxycycline at a 
concentration of 2pg/ml (a tetracycline analogue but more stable) in the culture media 
which was added every 48 hours. As it is possible to observe in figure 4.2 panel B a 
reduction of cell growth was observed beginning from 72 hours after the continuous 
induction with doxycycline. This experimental time point was picked up to treat the cells 
with the anticancer agent cis platinum (DDP) and a clonogenic assay was performed to 
test the cytotoxic activity of this drug in the presence or in the absence of doxycycline in 
culture media. As it can be observed in figure 4.3 panel A, no differences in the 
cytotoxic activity of DDP could be observed in the cells induced and in those non 
induced by doxycycline. Similar results were obtained treating the cells with different 
UV doses (figure 4.3, panel B). It was possible to perform the kinase assay on the 
dead kinase inducible clone thanks to the availability of the Chkl substrate peptide, 
(Cdc25C, aa250-256) following the procedure I described in material and methods. 
As it can be observed in figure 4.4 a residual Chkl kinase activity after doxycycline 
induction was present and this could explain the lack of the sensitization of this clone 
to the DNA damaging agents. The over-expressing exogenous protein can not 
completely abrogate the kinase activity of the endogenous protein which could actively 
participate in the G2 checkpoint induced by DNA damage agents such as
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Figure 4.3 Inducible dead kinase Chkl clone: response to different DNA damaging 
agents
Cytotoxic activity to DDP (panel A) and to UV (panel B) of the doxycycline inducible 
dead kinase clone. Cells were seeded in 6 well plates and grown in the absence (blue 
line) or in the presence (pink line) of 2 pg/ml of doxycycline. Treatments were 
performed at the indicated DDP and UV doses. Percentage of cells relative to controls 
was determined by clonogenic assay. The results are mean ± SD of at least three 
different experiments done in triplicate.
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Figure 4.4 Kinase activity of the inducible dead kinase Chkl clone
Autoradiography o f the kinase assay conducted to test the kinase activity of the Chkl 
protein in the clone inducibly expressing the dead kinase. The assay was performed as 
described in chapter 2.12. Briefly, the cellular extracts were immunoprecipitated with 
the Chkl antibody and then the recombinant GST-Cdc25C (aa 250-256) was used as a 
substrate o f the reaction in the presence o f 32P-ATP and detected by autoradiography 
after resolving in SDS-PAGE. The first lane represents the negative control incubated 
with GST only. The second lane represents the substrate phosphorylated by the non 
induced clone while the third lane outlines the residual substrate phosphorylated by the 
doxycycline induced clone.
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DDP and UV thus possibly explaining the lack of the expected increase in sensitivity to 
these agents in the clone induced with doxycycline.
4.4 SOMATIC CELLULAR KO STRATEGY
Taking advantage of the technique allowing the targeting of individual genes in human 
somatic cell lines and the identification and the isolation of the desired homologuos 
recombinants (Sedivy and Dutriaux, 1999; Chan et al., 1999), the colon carcinoma cell 
line HCT-116, which has been extensively used for the generation of somatic knock out 
cells for a variety of genes, was picked up to get a somatic isogenic cellular system 
Chkl-/-. Two recombinant constructs were designed and obtained by the molecular 
cloning strategy (as I described in materials and methods), thanks to the availability of 
the genomic DNA previously isolated and further described in the last chapter and 
containing exons 2 and 3 of the Chkl gene. Briefly, as it is possible to see in figure 4.5, 
the two constructs subcloned in the BSSK consisted of a 5’ arm containing the 5’ 
flanking region of the gene, the 5’UTR exon 1, intronl, and a 3’ arm containing exons 4, 
5, introns 3, 4 and part of the intron 5. Exons 2 and 3 and intron 2 were replaced with an 
antibiotic resistance cassette, either neomycin or hygromycin (as the two alleles should 
be targeted) whose molecular weight differences (± 400bp) with the original genomic 
sequence rendered possible a PCR screening of the positive clones. To get each o f the 
entire recombinant KO construct multiple step of cloning were necessary. The BSSK- 
NEO promoter less construct once linearized with an opportune restriction enzyme was 
stably transfected in the HCT116 cell line and the clones resistant to G418 were 
screened by PCR analysis taking advantage to the molecular weight difference between
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Figure 4.5 KO Chkl constructs
Schematic representation of the two KO constructs designed and obtained after different 
molecular cloning steps. The neomycin or hygromycin cassettes were inserted in the 
construct with the aim to replace the endogenous Exons 2 and 3 of the two alleles by 
homologous recombination thus creating a Chkl KO cellular system.
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the wt allele and the recombinant allele with the neo cassette present in the case of 
successful event of homologous recombination. The primers were designed to amplify 
the region correspondent to the resistant cassette inserted in the Chkl gene. The positive 
clones would show two distinct PCR products differing each other around 400 bp. At 
least 200 clones were screened trying to find the positive one but any homologous 
recombinant clone could be found. While I was screening the homologous recombinant 
KO +/- cells, I started to study and evolve in the laboratory the selective and efficient 
siRNA technique: short double strand RNA molecules which, after having been 
transfected in the cells, can specifically bind to the mRNA of the gene of interest 
causing its inactivation and subsequent degradation (as I described in chapter 2.9). After 
setting up the experimental conditions for siRNA specific inhibition of Chkl I neglected 
the time consuming and too complex KO strategy to focus on the siRNA technique 
strategy to inhibit the Chkl function.
4.5 siRNA STRATEGY: TRANSIENT SPECIFIC INHIBITION OF 
CHK1 AND CHK2
I originally designed different siRNAs specific for different Chkl cDNA targets which 
were in vitro transcribed using the Silencer siRNA construction kit (Ambion) and then 
screened after transfection in HCT-116 cells by Western blot analysis to verify their 
functionality. The Chkl siRNA duplex that more efficiently downregulated the 
expression of the gene (nucleotides 420-440 from starting ATG of Chkl cDNA), was 
picked up and chemically synthesized by Proligo. As I already described in my 
introduction, together with Chkl, the protein kinase Chk2 also plays a crucial role in the
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G2 checkpoint, thus representing another key molecular target to inhibit to increase the 
sensitivity to anticancer agents in cellular systems with G1 checkpoint defects. I thus 
decided to use in our experiments both Chkl and Chk2 siRNA duplexes in order to 
better define the relative contribution o f these two proteins in the G2 checkpoint 
activation and to provide a relative internal negative control to our specific transient 
transfections with either Chkl or Chk2 siRNA duplexes. I chose a validated 
commercially available Chk2 siRNA duplex (from Xeragon) to perform our 
experiments. As I previously mentioned I chose as an experimental system the parental 
HCT-116 cell line with an intact G1 checkpoit and its isogenic sublines with a defective 
G1 checkpoint due to p53 and p21 gene inactivations. These cell lines were transiently 
transfected with siRNA Chkl, siRNA Chk2 and with a combination of the two siRNAs. 
An almost complete suppression of Chkl and Chk2 expression was observed starting 
from 24 hours after transfection and persisting up to 96 hours in all the three systems 
tested. In figure 4.6 for each cell line studied the Western blot analysis showed the 
Chkl, Chk2 and actin protein levels 48 hours after mock transfection and at 48 ad 72 
hours after transfection with Chkl, Chk2 or both the specific siRNAs. It is important to 
note that the downregulation of the proteins of interest was specific as Chk2 levels 
remain constant after Chkl downregulation and the same observation is valid for Chkl 
after Chk2 downregulation. Actin levels were also detected in each of the cell line 
studied as additional internal control. In these experimental systems, no modification of 
cell growth was observed in the absence of DNA damage, not even when both the 
kinases were knocked down and in the presence or absence of p53 and p21. As it is 
possible to observe in figure 4.7 the growth of the cells was followed by counting the
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Figure 4.6 Western blot analysis to check for the specific Chkl and Chk2 inhibition 
by siRNA
Chkl, Chk2 and actin protein levels were detected by Western blotting analysis in the HCT- 
116, HCT-116 p53-/- and HCT 116 p21 -/- cell lines at different time points after mock 
transfection (48 hour), or transfection with Chkl, Chk2 or both siRNAs (48 
and 72 hour) as described in Material and Methods.
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Figure 4.7 Effect of the siRNA Chkl, siRNA Chk2 or both the siRNAs on the 
growth of the transfected cells
Cell growth curve o f the cell lines HCT-116, HCT-116 p53 -/-, HCT-116 p21 -/- either 
untransfected (mock) or transfected with siRNA for Chkl, Chk2 or both the proteins. 
The yellow box describes the legend. The cells were counted at 24, 48 and 72 hours post 
siRNA transfection. The values represent the mean o f at least three different experiments 
done in triplicate.
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samples from 24 to 72 hours after siRNA transfection. I next asked the question whether 
the complete downregulation of Chkl, Chk2 or of both the proteins was indeed 
associated with either a sensitivity of tumor cells to treatment by DNA damaging 
anticancer agents and/or with an abrogation of the G2-M block induced by the same 
treatments. DDP and IR were chosen as DNA damaging agents as their mechanism of 
action is quite clarified, both being able to induce a G2 block of the cell cycle and both 
being widely used in the clinical practice. For these experiments, 48 hours after 
transfection with siRNAs (time point at which an almost complete downregulation of 
Chkl and Chk2 proteins could be observed) cells were treated with the cross linking 
agent DDP and IR either to test cell survival by clonogenic assay and to monitor cell 
cycle perturbation (by FACS analysis) induced by these treatments as described in 
materials and methods. This investigation has been conducted in parallel in the three 
cellular lines studied (wt, p53-/-, p21 -/-) and for each cell line in mock untransfected 
cells and in Chkl, Chk2 or both the specific siRNAs transfected cells.
4.5.1 EFFECT OF CHK1, CHK2 AND BOTH PROTEINS DOWNREGULATION 
ON HCT-116 WT CELL LINE
As depicted in figure 4.8 panel A and C in the mock untransfected cells it is possible to 
observe a consistent G2 block at 24 hours after the end of the treatment (time point at 
which previous experiments indicated suitable to see a G2 block), with either DDP or IR 
conducted at 72 hours post transfection.
A slight reduction of the % of cells in the G2 phase was observable in cells transfected 
with siRNA Chkl and with both siRNAs (respectively 44% and 47% respect to 51% in
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mock cells) and treated with DDP, leading to approximately a 10% of G2 abrogation. 
siRNA Chk2 transfection did not modify the % of cells blocked in the G2 phase. An 
enhanced abrogation of the G2 block was on the contrary observed after IR damage 
(figure 4.8 panel C); in fact the % o f cells blocked in G2 after a dose of 12Gy of IR was 
42, 30, and 29 respectively in mock, siRNA Chkl and siRNA Chkl and Chk2, 
corresponding to a 28% of abrogation in siRNA Chkl and 30% in siRNA Chkl and 
Chk2 transfected cells. Again, downregulation of Chk2 did not cause any abrogation of 
the G2 block. The limited abrogation of the G2 block in parental HCT-116 cells after 
DDP treatment correlates with the lack of a different sensitivity to DDP treatment in 
these cells in which Chkl, Chk2 or both proteins were knocked down (figure 4.8 panel 
B). On the contrary in IR treated cells, a limited but consistent sensitization of about 
20% could be detected only in siRNA Chkl and in siRNA Chkl and Chk2 transfected 
cells, (figure 4.8, panel D).
Taken together these data would suggest that Chkl is not required for DDP cytotoxicity 
in wt p53 cells, having on the contrary a limited role in the cellular response to IR 
damage as already described in other cellular systems. Moreover, Chk2 does not seem to 
have any role in mediating DDP and IR induced G2 block of the cell cycle and in 
cellular sensitivity to such treatments. As I already described in materials and methods 
the sensitivity to DDP and IR was studied by performing a clonogenic assay on the cells 
treated at 48 hours after transfection which were then detached and seeded at low 
density.
189
A mock siRNA siRNA siRNA
Chkl Chk2 Chk1+ Chk2 B
I
I
1
DDP
c
100
g
soo 50 -
o
D
DNA Content
IR
5 10
DDP yM
15
too
u>
2c.oo 50 -
o
0 2 4 6 8
IRGy
Figure 4.8 Effect of Chkl, Chk2 and both proteins downregulation in the p53 wt 
HCT 116 cell line after DDP and IR treatments
PANEL A. Cell cycle analysis of mock transfected or siRNAs transfected cells treated 
or not with DDP 12.5 pM. The cells were fixed 24 hours after the end of the treatment 
and processed for cell cycle analysis as described in Materials and Methods.
PANEL B. Cytotoxic effect of DDP in mock transfected cells (■) and in cells transfected 
with siRNA Chkl (•  ), Chk2 ( A ) or both the siRNAs (□ ).
PANEL C. Cell cycle analysis of mock transfected or siRNAs transfected cells treated or 
not with IR 12 Gy. The cells were fixed 18 hours after the end of IR and processed for 
cell cycle analysis as described in Materials and Methods.
PANEL D. Cytotoxic effect of IR in mock transfected cells (■ ) and in cells transfected 
with siRNA Chkl (•  ), Chk2 ( A ) or both the siRNAs (□).
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4.5.2 EFFECT OF CHK1, CHK2 AND BOTH PROTEIN DOWNREGULATION ON  
THE HCT-116 CELL LINE p53-/- AND p21-/-
The same experiments were performed in the HCT116 derived cell lines in which p53 
and p21 have been inactivated by homologous recombination to better understand the 
interplay, if any among Chkl, Chk2, p53 and p21 in the cellular response to DDP and IR 
treatments. As depicted in figure 4.9 panels A and C when p53 -/- mock transfected cells 
were treated with DDP or IR, no G1 block could be observed and the majority of the 
cells (70%) were blocked in the G2 phase, as expected due to the lack of the p53 
checkpoint function. In Chk2 siRNA transfected treated cells the cell cycle profile was 
similar to the one obtained in mock cells. On the contrary, in Chkl siRNA and in siRNA 
Chkl and Chk2 transfected DDP and IR treated cells, a lower G2 block was observed. 
The calculated range of G2 abrogation for DDP was between 10 and 20%. This rate of 
abrogation was associated with a clear shift to the left of the dose response curve 
following DDP treatment, in cells transfected with only siRNA Chkl or with both the 
two siRNAs, (figure 4.9 panel B) with IC50 values changing from 9.9 pM (in mock 
trasfected cells) to 6.5 pM and 7 pM (siRNA Chkl and siRNA Chkl and Chk2 
transfected cells). Similar results were obtained after IR damage with an even higher 
degree of abrogation (31-50%) of the IR induced G2 block when the expression o f Chkl 
was abrogated either alone or in combination with Chk2 (figure 4.9 panel C). Again, the 
lack of Chk2 did not interfere with the cellular response to the two treatments and the 
observed effects with the double siRNA transfection are likely to be related to the lack 
of Chkl expression (figure 4.9 panel D). These data indicate that in p53-/- background is 
indeed possible to obtain higher abrogation of the G2 block associated with an increased
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Figure 4.9 Effect of Chkl, Chk2 and both proteins downregulation in the p53-/- 
HCT 116 cell line after DDP and IR treatments.
PANEL A. Cell cycle analysis of mock transfected or transfected cells treated or not 
with DDP 12.5 pM. The cells were fixed 24 hours after the end of the treatment and 
processed for cell cycle analysis as described in Materials and Methods.
PANEL B. Cytotoxic effect of DDP in mock transfected cells (■ ) and in cells
transfected with siRNA Chkl ( •  ), Chk2 (A ) or both the siRNAs (□ ).
PANEL C. Cell cycle analysis of mock transfected or transfected cells treated or not 
with IR 12 Gy. The cells were fixed 18 hours after the end of IR and processed for cell 
cycle analysis as described in Materials and Methods.
PANEL D . Cytotoxic effect of IR in mock transfected cells (■ ) and in cells transfected 
with siRNA Chkl (•), Chk2 ( A ) or both the siRNAs (□ ) .
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Figure 4.10 Effect of Chkl, Chk2 and both proteins downregulation in the p21-/- 
HCT 116 cell line after DDP and IR treatments
Cytotoxic effect of DDP (panel A) and IR (panel B) in mock transfected cells (■ ) and in 
cells transfected with siRNA Chkl ( •  ), Chk2 ( A ) or both the siRNA (□ ).
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sensitivity to treatment with DNA damaging agents than in p53 wt cells. Similar results 
have been obtained when HCT 116 p21 -/- cells were used, further indicating that the 
lack of the G1 checkpoint renders cells more sensitive to G2 abrogation. Figure 4.10 
reports the cytotoxic data obtained in HCT 116 p21 -/- mock, siRNA Chkl, siRNA 
Chk2 and siRNA Chkl and Chk2 transfected cells treated with DDP (panel A) and IR 
(panel B). A clear sensitization to both DDP and IR treatments was observed in siRNA 
Chkl and in both siRNAs transfected cells whereas no change in siRNA Chk2 
transfected cells again was found.
These data suggested that the inhibition of Chkl but not of Chk2 caused a greater 
sensitization to different DNA damaging agents (such as DDP and IR) in the cell lines 
with a defective G1 checkpoint than in the parental wild type cells. This effect was 
associated with a G2 abrogation of the cell cycle induced by the same treatment.
4.6 INDUCIBLE siRNA STRATEGY TO DOWNREGULATE CHK1
In order to solve the problem of the transient Chkl downregulation by the siRNA 
technique and trying to apply this model in an “in vivo” setting an inducible tetracycline 
system to obtain cellular clones stably expressing the Chkl siRNA was used. Briefly, as 
I described in materials and methods the siRNA target was subcloned in the pSuperior 
plasmid downstream to an HI promoter which is responsive to the Tet repressor 
expressed by the second plasmid, pcDNA/TR. In the absence o f tetracycline in the 
culture media, the Tet repressor binds to the promoter avoiding the expression of the 
siRNA. In the presence of tetracycline the Tet repressor detaches and the HI promoter 
gets activated expressing the siRNA of interest at first in a structure of a hairpin which
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permits the annealing of the sense and antisense sequences and then leading to the 
formation of the double strand RNA once the loop is cut by intracellular specific 
enzymes.
By using this inducible siRNA system it was possible to construct two pSuperior 
constructs: one containing a single siRNA against Chkl (21bp target sequence 
previously used in the transient expression Chkl experiments) and the other one 
containing two different siRNA Chkl target sequences (the already described target 
sequence and a second one validated by Zhao et al. (2002) with the attempt to further 
increase the degree and the duration of the inducible Chkl downregulation.
As discussed in materials and methods to get the double siRNA construct I had to 
perform additional cloning steps, as I had to include in the original plasmid a second HI 
promoter responsive to the Tet repressor.
As internal negative controls to these both single and double siRNA inducible plasmids, 
the correspondent scramble siRNA target sequences obtained by the proligo website 
database were also cloned in parallel.
The colon carcinoma HCT-116 p53 +/+ and p53-/- cell lines stably expressing the Tet 
repressor, were subsequently transfected with the single and double siRNA Chkl 
inducible pSuperior plasmids.
The clones were selected and screened as already described in materials and methods 
and the following sections of this chapter will describe the characterization of these 
clones which is still an ongoing project.
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4.6.1 SINGLE CHK1 siRNA INDUCIBLE EXPRESSION SYSTEM APPROACH
Stably expressing single Chkl siRNA tetracycline inducible clones were obtained both 
in the p53 wt and in the p53-/- HCT-116 cell line. By adding doxycycline, a 
considerable downregulation of the Chkl protein compared to the non induced cells 
starting from 48 hours after induction and up to 144 hours could be observed in the 
selected clones as it is depicted in figure 4.11 panels A and C. As it can be observed in 
figure 4.11 panels B and D, no differences in cell growth could be found in the presence 
or absence of the protein of interest in these clones, confirming the results obtained by 
the siRNA transient system. The effect of Chkl downregulation on the sensitivity to 
different anticancer agents such as DDP, etoposide (VP-16), UV rays was then studied. 
Preliminary data showed an increased activity in p53 deficient cells, doxycycline 
induced, compared to the p53 wt cells, confirming the data previously obtained with the 
transient transfection of siRNA. Figure 4.12 represents the results observed after the 
treatment with etoposide (panel A) and DDP (panel B) after the clonogenic assay 
performed in the HCT116 p53+/+ and p53 -/- cell line induced or not with doxycycline. 
The treatments with the drugs were performed at 72h post continuous induction with 
doxycyline. As it is possible to observe, the doxycycline induced cells p53-/- appear 
more sensitive to etoposide and DDP treatment compared to the doxycycline induced 
p53 wt cells. Figure 5.12 panel C shows the Chkl and actin protein levels detected by 
Western blot at the time of the treatment with the drugs, confirming an almost complete 
suppression of the protein of our interest. To verify if  the data obtained in vitro could be 
reproduced in an “in vivo” setting, these inducible cellular (p53 wt and p53 -/-) clones
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Figure 4.11 Characterization of the doxycycline inducible clones lacking Chkl 
obtained in the HCT-116 p53 +/+ and p53 -/-
Panel A and C. Chkl and actin protein levels were detected by Western blot analysis in 
the siRNA Chkl doxycycline inducible clones obtained in the HCT-116 p53 +/+ (A) and 
HCT-116 p53 -/- (C) at 24,48 and 72 hours post doxycycline induction.
Panel B and D. Cell growth curve of the siRNA Chkl doxycycline inducible clone 
obtained in the HCT-116 p53 +/+ (B) and p53-/- (C). The cells were counted at 24, 48, 
72 hours post the first doxycycline induction. The blue line represents the non induced 
cells while the pink line outlines the cells induced with doxycycline. Cells were induced 
every 48 hours with doxycycline. The values are the mean ± SD o f at least three 
different experiments done in triplicate.
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were transplanted in nude mice. Briefly, the clones, stably transfected with the 
tetracycline inducible system vectors, were allowed to grow in vitro and then 5xl06 cells 
of each clone were implanted subcutaneously in each flank of nude mice. The day after 
transplant, mice were randomized to receive or not tetracycline in the drinking water. 
Tetracycline was added every other day for all the duration of the experiment. The tumor 
volume of the induced and non induced mice was measured twice a week and the in vivo 
growth resulted comparable in the presence or in the absence of tetracycline as it is 
possible to observe in figure 4.13. Autopsies were performed on day 31 after tumor 
implant and tumors taken. Western blot analysis and immunohistochemical studies are 
ongoing to evaluate the effective downregulation of Chkl protein in those tumor tissues 
derived from mice tetracycline induced. This step of the investigation is actually 
ongoing as I had to incur in many different technical issues both in setting up IHC for 
the detection of human Chkl in transplanted tumors and to find a human specific Chkl 
antibody. In fact as regarding the Western blot analysis, the high presence of cellular 
infiltrates belonging to the mice did not lead to quantify the effective Chkl 
downregulation in vivo. After having confirmed the functionality of this inducible 
system in “vivo”, the next step will focus on the chemosensitivity of these tumors 
transplanted in the animals in the presence or in the absence of tetracycline.
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Figure 4.12 Characterization of the doxycycline inducible clones lacking Chkl 
obtained in the HCT-116 p53 +/+ and p53 -/-: response to DNA 
damaging agents
Cytotoxic effect of VP-16 (panel A) and DDP (panel B) in the siRNA Chkl doxycycline 
inducible clones derived from HCT-116 p53 +/+ (left part) or from HCT-116 p53 -/- 
(right part) cells line. The blue line represents the non induced cells while the 
doxycycline induced cells are indicated with the pink line.
Panel C. Chkl and actin levels detected by Western blot analysis in the doxycycline 
inducible clones at the times of the treatments with the drugs to further confirm the 
inducible downregulation of the Chkl protein kinase.
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Figure 4.13 In vivo growth of the siRNA Chkl inducible HCT-116 clones
In vivo growth of the HCT-116 clones stably transfected with the pSuperior plasmid 
inducible expressing the siRNA against Chkl and transplanted in nude mice. When the 
tumor was palpable, mice were randomized and either untreated (blue dots) or treated 
(pink squares) with tetracycline (added in the drinking water at 2 pg/ml).
201
4.6.2. DOUBLE CHK1 siRNA INDUCIBLE EXPRESSION SYSTEM APPROACH
Stably expressing double Chkl siRNA and double scramble siRNA tetracycline 
inducible clones were obtained in the p53+/+ HCT-116 cell line, while the screening of 
the clones in the HCT-116 p53 -/- cell line is still ongoing. The Western blot analysis 
conducted on these clones revealed an almost complete downregulation o f Chkl in the 
doxycycline induced cells starting from 48h up to 144 hours after the induction, while 
the induced scramble siRNA transfected cells presented the same protein level if 
compared with the non induced samples (figure 4.14, upper panel). The 
immunofluorescence analysis was also performed on the paraformaldehyde 4% fixed 
cells by staining them with a Chkl specific antibody. As it can be seen in figure 4.15, 
the cells transfected with the double scramble siRNA plasmid revealed a comparable 
almost ubiquitary expression of Chkl in the induced and non induced samples, while a 
specific decrease in Chkl expression was clearly detected in the induced double siRNA 
Chkl transfected cells thus further confirming the specificity and efficiency o f this 
inducible system. The cell growth curve did not reveal any appreciable difference 
between the induced and non induced cells (figure 4.14 lower panel). Experiments are 
ongoing with the aim to test the sensitivity to different anticancer agents in the induced 
and non induced cells and I am planning to transplant nude mice with the cells inducibly 
expressing the double siRNA against Chkl which the results in vitro have ascribed to 
downregulate very well (Western blot analysis and IF results) the protein o f our interest.
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Figure 4.14 Characterization of the double siRNA scramble and siRNA Chkl 
inducible HCT 116 +/+ clones
Panel A and C. Chkl and the internal control actin protein levels by Western blot 
analysis in the non induced clones or after 48 and 72 hours post induction with 
doxycycline 2pg/ml. Panel B and D. Cell growth curves of the clones either non induced 
(blue line) or induced (pink line) with doxycycline 2pg/ml every 48 hours. The results 
are mean ± SD o f at least three different experiments done in triplicate.
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Figure 4.15 Characterization of the double siRNA scramble and siRNA Chkl 
inducible HCT 116 +/+ clones: immunofluorescence analysis
Immunofluorescence analysis showing the specific and efficient downregulation of 
Chkl in the presence o f doxycycline. The cells seeded in 24 well plates on round 
coverslips were either induced or non every 48 hours with doxycycline and fixed 72 
hours after the first induction with 4% paraformaldehyde for 20 minutes. The 
immunofluorescence analysis was performed as described in materials and methods
204
4.7 DISCUSSION
The knowledge of the molecular mechanisms at the basis of the DNA damage 
checkpoint has important implications for both carcinogenesis and cancer therapy. It is 
becoming clear that tumor cells have checkpoint defects due to mutations of protein with 
checkpoint function (Liu et al., 2000; Wang et al., 1996). In particular cancer cells have 
defects in the G1 checkpoint and in this situation the G2 checkpoint acquired particular 
importance for the repair of the DNA lesions induced by different treatments. By 
abrogating the residual G2 arrest, it would be possible to specifically sensitize tumor 
cells to the cytotoxic effect of DNA damaging agents and data from the literature would 
suggest that this is indeed the case (Donzelli and Draetta, 2003; Luo et al., 2001). 
Emerging data from the literature have identified Chkl and Chk2 kinases as key 
regulators of the G2 checkpoint after DNA damage (Brown et al., 1999). Previous 
attempts using various strategies to downregulate the kinases of our interest such as the 
antisense strategy, the dominant negative strategy and KO strategy were unsuccesful and 
only the selective and efficient siRNA technique (Bunz et al., 1998; Dixon and Norbury, 
2002) allowed us to completely down regulate the expression of Chkl, Chk2 and both 
proteins either in HCT-116 parental cells with an intact G1 checkpoint and in its derived 
sublines lacking p53 and p21 proteins, thus having a defective G1 checkpoint. 
Interestingly enough, in our experimental systems the complete abrogation of the kinase 
proteins did not alter the cell growth in the absence of damage. Having set up the system 
for a complete abrogation of Chkl and Chk2 and checked that no cell growth 
interference was occurring, experiments with two different DNA damaging agents, a 
cross-linking agent, DDP and IR were performed aimed at investigating their role in the
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G2 checkpoint induced by both treatments both by monitoring the G2 perturbation of the 
cell cycle and by evaluating the cytotoxic effect of the drugs.
The data suggest that Chk2 has no role at all in the cellular response to DDP and IR 
treatments thus supporting the findings obtained in the HCT-116 Chk2-/- cells where no 
G1 and G2 checkpoints defects were observed after IR damage (Jallepalli et al., 2003). 
The fact that, even in a p53 and p21 deficient background, downregulation of Chk2 does 
not chemosensitize, strongly argues against any important role of Chk2 in mediating the 
cellular response to DNA damaging agents. However when Chkl was knocked down 
clear effects on cell cycle perturbation (a G2 abrogation ranging from 20 to 50%) and 
cell sensitization to both DDP (in a p53 and p21 deficient background) and IR (in a p53 
and p21 deficient background) treatments could indeed be observed (Figures 4.9 and 
4.10). Such data clearly reinforce the growing experimental evidence that the G2 
abrogation in a G1 checkpoint deficient situation would favor cell death (Donzelli and 
Draetta, 2003; Luo et al., 2001; Bartek and Lukas, 2003) and outlined the Chkl protein 
kinase as an important target to inhibit to improve the efficacy of anticancer agents in 
human tumors with a defective G1 checkpoint. The siRNA Chkl inducible tetracycline 
system was chosen to solve the problem of the transient nature of the synthetic siRNAs 
and most of all to apply this model in an tin vivo’ setting. Preliminary data obtained with 
stable cellular clones inducibly expressing one or two different siRNAs Chkl further 
confirmed the data obtained with the synthetic siRNAs as tetracycline induced p53-/- 
clones showed an increase sensitivity to different anticancer agents. Experiments are 
ongoing to verify the functionality o f this system in vivo. As for the siRNA transient 
system, I could not detect any relevant difference in cell growth in the stable clones
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tetracycline inducing the siRNA Chkl if compared with the non induced clones. While 
Chkl has been shown to be essential for mammalian development and viability as 
suggested by the early embryonic lethality in Chkl deficient mice and the acute lethality 
of Chkl deficient embryonic cells (Takai et al., 2000), Chkl -/- DT40 somatic cells 
obtained by homologous recombination could proliferate, even if at a slower rate due to 
an increased apoptotic cell death (Zachos et al., 2003). In our experimental system no 
modification of cell growth could be observed, not even when both kinases have been 
knocked down and in the presence or absence of p53 and p21, leading to the initial 
hypothesis that probably this protein is not essential for the human somatic cell lines. 
This aspect is actually still far to be completely understood and will be the subject of my 
next chapter.
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CHAPTER 5
INVESTIGATION OF THE PHYSIOLOGICAL ROLE OF 
THE PROTEIN KINASE CHK1 IN  DIFFERENT 
SOMATIC CANCER CELL LINES
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5.1 INTRODUCTION
Although a fundamental role in embryogenesis has been attributed to Chkl in the past 
(Chkl -/- mice die at E6.5 days), its role in human somatic cell lines still appears 
controversial. As I described in paragraph 1.7.1.2 of my introduction in the last 2-3 years 
different groups have focused their studies on this aspect. Gillespie and his group with 
the isolation and the characterization of the somatic lymphoma DT40 Chkl -/- avian cell 
line provided evidence that Chkl is not essential for the survival of this cell line (Zachos 
et al., 2003). These data corroborated the data obtained in the colon carcinoma cell line 
HCT116, where the down-regulation of Chkl by siRNA did have no effect on cell 
growth. During the time I spent in the laboratory directed by Yolanda Sanchez at 
Cincinnati University, US, I mainly focused on the physiological role of Chkl starting 
from the intitial observation of a possible inter-relationship existing between Chkl and 
two proteins (centrin2 and NTKL) involved in centrosome biology (Kato et al., 2002; 
Salisbury et al., 2002). The project starting points were the results previously obtained in 
Sanchez’s laboratory, from a binding screening of a human HeLa cDNA expression 
library using as a probe a phosphorylated human Chkl isolated from insect cells, where 
two proteins involved in centrosomes biology, centrin2 and NTKL, were identified as 
interacting with GST-pChkl. Preliminary data confirmed this inter-relationship as a 
kinase assay evidenced a clear “in vitro” phosphorylation of NTKL variant 1 by GST- 
Chkl, while a GST pull down assay showed the existence of an interaction between 
centrin-2 and Chkl (data not shown). The characterization and the biological 
significance of these inter-relationships are still under investigation being part of an 
ongoing project but also represented a starting point for the last part o f my investigation
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that I’m including in the thesis with the aim to better understand the effective 
physiological role played by Chkl in human somatic cancer cell lines.
5.2 CHK1 AND THE MITOTIC PHENOTYPE
Beside the putative inter relationship between Chkl and two centrosomes related 
proteins (Sanchez lab data), recently data published by Bartek J. and his group, did 
attribute to Chkl a role in the biology of the centrosomes. As I already described in 
paragraph 1.7.1.2.1 of my introduction, Chkl protein kinase was observed to be 
present not only in the nucleus but also in the centrosomes of interphase cells 
(Kramer et al., 2004). According to this study, Chkl would dissociate from 
centrosomes at the onset of prophase concomitant with centrosomes separation. The 
centrosomes play an important role in the spindle formation during mitosis, important 
for segregation of chromosomes and for a faithful transmission of the entire genome to 
the daughter cells. Defects in the spindle formation could bring to aberrant chromosomal 
segregation and to a change in chromosomal number and structure. In order to 
investigate the role, if any, of Chkl in determining a correct mitotic phenotype, I applied 
the siRNA technique to downregulate the Chkl protein in the cervical cancer cell line 
HeLa/E6, whose cDNA was previously used in the binding screening investigation just 
cited. The same transfection procedure and conditions that I set up for the previous part 
of my work in HCT-116 cells were also used in HeLa cells but, with the aim to increase 
the downregulation of the protein of interest I designed the double strand siRNA by 
introducing an asymmetry in the sequence as Zamore and his group recently described 
(Schwarz et al., 2003). I again ordered the duplex from Proligo and I used the same
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Figure 5.1 Western blot analysis in HeLa cells to test the Chkl downregulation by 
siRNA
Chkl and (3-tubulin protein levels were detected by Western Blotting Analysis in HeLa cells 
at 48 and 72 hours after mock transfection or transfection with either scramble or Chkl 
siRNA presenting an asymmetry in its sequence as described in materials and methods.
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previous concentration (60nM) to tranfect HeLa cells as I did for HCT-116 cell line. I 
also designed the correspondent siRNA scramble of the Chkl target sequence (a proligo 
database was used) and I transfected this duplex in parallel with the siRNA Chkl by 
using the same experimental conditions. As it is possible to observe in figure 5.1 Chkl 
protein levels were reduced to almost undetectable levels at both 48 and 72 hours post 
transfection with siRNA Chkl while the scramble siRNA and the mock untransfected 
samples basically showed comparable Chkl protein levels. The p-tubulin levels were 
detected as internal loading control. In the same experimental conditions, to observe the 
mitotic phenotype, set o f samples seeded on round coverslips were fixed and stained 
with the mitotic spindle marker a-tubulin and then with the nuclei stain DAPI as 
described in materials and methods. Thanks to this staining we could easily detect at the 
fluorescence microscope the number and the morphology of the mitotic cells present in 
the fixed samples both by the bright colour and very well distinguishable morphology of 
the mitotic spindle and by the evident chromosomes condensation of the mitotic cells. In 
figure 5.2 are reported two different fields corresponding to the siRNA scramble sample 
(left part of the figure) and the siRNA Chkl one (right part of the figure) at 72 hours 
post transfection. The mitotic phenotype of the siRNA scramble sample looked normal 
both in the mitotic spindle and in the chromosomes morphology similarly to what 
observed in the mock untransfcted cells (data not shown). On the contrary, as it can be 
easily observed in the right part of the figure 5.2, the mitotic phenotype of the siRNA 
Chkl sample looked abnormal both in the mitotic spindle and in the chromosomes 
morphology and structure. The 48h post transfection time point showed a comparable 
normal mitotic phenotype both in scramble and Chkl siRNA transfected samples (data
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Figure 5.2 Mitotic spindle staining in HeLa cells either scramble or Chkl siRNA 
transfected
Immunofluorescence analysis performed in HeLa cells, seeded on round coverslips, at 
72 hours post transfection with either scramble (left part) or Chkl (right part) siRNA. 
The cells on coverslips were fixed with paraformaldehyde 4% for 20 minutes and then 
stained with the mitotic spindle marker a-tubulin and with the nuclei stain DAPI. Two 
distinct fields of the siRNA scramble slide on the left and of the siRNA Chkl slide on 
the right are represented including clear examples of the mitotic figures phenotype 
observed.
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not shown). To double check that the cells presenting the abnormal mitotic spindle were 
in mitosis, an additional mitotic marker, the histone H3 phosphorylated at serine 10 was 
used to co-stain (together with a-tubulin) the scramble and Chkl siRNA transfected 
samples. The costaining was possible because of the different features of the secondary 
antibodies used for a-tubulin and Histone 3 phosphorylated in serine 10 staining which 
were respectively rat-FITC conjugated and mouse Cy3 conjugated. The results observed 
after the costaining showed that the cells with the abnormal mitotic spindle and 
chromosomes morphology observed in the siRNA Chkl transfected sample were 
effectively mitotic cells (fugure 5.4). Figure 5.3, representing the siRNA scramble 
transfected cells shows that only mitotic cells (looking normal in this sample) present the 
double staining. This experiment was repeated several times and the abnormal mitotic 
phenotype observed in the siRNA Chkl transfected cells was reproducible. Interestingly 
enough an accumulation of cells in mitosis after transfection with the siRNA Chkl 
compared to the siRNA scramble transfected ones was observed. Three independent 
experiments were analysed and the percentage of mitotic cells and of the different 
mitotic abnormalities was calculated as depicted in figure 5.5 and as the legend of the 
figure further explain. The analysis revealed an increased percentage of mitotic cells in 
the siRNA Chkl sample (20%).
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Figure 5.3 Mitotic figures in scramble siRNA transfected HeLa cells
Panel A. Immunofluorescence analysis performed in HeLa cells at 72 hours post 
transfection with siRNA scramble and stained with the two markers o f mitosis: a-tubulin 
(green,Alexa Fluor 488) and Histone 3 phosphorylated in serine 10 (red,Alexa Fluor 
594), like described in materials and methods. B panel represents two additional 
examples of mitotic cells taken from other fields o f the slides.
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Figure 5.4 Mitotic figures in Chkl siRNA transfected HeLa cells
Panel A, Immunofluorescence analysis performed in HeLa cells at 72 hours post 
transfection with siRNA Chkl and stained with the two markers of mitosis: a-tubulin 
(green,Alexa Fluor 488) and Histone 3 phosphorylated in serine 10 (red,Alexa Fluor 
594). B panel represents four additional examples of mitotic cells taken from other fields 
of the slides and confirming the abnormal phenotype observed in the Chkl siRNA 
transfected sample. A “loop spindle” phenotype can be observed in the second example 
from the left.
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Figure 5.5 Analysis of the mitotic figures in HeLa cells transfected with either 
scramble or Chkl siRNA
The data obtained are the mean± SD of three independent experiments. The percentage 
of mitotic cells was calculated among 300 cells (group 1). The percentage o f the 
different mitotic abnormalities (groups 2-5) was calculated among 70 mitotic cells. An 
example of “loop spindle” phenotype is represented in figure 5.4 B (second example 
from the left).
217
5.3 MITOTIC SPINDLE ABNORMALITIES: POSSIBLE
EXPLANATIONS
5.3.1 CENTROSOMES
In order to evaluate if the mitotic spindle and chromosomes abnormalities observed in 
the siRNA Chkl transfected cells, could be considered as a consequence of any 
centrosomes positioning/separation abnormalities, we synchronized the cells at the Gl/S 
boundary, cell cycle stage at which centrosomes duplication occur, to observe the 
relative positioning of the duplicated centrosomes and their separation schedule time. 
After 62 hours post siRNA scramble and Chkl transfection, cells were treated with HU 
2mM for lOh and then fixed at 72 h post transfection, immediately after release from 
HU and subsequently stained with a tubulin, DAPI and y tubulin, a centrosomes marker. 
As expected, we observed a decrease in % of mitotic cells in the siRNAs scramble HU 
treated cells (< 5%) compared to the scramble non HU treated ones (15%) as the HU 
treatment did synchronize the cells at Gl/S boundary thus leading to a decrease in 
mitotic cells (figure 5.8). In addition, as previously data in literature showed (Balczon et 
al., 1995), due to the HU treatment in a not functional p53 cell line (Hela/E6), the few 
percentage of mitotic cells observed in the siRNA scramble HU treated sample 
presented multipolar spindle related to multiple round of centrosomes duplication 
leading to centrosomes amplification. In figure 5.6 right panel, is reported an example of 
a multipolar spindle phenotype in a HU treated scramble siRNA transfected cells, while 
the left panel of this figure represents an example of a normal mitotic phenotype in the 
non HU treated siRNA scramble trasfected sample, with the two centrosomes well
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Figure 5.6 Mitotic figures in HU treated siRNA scramble transfected HeLa cells
Example of mitotic figure observed in siRNA scramble transfected HeLa cells either 
control (left part) or HU treated (right part). The cells were stained with the mitotic 
marker a tubulin, the centrosomes marker y tubulin and DAPI.
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positioned at the two spindle poles. On the other hand, in the siRNA Chkl HU treated 
sample, we could not observe a decrease in % of mitotic cells (31%), compared to the 
siRNA Chkl untreated sample (27%), (figure 5.8) suggesting that in this cell line the 
lack of Chkl caused a defect in blocking the cells in S phase after treatment with a DNA 
synthesis inhibitor. We also observed centrosomes amplification in the siRNA Chkl HU 
treated cells as well as in the scramble HU treated sample, although the centrosomes 
positioning in the siRNA Chkl HU treated cells was altered compared to the position of 
the centrosomes in the multipolar mitotic figures observed in the siRNA Chkl scramble 
HU treated cells. In the right panel of figure 5.7 A it is possible to observe two different 
examples of mitotic figures phenotype in the siRNA Chkl HU treated samples with 
centrosomes not positioned and organized as in the siRNA scramble HU treated sample. 
In fact in one case the three centrosomes present positioned close each other in just one 
spindle pole, while in the other example reported in the figure, it is possible to observe 
the presence of two centrosomes at the level of one of the two spindle poles present. The 
scheme described in panel B of figure 5.7 represents the possible centrosomes 
orientation observed in this sample. The non HU treated siRNA Chkl transfected 
samples (left panel of figure 5.7 A) basically presented the same mitotic phenotype 
already described in the previous paragraph. In figure 5.8 the percentage of mitotic cells 
and mitotic cells with multipolar spindle each group is summarized and is represented as 
mean ± SD of two independent experiments. The legend o f the figure further explains 
the criteria of this analysis.
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Figure 5.7 Mitotic figures in HU treated siRNA Chkl transfected HeLa cells
Panel A. Examples o f mitotic figures (two each) observed in siRNA Chkl transfected 
HeLa cells either control (left part) or HU treated (right part).
Panel B. Schematic representation o f the different possible centrosomes orientation 
observed in the siRNA Chkl HU treated sample.
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Figure 5.8 Analysis of mitotic cells in HeLa cells transfected with either scramble 
or Chkl siRNA and either treated or not with HU
Schematic representation of the percentage o f mitotic cells and mitotic cells with 
multipolar spindle in the 4 samples studied. The % of mitotic cells each group was 
calculated among 300 cells, while the % o f mitotic cells with multipolar spindle was 
calculated among 40 mitotic cells each group. The data represent the mean± SD of two 
independent experiments.
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5.3.2 PREMATURE MITOSIS
To further investigate the nature o f the accumulation of abnormal mitotic figures in 
siRNA Chkl transfected cells, a FACS analysis was performed to study the cell cycle 
profile of siRNA Chkl transfected cells compared to the siRNA scramble ones at 72 
hours post transfection (time point at which we could detect by IF the mitotic figures 
abnormalities). An increased percentage of S population in siRNA Chkl transfected 
cells versus siRNA scramble ones was observed (figure 5.9 A upper panel). An 
additional mitotic marker, cyclin B l, whose expression starts in late S phase and persists 
up to the metaphase-anaphase transition, was picked up to study its cell cycle dependent 
expression by FACS analysis. This analysis revealed an accumulation of cyclin B l 
positive population in a high percentage in S phase suggesting that probably part of the S 
population represents the “mitotic population” observed by the microscope analysis 
(figure 5.9 A lower panel). In figure 5.9 C the bi-parametric representation of cyclinBl- 
FITC and DNA content (PI) is depicted, clearly showing a higher amount of cyclin B l 
positive cells in the S phase of the siRNA Chkl sample compared to the siRNA 
scramble sample. In figure 5.9 B the Western blot analysis representing the control of 
the working downregulation of the Chkl protein, confirmed the increased levels of 
cyclinBl in the siRNA Chkl transfected sample. We hypothesized that in HeLa cells the 
lack of Chkl would lead to a premature mitosis before the completion of DNA 
replication. Probably the increased % of cells in mitosis observed by IF could include 
part of the S phase population observed by FACS, thus having a <4N DNA content. This 
would explain the incomplete chromosomes condensation observed in these abnormal 
mitotic figures.
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Figure 5.9 Analysis of the cyclin B l levels in HeLa cells at 72 hours post 
transfection with either scramble or Chkl siRNA
Panel A. Ethanol 70% fixed cells stained with cyclin B l and propidium iodide. FACS 
analysis was performed. The total population (upper panel) and the cyclinBl positive 
population (lower panel) cell cycle profile o f the two samples studied are represented. 
Panel B. Chkl, cyclinBl and (3 tubulin protein levels detected by Western blot analysis 
in the scramble and Chkl transfected samples at the same time point (72h) at which 
FACS and IF analysis were performed.
Panel C. Bi-parametric representation o f cyclinBl and DNA content in the control 
negative sample (secondary antibody only), siRNA scramble and siRNA Chkl samples. 
The arrows specifically indicate the cyclin Bl population in S phase.
5.4 INVESTIGATION ON THE POSSIBLE PHYSIOLOGICAL ROLE 
OF CHK1 IN  ADDITIONAL SOMATIC CELL LINES
In order to investigate if the accumulation in S phase observed by FACS analysis in the 
Chkl siRNA transfected HeLa cells, associated with a possible premature mitosis before 
completion of DNA replication, could be extended also to other cellular lines we studied 
the cell cycle perturbation in parallel in different cell lines transfected with either 
scramble or Chkl siRNA. Standard transfections conditions were used to transfect a 
wider spectrum of human somatic cell lines. We repeated this experiment in the HCT- 
116 p53 +/+ and p53-/- cell line, although previous data did not show any alteration in 
cell cycle profile at 72h post Chkl downregulation, (figures 4.8 and 4.9) in order to 
double check if the introduction of a mismatch in the double strand siRNA sequence 
would possibly modify the features previously observed. We also studied at 72 hours 
post transfection the cell cycle profile of two ovarian cancer cell lines, SKOV-3 and 
A2780 and of the osteosarcoma cell line U20S. As it is depicted in figure 5.10 in the 
HCT116 p53+/+ and p53-/- a comparable cell cycle profile in the cells with and without 
the expression of Chkl was observed (confirming the data previously shown). In the 
SKOV-3 ovarian cell line even if it was possible to observe a slight accumulation of 
cells in S phase in the siRNA Chkl transfected sample, this was not accompanied by any 
abnormality in the phenotype observed by IF (data not shown). On the other hand in the 
A2780 cell line a comparable cell cycle profile in the absence of Chkl as comparing 
with that one observed in the scramble siRNA transfected sample was observed. The 
immunofluorescence analysis conducted in parallel on these cell lines, revealed no 
mitotic phenotype abnormalities in the absence of Chkl (data not shown). On the
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Figure 5.10 Cell cycle profiles of siRNA Chkl transfected cells
FACS analysis performed on different human somatic cancer cell lines at 72 hours post 
transfection with either scramble or Chkl siRNA.
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contrary, by analysing the cell cycle profile of the U20S cell line it was possible to 
observe an accumulation of cells in S and G2-M phase, similarly to what was observed 
in the HeLa cell line (figure 5.9).
The U20S cell line was then further studied. Figure 5.11 A shows the Chkl and actin 
protein levels detected by Western blot analysis to confirm the downregulation o f the 
protein of interest at 72 hours post transfection. To investigate the cell cycle specific 
cyclin B l expression levels, the cells were double stained with cyclinBl and with ToPro 
and the FACS analysis was performed at 72 hour time point. As it is possible to observe 
in figure 5.11 B, the siRNA Chkl transfected cells apparently presented a consistent 
accumulation of cells in G2-M phase although, the percentage of positive cyclinB 1 cells 
in G2-M was comparable in the siRNA scramble and Chkl samples. The consistent 
amount of cyclin B l negative cells in G2-M in the siRNA Chkl transfected sample 
(represented by R3 box) led to the hypothesis that probably part of the apparent G2-M 
population observed could represent the G1 ratio of the tetraploid population (S and G2- 
M of this population represented by box R9) thus explaining the lack of expression of 
cyclin B l. No significant cyclinBl expression was observed in the S phase of the Chkl 
siRNA transfected sample suggesting that probably the S and G-M accumulation 
observed in U20S cells has a different biological significance respect to the one 
hypothesized in HeLa cells. The mitotic figures were also studied in this cell line by 
staining with a tubulin and DAPI thus confirming this hypothesis. In figure 5.12 the 
immunofluorescence analysis at 72h post siRNA scramble (upper part) and siRNA Chkl 
(lower part) transfection is depicted. No increase in the % of cells with mitotic spindle 
could be observed in the siRNA Chkl transfected cells compared to the siRNA scramble
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Figure 5.11 Analysis of the cyclin B l levels in U20S cells at 72 hours post 
transfection with either scramble or Chkl siRNA
Panel A. Chkl and actin protein levels detected by Western blot analysis performed at 
72 hours post transfection with either scramble or Chkl siRNA.
Panel B. Cell cycle specific expression o f cyclin B l performed on siRNA scramble and 
Chkl transfected U 20S cells. The biparametric analysis and the simple DNA content are 
represented for each sample. The R3 box represents the cyclin B 1 negative population 
while R6, R7 and R8 represent different levels of expression of cyclin B l. R9 box in the 
siRNA Chkl sample represents the tetraploid population present in this sample.
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Figure 5.12 Mitotic spindle staining in U20S cells either scramble or Chkl siRNA 
transfected
Immunofluorescence analysis after staining with a  tubulin and DAPI in U 20S cells 
either lacking or not Chkl expression.
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transfected ones. Only few of the mitotic cells in the siRNA Chkl sample appeared 
abnormal, but it was easily possible to detect an increased percentage of cells 
undergoing death and a higher incidence of cells with micro-polynuclei. On the other 
hand, the siRNA scramble transfected cells looked normal.
The cell growth of the U20S cells transfected either with scramble or Chkl siRNA was 
studied and it was possible to see that, starting from 72h post transfection, cells lacking 
Chkl expression stopped growing and/or started dying, (figure 5.13). This is a different 
result if  compared with the cell growth curve obtained from the HCT116 cell lines 
where we could never detect cell growth differences in the absence of Chkl (see figure 
4.7 for example). In fact in figure 5.14, to further underline this difference, the relative 
% of live cells considering the scramble siRNA sample as 100%, is reported in the 
HCT116 p53+/+ and p53-/- and in the U20S cell line at 96 hours post transfection with 
either scramble or Chkl siRNA. As it is possible to observe in the figure, only U20S  
cells survival was compromised by the lack o f Chkl expression.
To understand if apoptosis could be a possible mechanism responsible for the death of 
the cells lacking Chkl expression, the sulforodamine/DAPI staining was performed and 
confirmed the presence of apoptotic morphology in the siRNA Chkl transfected cells 
while the siRNA scramble transfected cellular morphology looked normal (figure 5.15). 
In addition in figure 5.16 the decreased levels of procaspase-3 observed by Western blot 
analysis would further suggest that death by apoptosis is occurring. In figure 5.17, lamin 
B staining confirmed the presence of apoptotic cells which have lost nuclear envelope 
integrity, while the micro-polynuclei still have intact lamin B. The significant increase in 
cell volume and the formation of micronuclei observed in the siRNA Chkl transfected
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Figure 5.13 Cell growth curve of U20S cells either scramble or Chkl siRNA 
transfected
The cells were counted at 24, 48, 72, 96, 120 and 144 hours post siRNAs transfection. 
The data represent the mean± SD of two independent experiments.
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Figure 5.14 Cell survival at 96 hours post siRNA Chkl transfection in different cell 
lines
Schematic representation of the percentage of cells still surviving at 96 hours post 
transfection with siRNA Chkl in HCT-116 p53 +/+, HCT-116 p53 -/- and U 20S. Data 
are expressed as relative % of scramble treated cells and are the mean ± SD o f two 
independent experiments.
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U20S cells (orange arrows in fig. 5.15 and fig. 5.17) would let think about another 
additional death mechanism which is still under investigation.
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Figure 5.15 Sulforodamine/DAPI staining of U20S cells either scramble or Chkl 
siRNA transfected
The green arrow outlines a typical apoptotic morphology while the orange one evidences 
an example of cell presenting micro-polynuclei which appears very frequent in this cell 
line lacking Chkl expression. Two distinct fields o f the siRNA scramble slide (upper 
part) and of the siRNA Chkl slide (lower part) are represented.
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Figure 5.16 Pro-caspase 3 levels to detect apoptosis in siRNA Chkl U 20S  
transfected cells
Panel A. Chkl, pro-caspase 3 and p-tubulin protein levels detected by Western blot 
analysis.
Panel B. Densitometric analysis o f the levels of pro-caspase 3. Data are expressed as 
percentage of siRNA scramble relative controls and represent the ratio between pro- 
caspase 3 and p-tubulin.
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Figure 5.17 Lamin B staining in U20S cells either scramble or Chkl siRNA 
transfected
Immunofluorescence analysis conducted on siRNA scramble and Chkl transfected cells 
fixed at 72 hours post transfection and stained with lamin B and DAPI. Nuclear 
envelope features in apoptotic cells (white arrows) and in cells with micro-polynuclei 
(orange arrow) are depicted.
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5.5 DISCUSSION
During the time I spent in the laboratory directed by Yolanda Sanchez at Cincinnati 
University, US, my work, subject of this chapter, mainly focused on the investigation of 
the physiological role of the protein kinase Chkl in human somatic cancer cell lines. Its 
role, in fact, appears still controversial although in the last years several groups gave 
some insights such as for example Gillespie and his group with the DT40 avian 
lymphoma cell line Chkl-/- characterization and Lam et al. with the Chkl heterozygous 
and homozygous KO conditional breast tissues characterization. The starting point of 
my investigation was to further understand the role o f the protein kinase Chkl in 
centrosome biology as recent experimental evidences attributed to Chkl a role in the 
biology of these small component of a cell (Kramer et al.,2004 and data unpublished in 
sanchez lab). Again the siRNA technique was used to downregulate the Chkl kinase 
protein and to investigate in HeLa cells, on a possible role played by this protein in 
determining a correct mitotic phenotype. Centrosomes in fact are involved in the mitotic 
spindle formation during mitosis, important for segregation of chromosomes and for a 
faithful transmission of the entire genome to the daughter cells. The data obtained in this 
cell line revealed that the lack of Chkl would lead to a defective mitotic spindle 
assembly accompanied by abnormal chromosomal condensation as the data depicted in 
figures 5.2-5.5 underlined. To understand the biological significance of the abnormal 
mitotic phenotype observed in cells lacking Chkl expression, different hypotheses were 
made and related experiments were performed. In the first instance I tried to explain the 
abnormal mitotic phenotype with a possible (still not clear) role played by Chkl in
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determining centrosomes positioning/orientation as the data described in the paragraph 
5.2 would suggest. In the second instance the cell cycle profile by FACS analysis was 
studied to deeply investigate the nature of the increased % of mitotic cells in the siRNA 
Chkl transfected cells observed by IF. The results revealed that the accumulation of 
cells in S phase was correlated with a high cyclin B1 expression in this S phase 
population in the siRNA Chkl transfected sample. These data suggest that in HeLa cells 
the absence of Chkl induces cells to undergo mitosis before the completion of DNA 
replication. This observation is in line to what has been recently observed (Niida et al., 
2005) in the conditional Chkl deficient mouse ES cells, where the authors detected by 
microscopic laser scanning cytometry, Histone 3 phosphorylated in serine 10 positive 
cells with a DNA content of less than 4N. These data also corroborated with the 
observation made by Lam et al. by studying the Chkl heterozygous and homozygous 
breast tissues where they could observe nuclei positive for both BrdU and for Histone 3 
phosphorylated in serine 10 staining, respectively replication and mitotic markers (Lam 
et al., 2004). The abnormal mitotic phenotype observed in siRNA Chkl transfected 
HeLa cells appeared similar to that one observed by Gillespie and his group in 
lymphoma DT40 Chkl -/- cell line after aphidicolin treatment while they did not observe 
this phenotype in the non treated Chkl -/- cells (fig. 5.18) (Zachos et al., 2005). In 
lymphoma DT40 Chkl -/- aphidicolin treated cells the entry in mitosis from S phase has 
been explained with the loss of replication capacity determined by the degeneration of 
viable replication structures which are normally stabilized by Chkl during replication 
arrest. The premature mitosis before completion of DNA synthesis observed in HeLa 
cells in the absence of replication arrest could be
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AChk1-/-{+Aph, 12h) WT (+ Aph, 12h)
Figure 5.18 Possible explanation for the abnormal mitotic phenotype observed in 
siRNA Chkl transfected HeLa cells
Comparison between the “loop spindle” morphology observed in siRNA Chkl 
transfected HeLa cells and the mitotic phenotype observed in avian lymphoma DT40 
Chkl-/- cell line isolated by Zachos et al. and treated with Aphidicolin for 12 hours.
Panel A. Higher magnification of a “loop spindle” mitotic cell observed in HeLa cells at 
72 hours post transfection with siRNA Chkl and co-stained with anti a-tubulin and anti 
Histone 3 phosphorylated in serine 10.
Panel B. Figure derived from a paper by Zachos et al. where they showed the mitotic 
phenotype observed in Chkl-/- cells after replication block induced by aphidicolin. 
(Panel B modified by Zachos et al., 2005).
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explained by the possibility that in this cells line Chkl is also necessary for the 
maintenance of viable replication structures during normal S phase progression. This 
hypothesis had been made also to explain the formation of DNA breaks and pH2AX 
activation recently observed by Bartek and his group in U20S cells where Chkl has 
been inhibited either by siRNA or by specific inhibitors (Syljuasen et al., 2005). The 
hypothesis of the entry in mitosis before the completion of DNA synthesis could in part 
also explain the abnormal centrosome positioning/orientation observed and described in 
the paragraph 5.2.1 as probably in these cells together with the incomplete chromosomal 
condensation, centrosomes separation (which usually happens in late G2) did not 
completely occur as well.
To investigate whether this phenomenon was restricted to the HeLa cell line, siRNA 
Chkl transfection was conducted on a wider spectrum of somatic cell lines. Among 5 
different somatic cell lines only the U20S osteosarcoma cell line presented a similar S 
phase accumulation although the IF analysis revealed an increased percentage of cells 
undergoing death and no accumulation of cells with mitotic spindle. The cell growth 
curve showed a substantial arrest and/or death of these cells in the absence of Chkl 
which we could never observe in the previously studied colon carcinoma cell system 
HCT116 where this protein kinase is unlikely to be essential for the viability of the cells. 
These data suggest that the lack of Chkl may have different consequences depending on 
the intrinsic genetic background of the cell line studied.
Preliminary data, such as the DAPI/sulforodamine staining and the investigation of the 
levels of pro-caspase 3, revealed that apoptosis is occurring in U20S cells when 
transfected with the siRNA Chkl. A high percentage of cells presenting micro­
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polynuclei was also observed, suggesting that these cells could be dying by another 
different mechanism. Alternatively the cells presenting this morphology could represent 
the step just prior to apoptosis. The cell cycle specific expression of cyclin B1 revealed 
that a large part of the diploid G2-M cells did not express the mitotic marker thus 
hypothesizing that a certain percentage of G1 cells belonging to the new tetraploid 
population could also be included in this population. Recently, another group had 
studied the U20S cells lacking Chkl both by siRNA transfection and by specific 
inhibitors finding out that in this cell line the lack of Chkl causes a series of 
consequences such as increased DNA replication, phosphorylation of ATR targets and 
DNA breakage, although they could never detect sign of apoptotic nuclear morphology, 
differently from the results just described.
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CHAPTER 6 
GENERAL DISCUSSION
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The experiments described in this thesis were aimed at elucidating the molecular 
mechanisms regulating the G2 checkpoint after DNA damage and at investigating the 
key protein kinase regulator o f this checkpoint, Chkl, as a potential therapeutic 
target for new cancer treatments. The main idea of this strategy is to combine 
standard chemo or radiotherapy with drugs that inhibit Chkl in order to inhibit the S 
and G2 checkpoints both activated by this kinase protein in response to DNA 
damage, with the aim to increase the therapeutic index. Cancer cells, could be more 
sensitive to such combined treatments with respect to normal cells, since they lack 
the normal G1 checkpoint, due to the high incidence of p53 mutations in human 
tumors, and rely only on the S and G2 checkpoints to repair the damage (Dixon and 
Norbury, 2002). Some G2 abrogators are currently proposed to test this hypothesis, 
and promising results have been obtained with some of these inhibitors such as 
UCN-01 or CEP-3891 (Syljuasen et al., 2004). The mechanisms on which the 
observed increased cytotoxic activity is based, are still to be defined. In fact, these 
inhibitors appear to be far from highly specific for Chkl thus masking the effective 
contribution of this kinase on the effects observed (Bunch and Eastman 1996; Husain 
et al. 1997; Monks et al. 2000). A large part of the work described here was aimed at 
searching for a suitable strategy to “specifically” inhibit the function of Chkl in human 
somatic cancer cell lines growing in vitro with the final goal to increase the cytotoxic 
activity o f anticancer agents in cells with either an intact or a compromised G1 
checkpoint. For this purpose I focused the investigation on the cleanest isogenic cellular 
system available in our laboratory, represented by the colon carcinoma cell line HCT- 
116 wt and its isogenic systems with either p53 or p21 inactivated by homologous
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recombination (thus having a compromised G1 checkpoint). In chapter 4 the different 
strategies aimed at inhibiting Chkl are described (chapters 4.1-4.4). The most successful 
strategy, which made this investigation possible was the highly specific and efficient 
small interfering RNA technique. The Chkl siRNA chosen after accurate validation 
permitted the reduction of Chkl expression to almost undetectable levels in the isogenic 
cellular system studied (chapter 4.5). The data obtained (sections 4.5.1-4.5.2) indicate 
that on a compromised G1 checkpoint background it is possible to achieve higher 
abrogation of the G2 block associated with an increased sensitivity to treatment with 
DNA damaging agents than on an intact G1 checkpoint background. These experiments 
could also be validated in an “in vivo” setting and the siRNA strategy might render this 
objective possible. In preparation of such experiments in mice the specific Chkl cDNA 
target has been cloned in a specific tetracycline inducible plasmid under the control of 
an HI promoter and cellular clones stably expressing the Chkl siRNA have already been 
obtained (chapters 4.6.1-4.6.2). Once the functionality of this siRNA inducible 
expressing system will have been confirmed in mice, the next crucial step will focus on 
the investigation of the chemosensitivity of these tumors, where it is possible to 
downregulate Chkl upon addition of tetracycline in mice drinking water. By using the 
small interfering RNA strategy, the protein kinase Chk2 was downregulated in parallel 
in the same experimental isogenic system alone or together with the protein kinase Chkl 
(sections 4.5.1-4.5.2). The results obtained support the notion that Chk2 does not have 
any key role in mediating the cellular response to DNA damaging agents, at least in the 
systems studied, although overlapping functions with the protein kinase Chkl have been 
attributed to Chk2 (Bartek and Lukas, 2003). Taken together these data further
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corroborate Chkl as possible specific target for inhibition to lead to novel cancer 
therapy. The results reported in chapter 3 are aimed at increasing the knowledge o f the 
links between the putative therapeutic target Chkl and the different proteins 
participating in the checkpoint response. In particular to define the role of the 
oncosuppressor p53 in the regulation of Chkl better, the structural and functional 
characterization of the 5’ flanking region of the human Chkl gene was investigated. 
Previous studies had shown a reciprocal regulation between Chkl and p53. Chkl can 
contribute to the phosphorylation and activation of p53 soon after DNA damage, and at 
later time points Chkl would be downregulated in a p53 dependent manner with the aim 
to resume the cell cycle once the damage has been repaired (figure 3.1) (Damia et al., 
2001; Gottifredi et al., 2001). The understanding of the inter-relationships existing 
among the different checkpoint pathways (G l, S, G2-M checkpoints) is o f particular 
importance in determining the final cellular response to anticancer treatments. The 
results (chapter 3.5.1) suggest that the oncosuppressor p53 is unlikely to need to bind 
directly to the DNA for negative regulation of the Chkl gene, as the mutated form of 
p53 in the DNA binding domain was equally effective in downregulating the Chkl 
promoter. The results described in chapter 3.5.3 also show that E2F1 can positively 
regulate the Chkl promoter. This interesting connection can be placed in a larger 
scenario, in which both Chkl and E2F1 regulate the cell cycle progression under 
unstressed conditions. Recent experimental evidence suggests that Chkl has a crucial 
role in regulating the Cdc25A turnover in the absence of DNA damage by direct 
phosphorylation on multiple Cdc25A residues (Sorensen et al., 2003; Zhao et al., 2002; 
Sorensen et al., 2004). By regulating Cdc25A turnover, Chkl would modulate the
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Cdc25A phosphatase activity, and thereby its capability to activate cyclin E/A cdk2 
complexes that regulate S phase entry and progression, respectively. Interestingly 
Cdc25A expression can be transcriptionally regulated by E2F1. The complex role played 
by E2F1 in regulating the promotion of the S phase, would include the finely 
coordinated induction of a powerful inducer of DNA replication like Cdc25A, and of the 
inhibitor of this activity, such as Chkl, which by regulating the Cdc25A turnover would 
prevent the unscheduled and excessive initiation of DNA replication. The p53 dependent 
inactivation of the E2F1 transcriptional factor, which occurs after DNA damage, through 
the transactivation of p21, can indirectly explain the p53 dependent downregulation of 
the Chkl gene.
The data obtained also suggest the existence of a positive regulation o f the Chkl 
promoter by the AN isoform of p73a and a dominant negative action on the p53 
activity (chapter 3.5.2), thus suggesting that upon damage a ANp73 dependent 
upregulation of Chkl protein levels would help in inducing the G2-M block and the 
repair of the damage, thus counterbalancing the negative activity exerted by p53 
upon damage at later time points. It would be interesting to investigate the possible 
modulation of the Chkl promoter by TAp73 isoforms. Experiments are ongoing to 
elucidate this potential modulation. Recent experimental evidence suggests that a 
Chkl dependent regulation o f p73 occurs after DNA damage (Urist et al., 2004). 
Chkl has been ascribed to have a role in the modulation of the stabilization and 
activation of E2F1 after DNA damage, which is involved in the activation o f the TAp73 
promoter, thus possibly attributing to Chkl an indirect role in the apoptotic pathway 
induced by p73 activation.
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The results obtained by the characterization of the 5’ flanking region of the Chkl gene 
support the evidence that the different players of the checkpoint pathways have to be 
considered as interconnected with each other in exerting their function.
The third part of my thesis (chapter 5) focuses on the investigation of the physiological 
role of Chkl in cancer somatic cell lines. Much remains to be understood and clarified 
in terms of the role of this protein kinase in the cells, not only in the presence but also in 
the absence of genotoxic agents. The downregulation of Chkl by siRNA in the HCT- 
116 isogenic cellular systems did not alter cell growth or compromise survival of these 
cells independently from the status of p53 and p21. This finding allowed the subsequent 
step of the investigation which addressed the effect of the lack of Chkl in the presence 
of genotoxic agents. This observation together with the data recently obtained by Zachos 
et al. on the unique available vertebrate Chkl KO somatic cellular system, led us to 
hypothesize that Chkl probably was not essential for the survival of human somatic cell 
lines (Zachos et al., 2003). However the characterization of the mouse Chkl deficient 
conditional KO in mammary glands model and the essential role attributed to Chkl in 
mouse embryogenesis (not viability of Chkl KO mice) (Takai et al., 2000; Lam et al., 
2004), together with the data reported here on U20S cells (chapter 5) strongly argue 
against the hypothesis that Chkl is unessential for cell survival, a notion which can not 
be universally validated. In adult normal proliferating somatic cells in vivo, the lack of 
Chkl resulted in cell lethality mediated by a currently unknown apoptotic pathway. 
Interestingly, Chkl haploinsufficiency resulted in general cell cycle mis-coordination 
due to inappropriate entry into S phase, accumulation of DNA damage in S phase and 
uncontrolled mitotic entry in the presence of a damaged S phase (Lam et al., 2004). On
the other hand, the siRNA Chkl transfected U20S cells reported in this thesis provide 
an example of lethality observed in human somatic tumor cells at 72 hours post Chkl 
downregulation, which occurs in part by apoptosis and in part by an unresolved 
mechanism (chapter 5.5). The effects of the lack of Chkl in U20S have been recently 
studied at 48 hours after Chkl downregulation (Syljuasen et al., 2005). A general cell 
cycle mis-coordination similar to what has been described in the Chkl heterozygotes 
mammary glands was observed, although no sign of apoptosis or altered cell 
morphology was found. One might hypothesize that the possible difference in extent of 
downregulation registered in this cell line between 48 and 72 hours post Chkl siRNA 
transfection can in part explain the different result. The abnormal mitotic phenotype 
observed in HeLa cells at 72 hours, but not at 48 hours, post siRNA Chkl transfection 
(chapters 5.2-5.4) could be explained by the hypothesis that cells must go through two 
cycles and a mitosis without Chkl in order to cause lethality. From siRNA Chkl 
downregulation in HeLa and U20S cells and from the recent experimental evidences 
reported in the literature, the role played by Chkl under unstressed conditions in 
regulating the normal progression of the cell cycle appears evident. This fact could 
correlate with the cell cycle dependent expression of Chkl from S to G2-M phases, thus 
suggesting that this protein may have a more fundamental role in proliferating cells than 
in differentiated ones. It could be interesting to explore which genetic factor protects 
Chkl deficient HCT-116 and lymphoma DT-40 cells from lethality. Nevertheless, to 
study the effect of Chkl downregulation in a wider spectrum of human normal and 
cancer somatic cells and tissues could be a valuable strategy to characterize definitively 
the effects of the absence of Chkl. However the “complex world” represented by any
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different normal and especially tumor cell type, might render this attempt very difficult, 
if not impossible. In any case, as death of nontumor proliferating cells limits the efficacy 
of many current chemotherapeutic treatments, if Chkl inhibition causes toxicity, this 
may limit the effectiveness o f the treatment. More efforts should be invested in the 
exploration of whether tumor cells gain resistance against the loss of Chkl function 
more easily than normal cells, as this issue will be critical for the success of the 
inhibition of this protein as an anticancer strategy.
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8.APPENDIX
8.1 LIST OF ABBREVIATIONS
53BP1 p53 binding protein 1
5-FU 5-fluorouracil
aa aminoacid
APC anaphase promoting complex
ATM ataxia-telangectasia mutated gene
ATP adenosine 5’ triphospate
ATR ATM-realted gene
ATRIP ATR-interacting protein
bp base pairs
BRCA 1 breast cancer-associated gene 1
BSA bovine serum albumin
CAK cdk activating kinase
CDK cyclin-dependent kinase
cDNA complementary deoxyribonucleic acid
CFU colony forming unit
Chkl checkpoint kinase 1
Chk2 checkpoint kinase 2
CMV cytomegalo virus
dCTP deoxy-cytidine-5 ’ -triphospate
DDP cis-dichloro-diamine-platinum
DMSO dimethylsulphoxide
DNA deoxyribonucleic acid
DNA-PK DNA-dependent protein kinase
dNTP nucleotides
DSB double-strand breaks
DTT dithiothreitol
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AN N-terminal deficient
ECL enhanced chemiluminescence
EDTA ethylenediaminetetraacetic acid
FCS fetal calf serum
GST Glutathione S-transferase
h hour
H2AX Histone-2A family, member X
HAT Histone acetyl transferase
HEBS HEPES-Buffered Saline
HU Hydroxyurea
IC50 concentration inhibiting the growth by 50%
IPTG isopropyl p-D-thiogalactoside
IR ionizing radiation
Kb kilobase pairs
KDa kilodaltons
KO knock-out
1 liter
LB Luria-Bertani
LOH loss of heterozygosity
MCS multiple cloning site
MDC1 mediator of DNA damage chekpoint 1
MDM2 mouse double minute 2
mRNA messenger ribonucleic acid
NBS-1 Nijmegen breakage syndrome-1
OD optical density
o/n over night
PAC PI artificial chromosome
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
PMSF phenylmethylsulphonyl fluoride
292
Rb Retinoblastoma
RDS radioresistant DNA synthesis
RNA ribonucleic acid
RPA replication protein A
SAM domain sterile alpha-motif domain
SD standard deviation
SDS sodium dodecylsulphate
siRNA small interfering RNA
SMC-1 structural maitenance of chromosomes
ssDNA single-strand DNA
TA transactivation
TBS tris buffered saline
TEMED N ’ ,N,N’ ,N’ -tetramethylethylenediamine
Tet Tetracycline
UV ultra violet
UTR untranslated region
V Volts
wt wild type
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8.2 LIST OF PUBLICATIONS
Full publications by the candidate on topics not associated with the work described 
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